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ABSTRACT 
 
Dietary docosahexaenoic acid (DHA) (22:6 n-3) has been linked to many health 
benefits in sedentary populations, positively altering lipid profiles and reducing 
inflammation.  The prospective impacts of DHA supplementation in an athletic 
population during intensive physical training are less clear.  The first investigation 
describes inflammatory responses and the second describes lipid and lipoprotein 
responses during intensive physical training with DHA supplementation in football 
athletes. 
Sixty NCAA Division I football players (20 ± 1.5 years, 187.4 ± 6.1 cm, 105.7 ± 
18.9 kg) were randomly assigned to 2 g•day-1 DHA (n=28) or corn-oil placebo (n=32).  
Blood samples were collected at voluntary summer training (Summer), 30 days after 
Summer (Pre-camp), and 24 days after Pre-camp (Post-camp).  Selected cytokines 
(multiplex assay), WBC #, percent leukocytes, total cholesterol (TC), triglycerides (TG), 
LDL, HDL, IDL, and VLDL cholesterol (-C) and lipoprotein particles were analyzed.  
One sample t-tests (α=0.05) were used to assess differences in percent change of 
cytokine concentration, leukocyte concentration, lipoprotein concentration, particle 
numbers, and density at each time point; independent t-tests (α=0.05) were used for 
differences between groups at Summer. 
Eotaxin and monocyte chemoattractant protein-1 (MCP-1) elevations were 
significantly attenuated in the DHA group during preseason camp compared to Placebo 
(P < 0.05). Regulated on activation, normal T cell expressed and secreted (RANTES) 
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was significantly elevated in both groups (P < 0.05); however, the percent change 
increase in the Placebo group was 2-fold that of the DHA group.  White blood cell 
counts decreased at Post-camp (P < 0.05) in both groups.  Pre-camp percent change TG 
was significantly (P < 0.05) increased only in the Placebo group.  Post-camp percent 
change TG and HDL particle number in the DHA group was significantly (P < 0.05) 
reduced.  LDL4 number significantly increased in the DHA group (Post-camp, P < 0.05), 
and the Placebo group decreased in LDL-C (Pre-camp, P < 0.05).  Both groups had 
increased HDL2b-C and HDL2a-C at Pre-camp (P<0.05).  Pre-camp LDL3-C and Post-
camp LDL4-C increased in the DHA group (P<0.05).  RLP-C increased in the Placebo 
group (Pre-camp, P<0.05).  Pre-camp HDL density and Post-camp LDL density 
decreased in the Placebo group.  The DHA group decreased HDL density during 
preseason, but LDL density remained constant. Summer IDL-C was significantly (P < 
0.05) higher in the DHA group. Percent change VLDL number was significantly (P < 
0.05) increased during preseason camp.  There was no difference in lipoprotein-a and C-
reactive protein between groups. TC, HDL-C, and RLP number did not change over time 
nor differ between groups.  Pre-camp homocysteine increased, while Post-camp insulin 
significantly (P < 0.05) decreased in the DHA group. 
These investigations further our knowledge of a particular omega-3 fatty acid 
(DHA) as a potential lipid mediator to mitigate cardiovascular risk, as well as an 
inflammatory modulator for possible overtraining.  Adequate dosage for the anti-
inflammatory and lipid profile improving effects of DHA in a sedentary population is 
still unclear for this particular athletic population.   
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CHAPTER I 
INTRODUCTION AND REVIEW OF LITERATURE 
 
Chapter I will provide a study proposal with review literature.  Chapters II and III 
are intended to serve as separate manuscripts to be submitted for publication in a peer-
reviewed journal.  Chapter IV provides suggestions and limitations for future studies.  
This document will highlight the interaction of docosahexaenoic acid (DHA) and 
its potential effects on Division I football athletes during strenuous training.  To the 
author’s knowledge, this study was the first to highlight this particular omega-3 
supplementation in an elite group of football athletes during a rigorous training period.  
Two specific and complementary aims were identified with the goal of clarifying the 
potential benefits of algal DHA in this athletic population.  The literature review links 
the descriptive interactions among exercise, inflammation, blood lipids, and 
polyunsaturated fatty acids.  The resultant information will prove useful to researchers, 
practitioners, athletes, and the public. 
Polyunsaturated fatty acids (PUFA) have been of great interest for several years 
in relation to risk reduction and possible prevention of multiple diseases, including 
diabetes, cardiovascular disease, metabolic syndrome, asthma, Alzheimer’s and other 
nervous system disorders (30, 130, 162, 178).  In particular, total dietary intake of omega-3 
fatty acids (FA) is a focus of current dietary research.  Omega-3 FAs have a basis in 
animal models for acting as neural protective/recovery agents following head trauma, 
like concussion (10, 217), partly stemming from anti-inflammatory compounds produced 
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from DHA, such as D-Series resolvins and neuroprotectins (25, 32, 97).  When DHA and 
other omega-3 FAs are discussed in context of sports medicine, it is often concerning 
supplementation in concussion prevention and treatment (15, 158).  American football is 
known, in research and also in the public media, as being a sport with the potential for 
numerous concussion incidents, as well as other injuries (4, 48, 56).   
American football is a high intensity sport that requires speed, strength, and 
power.  The ability to make a variety of plays is necessary.  A high level of athleticism is 
needed to play the sport, as not only does the athlete need to be able to pass, run, and 
avert a tackle, but must also perform in situations that lead to a collision with other 
players.  These impacts result in many injuries each season (3, 48, 56, 75, 98, 138).  Herbenick 
et al. (75) found that of out of 1,199 documented injuries (a study spanning 2002-2005), 
38.7% of those injuries occurred during preseason or the first week of season.   
In preparation for the college season, football players participate in preseason 
camp, previously known as two-a-days, where they undergo weeks of training with 
numerous conditioning, resistance exercises, and sport practice sessions regulated by 
legislation by the National Collegiate Athletic Association (NCAA) (134).  Even with 
training guidelines, there still remains a possibility that a football player, preparing for 
the upcoming season, could be over-trained during this preparatory period of training.   
Overtraining syndrome (OTS) is defined by an increase in training volume (weeks or 
months) with a concomitant decrease in performance (180) which can also include the 
accumulation of non-training stressors that show not only physiological but also 
psychological symptoms (69).   Indicators of overtraining can vary from study to study, as 
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well as from variations in coaching style. These indicators can include: decreased 
muscular strength, decreased work capacity maximums, loss of coordination, persistent 
high fatigue ratings, decrease in the quality of sleep, and/or decreased maximal heart rate 
(114, 121, 180).   
Moderate exercise can lead to attenuation in illness rates, that is, a drop in 
frequency of both viral and bacterial infections (139, 140).  Conversely, when exercise 
becomes chronic and/or too strenuous, an inverse effect appears and the chance for 
infections increases (21, 139, 140, 150, 152, 153).  All the physical work football teams perform 
to prepare for the season and to maintain performance throughout the season can have a 
cumulative effect which could potentiate a state of over-inflammation.  That is, with all 
the seasonal practice, the excess amount of exercise could lead to an over-trained state 
which could also be associated with over/prolonged inflammation. 
A strategy to combat this state of over-inflammation is nutritional intervention.  
One nutrient of particular interest is the omega-3 fatty acid, DHA, to aid in regulation of 
the inflammation process.  Regulation and modification of inflammation could have the 
potential to allow the athlete to recover sooner and adapt more efficiently to additive 
stimulus. 
Inflammation 
Inflammation is a natural response to stress (physical, chemical, or 
psychological) by the body. It is the first step in the body’s healing process, in which 
repair cells are directed from the blood into the injured tissue.  Inflammation in response 
to exercise is essential to the sustainability and adaption of the working skeletal muscle 
 4 
 
(109, 145, 150, 153).  In this document, inflammation and immune function will be linked 
together to demonstrate the communication and action following a stress, such as 
multiple exercise bouts.  Acute (short-lived) inflammation is necessary, but problems 
arise when inflammation persists (chronic inflammation). Besides rheumatoid arthritis or 
tendonitis, chronic inflammation accompanies many other disease states, such as 
atherosclerosis, coronary heart disease, diabetes, obesity, and certain forms of cancer (97, 
132, 156, 162). 
The two main phases of inflammation are the acute response phase and 
resolution phase.  During the acute response phase, there are several characteristics 
associated with repair signaling, including increases in blood flow and vasodilation, as 
well as chemical messengers that affect transient time and vascular permeability.  There 
are many cell types of numerous functions and interactions that take place during this 
first phase.  A cellular overview consists of neutrophils moving into the damaged area 
with maturing monocytes (into macrophages) ensuing, of which proliferation will occur 
and redirection/reprogramming of indigenous macrophages to handle cellular 
deconstruction and the rebuilding process (172).   
The second phase of inflammation is the resolution phase.    The reversal or 
removal of the inflowing granulocytes is considered by some to be a marker of 
inflammation resolution, as the macrophage and lymphocyte population of the tissue 
returns to baseline concentrations that were present prior to the increased cell population 
from the initiation phase of inflammation (62).  Excessive stimulation of neutrophil 
production and function can change a skeletal muscle repair model into a damaging 
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process until some intervention can rectify the initiation process and proceed to the 
resolution phase (197).  If the resolution phase cannot be initiated and the acute response 
phase is prolonged, then the body is placed into a state of chronic inflammation, whether 
it is low-level or high-level.  
Prostaglandins, or lipid mediators, play an integral role in the resolution phase, as 
they regulate how leukocytes are removed from the tissue area (118, 172, 212). The various 
roles of lipid mediators in the inflammation process make lipids and their constituents 
prime candidates for supplemental intervention to optimize the inflammation process.   
The immunological connection between overtraining and how adaptation relates 
to cytokine formation has been defined as the cytokine hypothesis of overtraining 
(180).  Microtrauma found in bones, connective tissue, and skeletal muscle has been 
linked to participation in training and competition (121, 181).  This microtrauma could 
potentiate the cytokine response necessary to initiate the acute inflammation 
phase.  Continual microtrauma without time to recover could extend acute inflammation 
to chronic inflammation, ultimately leading to a systemic immune/inflammatory 
response (180). Testing for overtraining and distinguishing between overtraining and 
overreaching is complex and many times symptoms or indicators are anecdotal in nature 
(69, 126).  The term overreaching can be applied to strenuous activity that requires a 
recovery period that lasts days or weeks (121).  This continuous training, with insufficient 
recovery, can extend past overreaching for adaptation and may lead to overtraining 
syndrome (126, 174).  Furthermore, heavy excessive exercise in the absence of regenerative 
time, can lead to repeated transient immune dysfunction (57) . 
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The use of non-steroidal anti-inflammatory drugs (NSAIDs) has been common 
practice for treating many sports related injuries.  Studies have examined the 
inflammatory responses following heavy eccentric exercise with and without commonly 
used NSAIDs, ibuprofen and acetaminophen (157, 198).  Prostaglandins are eicosanoid-
derived regulators of inflammation (25, 32).  Prostaglandin E2 (PGE2), a pro-inflammatory 
prostaglandin, is associated with the acute phase of inflammation and mediates the influx 
of neutrophil exudates to the exercised muscle (198).  Opposite in function to PGE2, is 
Prostaglandin F2α (PGF2α) which affects the neutrophil chemotaxis during the resolution 
phase of inflammation (41).  Interestingly, heavy eccentric exercise and the administration 
of either maximal consumer dosages of ibuprofen or acetaminophen resulted in 
attenuated PGF2α concentrations and PGE2 concentrations that were attenuated with 
acetaminophen, but not affected by ibuprofen, when compared to placebo (198).  Further 
analysis of macrophage and neutrophil concentrations showed no difference in treatment 
groups, as all exhibited elevated macrophage count following heavy eccentric exercise; 
no group had a significant change in neutrophil concentrations pre- or post-exercise, as 
well as with treatment groups (157).  The attenuated PGF2α without change in leukocyte 
concentration effects suggests that NSAIDs do not alter the acute phase of inflammation 
but have the possibility to blunt the resolution phase (157, 198).  Additionally, this alteration 
in cellular repair timing has been shown to attenuate protein synthesis of the stimulated 
muscle (41, 157, 198). 
Researchers have investigated other possible interventions to regulate the 
prolonged initiation phase of inflammation, including nutrient compounds with possible 
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anti-inflammatory effects.  Compounds include fatty acids, fish oils, quercetin, 
carbohydrate isoforms, antioxidants, nitrites, and bicarbonates (26, 92, 136, 139).  The use of 
polyunsaturated fatty acids and their role in resolvin and protectin formation are major 
topics of research addressing inflammation and immunomodulation (29, 30, 59, 97, 172, 208).  
Later in this chapter, the importance of resolvins and protectins derived from different 
omega-3 fatty acids will be explored. 
Inflammation and Exercise 
Inflammation is an essential element of the training and preparation that all 
athletes undergo to become bigger, faster, and stronger (109).  The acute response phase is 
necessary for repair and has the potential to effect muscle adaptation (109, 120, 145).  
Intracellular neutrophil populations (from cytokine signaling) begin to increase 
immediately post exercise and remain elevated for several hours after, during the acute 
phase of inflammation (152). Acute bouts of exercise have resulted in reductions in 
inflammation (13, 140, 175).  Following a resistance training session with 3 x 10 repetitions 
at 60-70% repetition-max, untrained individuals had increased leukocyte formation 
(66%) which returned to baseline concentrations within 30 minutes, compared to almost 
double that when exposed to aerobic exercise of similar caloric expenditure (175).   
Routine, moderate exercise has been linked to reductions of proinflammatory 
cytokines and chemokines, fibrinogen, C-reactive protein, interleukin-6 (IL-6), and 
tumor necrosis factor-alpha (TNF-α) (57, 99, 117, 147, 184).  Issues arise when overtraining 
occurs or time for recovery is limited (137, 140).  Brenner et al. (19) states that strenuous 
physical activity can elicit mild clinical injury which could potentiate excessive 
 8 
 
immunosuppression and inflammation comparable to clinical sepsis.  In contrast, a 2005 
review on the role of exercise in cytokine regulation explained that the exercise cytokine 
response was different from responses present in severe infections (156).  The main 
difference was with contracting skeletal muscle. In this instance, there is less of an initial 
proinflammatory effect of TNF-α, which, in a sepsis situation, would lead to a lower 
production of IL-6, but this was not the case (156). 
Additionally, IL-6 from muscle has a different cascade of responses (including 
acting both pro and anti-inflammatory), acting as a myokine, which can be elevated post-
exercise from resistance or endurance training (156).  IL-6 is considered the most 
prominent cytokine messenger originating either in the muscle cell or of systemic origin 
during physical activity (99).  IL-6 has both pro-inflammatory and anti-inflammatory 
properties (55, 57, 100, 156).  Extracellular IL-6 acts a proinflammatory messenger, directing 
neutrophils to the site of repair while intracellular IL-6 (from muscle tissue mononuclear 
leukocytes) signals the up-regulation of anti-inflammatory cytokines IL-1ra, IL-8, IL-10  
while inhibiting TNF-α (promoting the resolution phase of inflammation) (55, 99, 100, 145, 
156).  The inhibition of TNF-α by IL-6 has been described as a glucose and lipid 
modulator during and after exercise with termination corresponding with glycogen 
resynthesis (99). 
It has been suggested that heavy exertion (i.e., prolonged endurance exercise) 
leads to a compromised immune system (140).  Upper respiratory tract infections have 
been linked to prolonged heavy exertion training and show elevations in both IL-6 
(proinflammatory response) and IL-1ra (anti-inflammatory response) concentrations (140).  
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Two and a half hours of intense running by 30 marathoners led to a 5.5-fold increase in 
IL-6 immediately post-run, as well as IL-1ra increasing 127% 1.5 hours post-run (136).  
For an athlete, training and competition is sometimes combined with malnutrition, 
weight loss, mental stress, and lack of sleep, which can all be detrimental to the immune 
system (140). 
Polyunsaturated Fatty Acids 
Polyunsaturated fatty acids (PUFA) are fatty acids that contain at least two 
carbon-carbon double bonds.  The naming convention for unsaturated fatty acids follows 
numbering from the methyl end of the chain, instead of the carboxylic acid end.  The 
methyl end is also termed the “omega” end and denoted as ω-# or n-# (Fig. 1).  The 
number associated with n or ω is the location of the first carbon-carbon double bond 
starting from the methyl end.   
PUFA are often deemed “good” fats for improving lipid profiles and reducing 
cardiovascular disease risk. The two families of omega-6 and omega-3 fatty acids are 
located in most phospholipid bilayers of cellular membranes (125).  Of the known PUFAs, 
omega-6 and omega-3 fatty acids have both negative and positive impacts on 
inflammation and blood lipid profiles (125).  Both of these fatty acid groups are essential – 
that is, must be consumed in the diet, because they cannot be synthesized de novo in 
animals (125, 176, 178, 207).  Arachidonic acid (AA) (20:4n-6) and its essential precursor 
linoleic acid (LA)(18:2n-6) are considered to be proinflammatory, and are found in 
lymphocyte and monocyte membranes in high concentrations (25, 30, 31, 125).  The products 
from AA include eicosanoids, reactive oxygen species, and adhesion molecules (25, 30, 31, 
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125).  The three main omega-3 PUFA; eicosapentaenoic acid (EPA)(20:5n-3), DHA 
(22:6n-3), and their essential precursor α-linolenic acid (ALA)(18:3n-3),  are considered 
to be less inflammatory and are involved in the resolution of inflammation (30, 32).  
Linoleic and α-linolenic acids are competitive inhibitors of the metabolism of each other, 
and their derivatives compete for inclusion into phospholipids of cell membranes.  The 
integration of omega-3 fatty acids into phospholipid cell membranes can affect 
membrane compositions of multiple tissues (60, 76), as well as impact stress kinetics and 
inflammation signaling through alterations in lipid rafts and inhibition of receptor sites 
(28, 30, 32).   
 
Figure 1. Bond-line structures for polyunsaturated fatty acids: LA, AA, ALA, EPA, and DHA.  Number following C 
represents number of carbons.  Number after “:” represents number of double-bonds.  LA and AA have the first 
double-bond at 6th carbon from methyl end (ω-6). ALA, EPA, and DHA have the first double-bond at 3rd carbon from 
methyl group (ω-3). 
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Linoleic acid is the major PUFA found in Western diets.  Second to that is ALA.  
Both LA and ALA sources are found in plants, while marine organisms are the major 
sources of ALA derivatives.  ALA serves as a precursor for EPA and DHA, while LA 
serves as a precursor for arachidonic acid (AA). Mammals lack the capacity to 
synthesize EPA and DHA because of an inability to desaturate 16- or 18-carbon FAs that 
are more than nine carbons from the carboxyl end (183).  The conversion of ALA to EPA 
or DHA is limited in humans because of the inadequate amount of delta-6 desaturase, 
and delta-5 desaturase (14, 88, 94, 176).  There is a competitive inhibition of the delta-5 and 
delta-6 desaturase enzymes by LA on ALA to EPA; the result is increased production of 
AA (207).  Delta-6 desaturase is a rate limiting step of this pathway (14). Additionally, the 
consumption of trans-fatty acids impedes the production of AA, EPA, and DHA by 
negatively affecting the elongases and desaturases associated with the metabolism of LA 
and ALA (177).  Though limited, brain, liver, intestinal mucosal, and retina endoplasmic 
reticulum tissue membrane are the primary sites for both delta-5 and deta-6 desaturases 
(119).  The main sites of omega-3 and omega-6 fatty acid storage are in the phospholipid 
layers of cytoplasmic lipid bodies, glycerides, organelle membranes and cell membranes 
(168).   
In a rested state, phospholipids contain more PUFAs than monounsaturated fatty 
acids (MUFAs), while the opposite is true for triglycerides in humans.  Following 
exercise training, muscle triglyceride content can be elevated with increased total PUFA 
in the triglyceride by decreasing total MUFA carrying very low density lipoprotein 
(VLDL) (5, 201, 213).  Nikolaidis and Mougios (141) concluded that the rate of uptake for 
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unsaturated fatty acids in skeletal muscle is greater than that of saturated fatty acids 
entering the same tissues during exercise.  The effects of acute and chronic exercise on 
the plasma fatty acid profile have been demonstrated in several studies (83, 86, 128, 201, 213).  
Rodent models (8, 9) using chronic exercise have demonstrated effects on adipose tissue 
such as decreasing delta-9 desaturase activity (lowering MUFA formation) while 
favoring elongase activity (increasing PUFA formation) in skeletal muscle (141).  
The incorporation of PUFA, such as DHA, into erythrocyte cell membranes can 
be used as a systemic marker of overall fatty acid content in tissues (187), since de novo 
synthesis of erythrocyte phospholipid membrane free fatty acids does not occur.  Thus, 
phospholipid constituents are collected from plasma lipids to construct the erythrocyte 
cell membrane (38).  Studies have reported that, within one month of omega-3 
supplementation in humans, omega-3 PUFA concentrations reach a steady state when 
measuring total plasma lipids, thus incorporation into erythrocytes (a FFA systemic 
composition tissue marker) will have lower kinetics and represent a longer period of 
membrane structure and composition (111).  
Diet has the potential to alter plasma and erythrocyte cell membrane FA 
composition (149, 187, 207).  Sun and colleagues (187) compared food frequency 
questionnaires to plasma and erythrocyte FA concentrations of 306 US women aged 43-
69 and determined DHA concentrations in erythrocyte and plasma provided the strongest 
correlations with those who had ingested a diet high in marine foods.  Similarly, Patel 
and colleagues (149) found plasma phospholipid fatty acids were strongly correlated with 
the reported intake of omega-3 and omega-6 fatty acids in food frequency questionnaires 
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from diabetic patients.   Analyzing 4,902 plasma phospholipid fatty acid samples, in a 
study comparing consumption of plant-derived ALA intake with intake of fish, Welch 
and colleagues (207) found an increase in DHA and EPA in the fish-eaters compared to 
the non-fish-eaters.  
Erythrocyte cell membrane FA composition, especially n-3 fatty acids, has been 
proven to be a reliable detection method for long-term consumption of fatty acids (149, 186, 
187).  Though not as highly correlated as adipose tissue samples (63), researchers have 
shown a higher correlation of erythrocyte PUFA content with intakes based on food 
frequency questionnaires than with plasma PUFA content (149, 187).  In a population of US 
women, it was determined that plasma FA composition corresponds with PUFA intake 
of past weeks, while erythrocyte PUFA content reflects intake of past months (187).  The 
difference in the ability to detect long-term versus short-term PUFA intake may be due 
to the fact that erythrocyte half-life is one hundred-twenty days, which is greater than the 
half-life of circulating plasma lipoprotein (6).  Cao and colleagues (34) reported elevated 
DHA concentration in erythrocyte cell membranes  for as long as 16 weeks post-
supplementation of a 2g •day-1 fish oil (1296 mg EPA + 864 mg DHA) following 8 
weeks of supplementation in a sedentary population;  plasma phospholipid DHA 
concentration decreased sooner than erythrocyte cell membrane DHA concentration 
once supplementation ceased (within two weeks post-supplementation). 
Both exercise and diet may combine to affect plasma lipids and erythrocyte 
membrane composition.  Results of exercise training are inconsistent among populations 
of sedentary individuals, sprinters, and long-distance runners.  When compared, the 
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sedentary participants and sprinters had higher ratios of saturated to unsaturated fatty 
acids in erythrocyte cell membranes, while the long-distance runners’ unsaturated fatty 
acids were higher in total PUFA concentrations (96). 
Polyunsaturated Fatty Acid Sources and Common Diets 
Anthropologists have determined that ancient wild game and livestock had 
higher omega-3 contents than present day diets.  Livestock diets for cattle have changed, 
causing a shift from omega-3 FA to omega-6 FA in meat, but the food industry is 
compensating. Supermarkets now carry omega-3-enriched eggs and cereal, as well as 
DHA-enriched milk.  Other sources include walnuts, kale, soy beans, Brussels sprouts, 
collard greens, winter squash, and tofu. Wild animal carcasses have more total FA, 
increasing total omega-3 FA than farm raised animals.  Differences can be attributed to 
vegetation available.  The major sources of omega-3 fatty acids today in humans are 
canola oil, flax seed, Salmon, Halibut, and other cold water fish, or direct fish oil 
supplementation. To avoid concern about mercury and other metal concentrations found 
in fish, algal (water algae)-based oil supplements come in purified forms.   Researchers 
have suggested that healthy diets should have a 1:1 or 1:2 ratio of omega-3 to omega-6, 
but ratios common to the typical US diet vary within a 1:6 to a 1:20 range (32, 33). In 
2000, U.S. omega- 3 intake was only 1.6 g•day-1 (0.04 g•day-1 EPA, 0.07 g•day-1 DHA) 
compared to that of 15.9 g/d omega-6 (53). 
The American Heart Association issued recommendations for consumption of 
omega-3 PUFA (115).  Those individuals without documented coronary heart disease are 
advised to consume at least two oily fish meals per week (115).  This level of dietary 
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consumption would provide approximately 500 mg•day-1 of combined EPA + DHA (72).  
Those with documented coronary heart disease are advised an intake of at least 1 g•day-1 
of combined EPA+DHA, whether by oily fish or through supplementation (115).  
Individuals needing to lower triglycerides are recommended to ingest 2 – 4 g•day-1 of 
combined EPA + DHA (115).  The EPIC-Norfolk cohort stated that vegans and non-fish 
vegetarians and meat eaters might have slightly different rates of enzymatic processes 
for DHA formation, and the total EPA and DHA fatty acid membrane incorporation is 
lower than that of fish or fish oil eaters 5% EPA and 0.5% from DHA (207). 
Recommendations for macronutrients in an athlete’s diet have varied from expert 
to expert.  In 2009, Wagner (202) noted experts in sports nutrition generally recommend 
ranges of 55-65% carbohydrate, 15% protein, and the rest of the calories from fat for 
athletes.  Specific to American football, Holway and Spriet (82) reviewed nutritional 
strategy studies (involving 3-day recall) and found macronutrients for college players to 
range 39-53% carbohydrate, 16-22% protein, 23-41% fat, with possible variations 
between positions.  There are few data describing specific PUFA amounts in their diet of 
an athletic population.  Associations to a Western diet are usually extended to the 
American sport athlete, which would be low in PUFA content.  Posner (160) reported fat 
intake for North Americans was approximately 38% of total energy consumed.  For the 
United States, 66% of the fat consumed comes from an animal source, while the rest is 
from plants (92).  This ratio leads to a diet with higher saturated fat consumption than 
unsaturated fat consumption.  A study by Clark et.al. (40), comparing preseason to 
postseason eating habits of Division I female soccer players, showed larger amounts of 
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total fat (grams) consumed at preseason, though percent energy contribution was 2% 
lower.  Additionally, it was noted that even with changes in total caloric intake, 
carbohydrate intake was still not sufficient for optimizing glycogen stores.  Instead, high 
fat and high protein diets were reported, which were less nutrient dense, in addition to 
the lower percent carbohydrate intake. (40) 
Effects of Polyunsaturated Fatty Acids on Inflammation 
Research on polyunsaturated fatty acids role in chronic inflammation and 
immune response, especially omega-3 fatty acids anti-inflammatory effects, continues to 
grow (25-32, 36, 59, 97, 132, 162, 209).  Of particular interest is the effect of omega-3 fatty acids 
on cytokine production and signaling.  Cytokines are proteins that mediate both phases 
of the inflammation process.  There are cascades of signaling performed by the 
cytokines and many times found to be “redundant signaling”, as some cytokines share 
the same the effect (97).  Serving as precursors to cytokines, the formulation and 
placement of the lipid mediators influences the release and initiation of different 
granulocyte cytokine signaling (30, 32, 97, 132).  AA competes with EPA and DHA for 
phospholipid membrane space which can influence inflammatory signaling (28, 29, 119, 177).   
 Arachidonic acid freed from the cell membrane leads to the development of 
various types of proinflammatory eicosanoids.  AA can be converted by 
cyclooxygenases (COX-1 & COX-2) into 2-series prostaglandins (i.e. PGE2) and 
thromboxanes.  AA can also be metabolized by lipoxygenases (15-LOX, 12-LOX, and 
5-LOX) to create 4-series leukotrienes and hydroxyeicosatetraenoic acid. (21, 32)  During 
the acute phase, series-2 prostaglandins promote not only neutrophil infiltration, but also 
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neutrophil phagocytosis (166).  Superoxide anions are byproducts from neutrophils and 
macrophages breaking down cellular debris (172, 197).  If the intracellular concentration of 
superoxide anions remains elevated, non-damaged cellular structures will break down 
which can result in further injury (197). 
In contrast, EPA and DHA are metabolized by the cyclooxygenases and 
lipoxygenases resulting in eicosanoids with either lesser potency or opposite functions 
than their AA derivative counterparts (2-series prostaglandins) (29).  EPA is converted by 
COX-2 into 3-series prostaglandins, thromboxanes, and E-series resolvins.  Interaction 
with 5-LOX leads to 5-series leukotrienes.  Similarly, DHA can give rise to D-series 
resolvins and neurprotectins. (25, 32, 97)  Refer to Figure 2 for a flow diagram of the two 
phases of inflammation and the roles of AA, EPA, and DHA. 
The following summarizes three possible mechanisms of how DHA influences 
inflammation:  (1) membrane lipid raft theory with cascading effects on selective 
eicosanoid production opposite that of AA; (2) the use of the PUFA as fuel for 
neutrophils and leukocytes; and (3) intracellular inhibition of cytokine gene expression 
(205).  First, the physical cell membrane alteration shifts lipid rafts in such a way that it 
reduces binding sites for cytokine receptors, thus blocking or inhibiting the receptors (36).  
It is also suggested that the unique structure of DHA lends itself to integrating into the 
cell membrane and changing properties including fluidity, resident protein function, 
phase behavior, and ion permeability (36).  Additionally, DHA intake can take the place 
of AA in the phospholipid bilayer of the cell, which reduces the number of pro-
inflammatory cascade signaling mediators.  Four and a half months of algal DHA has 
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been shown to increase mean plasma phospholipid DHA by 193% and EPA by 50%, 
while decreasing AA concentrations by 25% (135).  Some suggest that the need for fatty 
acids is up-regulated during periods of injury where fatty acids act as an energy source, 
as well repair mediators (195).   
 
Figure 2. Acute and resolution phases of inflammation. Upon mechanical stress, extracellular leukocytes enter cell near area of 
damage (acute phase of inflammation).  The influx of leukocytes activates the lipopoxin B receptor which works in tangent with 
omega-3 fatty acids in phospholipid membrane to attenuate the increase in intracellular leukocyte population.  Arachidonic acid (AA) 
derives prostaglandin PGE which signals phagocytosis and endocytosis of debris/damage structures.  Once sequestered, neutrophil 
(Neu) proliferation is disabled and Neu apoptosis is initiated (additionally signaling from intracellular AA).  Resolution of 
inflammation is promoted by prostaglandins and eicosanoid communicators from docosahexaenoic acid (DHA) and eicosapentaenoic 
acid EPA signal the monocyte (MON) maturation into cell specific macrophages (MPH) to remove apoptotic Neu from damaged site 
until intracellular leukocyte concentrations return to homeostasis.  
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As many of these cytokines directly or indirectly affect neutrophil and 
monocyte/macrophage function, the effect of DHA must be considered when examining 
the production of free radicals by inflammatory cells.  Free radical production in the 
skeletal muscle serves multiple functions during the inflammatory process (109).  Besides 
reducing responses to proinflammatory cytokines, DHA and other omega-3 fatty acids 
have been demonstrated to show reductions in monocyte and neutrophil chemotaxis 
properties (132).  These free radicals assist in the degradation of damaged cellular material 
(109).  Moreover, the free radicals act as trigger mechanisms for redox sensitive signaling 
pathways that promote skeletal muscle hypertrophy (109). Monocyte/macrophage function 
during the resolution phase of inflammation functions to induce proliferation and 
differentiation of skeletal muscle cells; this activation is induced by IFN-γ (109).  
Additionally, it is thought that DHA could incorporate into neutrophil membranes at 
similar rate as in erythrocytes and, in turn, reduce superoxide production (78).  These 
elevations in macrophage population have usually been reported days after a resistance 
exercise session (109).  DHA is converted into resolvin D series, as well as protectin D 
series lipid mediators that promote the resolution phase, working to bring about tissue 
homeostasis with regards to granulocyte population (172).  
Figure 3 diagrams potential key cytokine signaling in skeletal muscle.  During 
the acute phase, monocyte chemoattractant protein-1 (MCP-1) and interferon gamma 
(IFN- ᵞ), promote the maturation of monocytes into macrophages (173, 185). Tumor 
necrosis factor alpha (TNF- α) promotes apoptosis of the sequestered neutrophil and 
structural debris (33, 145, 184).  Interleukin-6 (IL-6) signaling, during the acute phase, 
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directs mature macrophages to engulf damaged tissue and recruit more macrophages 
(173).  Interleukin-1 (IL-1) works in conjunction with IL-6 to signal neutrophil 
migration to macrophage sites (33).   Membrane bound, interleukin-1 beta (IL-1b) 
stimulates TNF- α to direct post-used neutrophils for apoptosis (33, 173, 185).  To indirectly 
regulate both the maturation of macrophages and sequestration of leukocytes out of the 
cell, interleukin-15 (IL-15) influences the balance of IFN- ᵞ and TNF- α (185). 
During the resolution phase, interleukin-1 receptor alpha (IL-1ra) inhibits IL-1b 
and reduces concentrations of TNF- α (33, 145, 184).  IL-6 takes on an anti-inflammatory 
characteristic, as it promotes the maturation of monocytes to drive the neutrophil 
remnants out of the cell and into the lymphatic circulation (33, 100, 145, 184). Interleukin-10 
(IL-10) and interleukin-13 (IL-13) suppress macrophage functions which can lead efflux 
of intracellular leukocyte debris (33).  Eotaxin also influence the efflux of leukocytes out 
of the cell into circulation (173).   
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Figure 3. Cytokine signaling of potential key messengers. During the acute phase, monocyte chemoattractant 
protein-1 (MCP-1) and interferon gamma (IFN- ᵞ) promote macrophage formation.  Tumor necrosis factor alpha 
(TNF- α) and interleukin-6 (IL-6) signal the sequestration of cellular debris.  Interleukin-1 (IL-1) promotes 
macrophage formation as well as enhanced IL-6 signaling. TNF- α is up regulated by interleukin-1 beta (IL-1b) and 
interleukin-15 (IL-15); IL-15 also augments IFN- ᵞ. During the resolution phase, Eotaxin and IL-6 promotes efflux of 
cellular debris.  Interleukin-1 receptor alpha (IL-1ra) inhibits IL-1b (initial leukocyte influx).  IL-6, interleukin-10 
(IL-10), and interleukin-13 (IL-13) signal packaging and phagocytosis of cellular debris. 
 
Lipoproteins, Exercise, and Polyunsaturated Fatty Acids 
Lipoproteins. Couriers of cholesterols and triglycerides are known as lipoproteins and 
are classified by density, which also contributes to their distinct roles in lipid 
metabolism.  Figure 4 depicts a flow schematic for lipoprotein metabolism.  Major 
lipoprotein fractions, from most dense to least dense, include: high density lipoprotein 
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(HDL), low density lipoprotein (LDL), intermediate density lipoprotein (IDL), VLDL, 
and chylomicrons.  Part of the identification of each lipoprotein is the type of 
apolipoprotein associated with it.  Apoliporoteins act as regulators to 
conformation/composition and movement of cholesterol esters and triglycerides for each 
lipoprotein.  Though many forms exist, isoforms of Apolipoprotein A and B are the 
primary signalers for lipid metabolism (37).  Starting in the gut, apolipoprotein A1 is 
associated with HDL formation and migration of cholesterol to the liver while 
Apolipoprotein B48 is the primary signal reference protein of chylomicrons as 
lipoprotein lipase removes triglycerides for use in peripheral tissues before the remnant 
chylomicrons reach the liver.  Conversely, another form of Apolipoprotein B, B100 is 
active on lipoproteins leaving the liver, with VLDL leading to IDL to LDL as 
triglycerides are extracted. (37, 65) 
HDL and its subfractions function to return cholesterol (reverse cholesterol 
transport) from peripheral tissues to the liver and adipose tissue. HDL also works as a 
reference lipoprotein that can donate cholesterol to chylomicrons, VLDL, IDL, and LDL 
through the action of cholesterol ester transfer protein (CETP), as well as contribute to 
coenzymes for membrane receptors for influx of lipids into cells.  Key signaling 
involves communication of the lipoprotein surface proteins, apolipoproteins, and the 
enzyme lecithin cholesterol acyl transferase (LCAT) to convert cholesterol into 
cholesterol esters.  Nascent HDL-C is initially comprised of apolipoprotein A1, which 
acts as a receptor to collect cholesterol esters.  As nascent HDL-C accumulates more 
cholesterol esters, the esters are packed tightly by LCAT creating a cholesterol-dense 
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HDL3-C in conjunction with ATP binding cassette A1.  HDL3-C via LCAT further 
incorporates more esters from surrounding tissues creating a less dense (not packed as 
tightly) but larger HDL2-C, which is the mature form of HDL-C and more buoyant, 
which will be transported back to the liver (37, 65, 161).  At this point, HDL-C reverts back 
to nascent HDL-C and can begin scavenging for cholesterol esters; the cholesterol 
delivered back to the liver can either be discarded in bile salts through the digestive 
system or packaged with triglycerides and sent to peripheral tissue in the form of VLDL-
C (37). 
Lipoprotein lipase (LPL) is used to hydrolyze/breakdown lipoproteins.  Bonding 
to the endothelium, LPL can sequester circulating VLDLs and extract triglycerides 
through hydrolysis and capillary uptake for storage in adipose tissue as well as muscle, 
and the remnant chylomicron can be redirected back to the liver and converted to LDL.  
LPL works similarly in extraction from VLDL to skeletal muscle tissue (triglycerides for 
storage/energy, such as fatty acids); and extracting phospholipids for membrane repair.  
Interestingly, absorption of fats by the intestine, and the transportation and delivery of 
fats to skeletal muscle are both executed primarily by VLDL, and especially 
chylomicrons (91, 92, 143).  Cholesterol from bile salts (reabsorption), along with dietary 
forms, can be absorbed through the intestinal lumen and packaged by the endoplasmic 
reticulum and Golgi apparatus, along with apolipoprotein B48, to form chylomicrons in 
circulation; the other alternative is packaging of absorbed cholesterols from digested 
sterols that are then transferred through the ATP binding cassette A1 channel to nascent 
HDL-C (37).  In combination with CETP, cholesterol collected by HDL-C can not only be 
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directed to the liver, but also to VLDL-C, which can go directly to peripheral tissue, or 
be further transferred to IDL-C and LDL-C for peripheral tissue use. 
 
 
Figure 4. Lipoprotein transport. Chylomicron (Chylo), very low density lipoprotein (VLDL), 
intermediate density lipoprotein (IDL), low density lipoprotein (LDL); high density lipoprotein (HDL).  
HDL donates apo proteins as well as acts in reverse cholesterol transport. Nascent HDL to HDL3 to 
HDL2 to liver. 
 
Exercise and Lipids. Cardiovascular risk is decreased when individuals engage in 
habitual exercise (105), which is associated with decreased LDL-C and triglycerides as 
well as increased HDL-C.  In general, exercise training has been shown to decrease 
plasma triglycerides (105).  Research using exercise interventions has noted that the 
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intensity of exercise is not the main determinant in lipid and lipoprotein alterations; 
exercise volume could cause greater changes (51).  Exercise volume in terms of caloric 
expenditure with a threshold of 1200-1500 kcal/week seems to be essential for 
alterations to blood lipid and lipoprotein profiles (51, 58).  Studies using energy 
expenditures ranging from 1200-2200 kcals per week led to reductions of 5 to 38 mg/dL 
of triglycerides and increased HDL-C concentrations of 2 to 8 mg/dL (51).    
Acute exercise has been demonstrated to reduce triglycerides by 14-50%, while 
following a regular exercise regime has been reported to have reductions of 4-37% (51).  
Acute aerobic exercise increases HDL3-C content while decreasing triglyceride and 
phospholipid content (61).  Notably, Crouse et. al. (42) reported an exercise session of 350 
kcal expenditure at 50 to 80% VO2max to cause elevations in HDL-C 24 hours post-
exercise in an hypercholesterolemic population; suggesting a different starting 
point(exercise volume) for altering lipoprotein profiles for specific populations.   In 
trained subjects, a single exercise session can elicit 10-25% increases in HDL and 
reductions in triglycerides (50).  Following a 350 kcal training session, untrained 
individuals with hypercholesterolemia demonstrated an increase in HDL-C 
concentration the next day after the exercise session (42).  HDL-C can increase by 4-22% 
following training with increases ranging from 2-8 mg/dL (51).  Durstine and colleagues 
(51) found that the potential for HDL alterations is more likely with training greater than 
12 weeks.   Again, it is theorized that increases in HDL-C are in a dose dependent 
relation to volume.  Ferguson et. al. (58) found that 800 kcal exercise session did not 
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affect HDL-C and that exercise sessions at 1100 kcal or above resulted in increases of 
HDL-C 24 hours post exercise in untrained subjects.  
The effects of resistance training on blood lipid and lipoprotein concentrations 
have been mixed (105, 106, 110, 179, 193).  LDL-C reductions, without alterations in 
triglyceride or HDL-C, have been noted with resistance training (18).  In contrast, other 
resistance exercise training regimes have shown no change in LDL-C, while HDL-C 
increased and triglycerides decreased (189).  
It is possible that subclasses of LDL-C could be changed with training, while 
leaving total LDL-C unchanged (188).  Caloric restriction increases LDL large particles 
while decreasing small particle LDL, demonstrating a change to more buoyant 
lipoprotein forms (211). Another exception to this caloric expenditure threshold seems to 
be VLDL, which is more affected by dietary interventions (such as low fat or calorie 
deficient), than by an exercise intervention (51).   
Several studies have shown there to be no change in cholesterol except when 
associated with a decrease in percent bodyfat (5, 43, 188).  LPL activity has been reported to 
be elevated after a variety of acute exercise training regimes (188).  With exercise, LDL 
particles become richer in cholesterol and increase in size (85).  Exercise reduces LDL 
mass and increases HDL2 mass 
(210).  It has been suggested that LPL activity following 
training is responsible for the transfer of LDL mass to smaller HDL particles, leading to 
the larger mass of HDL (105, 113).  Superko (188) suggests the main LDL component being 
transferred is cholesterol, as LPL activity and HDL cholesterol concentrations have been 
strongly correlated. 
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Endurance training has been shown to lead to elevated LCAT activity, but some 
studies have demonstrated mixed results (123, 192).  The same mixed results apply to 
CETP, as trained individuals show increased concentrations of CETP, but those who had 
associative weight loss following a training program had reductions in CETP (67, 171).  
Durstine and colleagues (51) concluded that endurance exercise training (whether in 
cross-sectional or longitudinal studies) results in a decrease in triglyceride 
concentrations relative to baseline concentrations.  Additionally, Durstine and colleagues 
(51) concluded that endurance exercise training has yet to be shown to alter plasma 
cholesterol (in absence of dietary intervention), unless prolonged. Figure 5 depicts a 
flow schematic long chain fatty acid transport and cell membrane integration.   
Fat Store Utilization. The fatty acid composition of adipose tissue could affect several 
systemic functions, as adipose tissue has endocrine and paracrine abilities (141). Lower 
body sub-cutaneous adipose tissue has an attenuated lipolytic rate during exercise (7, 84). 
It has been suggested that 10-15% of fat oxidation during exercise is derived from 
intramuscular triglycerides (IMTG) (84).  Extramyocellular triglycerides are considered to 
be a lesser source of free fatty acids than IMTG, as they are spaced between muscle 
fibers in relatively small lipid vacuoles (84).  Fat utilization is enhanced following 
endurance exercise training (81).  This use of fat appears to be attributed to an increase in 
rate of oxidation, but not mobilization (84).  Diet can affect fatty acid oxidation and 
liberation from adipose tissue during exercise (84).   
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Figure 5. Long chain fatty acid transport and integration into the cell.  Hepatic VLDL and albumin bound 
FFA are transported and received by FAT/CD36 of capillary beds.  Within the cellular interstitial space 
FAT/CD36 as well as FATP transport FFA through cell membrane, during this point FFAs can integrate 
into cell membrane phospholipid bilayer and act as mediators in the inflammation process.  Fatty acids in 
the cytosol are transferred in the form of fatty acyl-CoA to lipid droplets in the muscle or through a series 
of shuttling facilitated by CPT1, CAT, and CPT2 to reach the inner mitochondrial membrane for β -
oxidation. 
 
Diet and Lipids.  Schwingshackl and Hoffmann (170)  produced a systemic review and 
meta-analysis of low-fat, low protein, and high protein diets on metabolic markers 
including lipoproteins.  Notably, the strongest correlation to any alteration in lipoprotein 
profiles was with high protein diets and increased HDL-C concentrations.  Not as clearly 
elucidated, was the connection between high protein diets and reduced triglyceride 
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concentrations.  Effects or lack of effect on LDL-C and VLDL-C varied greatly from 
study to study and the authors noted the possible influence of increased dietary fat intake 
in subjects who eat high protein diets, compared to low protein diets. (170)  Miller et. al. 
(127) compared the Atkins (high fat, low carbohydrate), Mediterranean South Beach (high 
polyunsaturated fat), and Ornish (low fat, high carbohydrate) diets over a 20-week 
period (4 weeks of each diet, with a 4 week washout period in-between).  Additionally, 
diets were adjusted weekly to insure no weight gain or weight loss throughout the study.  
Interestingly, the South Beach and Ornish diets were associated with reductions in total 
cholesterol and LDL-C, while the Atkins, with its higher saturated fat content, showed 
increases in both total cholesterol and LDL-C.  Moreover, the Atkins diet also resulted in 
subjects having impaired brachial artery flow-mediated dilation. (127)  Grundy and 
colleagues (66) conducted a shorter, two-week diet intervention with three different diets 
consisting of high saturated fatty acid and high cholesterol (High Sat+Chol), high 
monounsaturated fatty acid and low cholesterol (High Mono), and low fat with high 
carbohydrate (Low Fat).  Both Low Fat and High Mono reduced total cholesterol and 
LDL-C.  Low Fat also reduced HDL-C while High Mono maintained HDL-C 
concentrations, making this diet advantageous to those needing to reduce total 
cholesterol and LDL-C, while preserving the cardioprotective factor of HDL-C.  (66)   
Besides macronutrient composition, other contributing effects of a dietary intervention 
are important to consider, for example, whether or not the diet resulted in weight loss of 
the subjects.  The majority of dietary interventional studies conducted that were 
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associated with beneficial changes in lipoproteins and blood lipids, had either a decrease 
in body fat and/or body weight (46, 49, 127, 193, 210, 211).  
Polyunsaturated Fatty Acids and Exercise.  Supplementation of polyunsaturated fatty 
acids has been linked to positive cardiovascular health outcomes and enhanced fat 
metabolism, which has the potential to augment the benefits of physical activity, 
including decreased body fat and oxygen consumption efficiency at submaximal 
exercise (103, 130, 133, 154, 155, 176, 203).  Additionally, supplementation of omega-3 FAs, 
specifically DHA and/or EPA, can suppress effects of endogenous omega-6 FAs and 
compete for positioning on cell membranes, leading to decreased platelet aggregation, 
increased dilation of blood vessels, and as well as increased circulatory responses, such 
as blood flow and vascular conductance (23, 131, 196, 203). 
Peoples et. al. (155) noted lower heart rate, rate pressure product, and whole body 
oxygen consumption at submaximal workloads in healthy individuals supplementing 
with 8 g•day-1 fish oil when compared to supplementation with 8 g•day-1 olive oil and 
exercising at similar incremental workloads (up to 55% VO2max).   In a follow-up study, 
Peoples et. al. (154) demonstrated higher oxygen efficiency (less oxygen consumption to 
maintain similar levels of force and duration until fatigue) in contracted Wistar rat 
hindlimbs when fed omega-3 FA rich diets, compared to omega-6 FA rich diets.  
Additionally, Walser and colleagues (204)  examined the effects of supplementing 3 
g•day-1 EPA + 2 g•day-1 DHA or safflower oil control over a six week period on 
vasodilation and blood flow during rhythmic exercise (30% of maximal handgrip 
tension).  Main determinants measured were mean arterial pressure, heart rate, and 
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brachial artery vascular conductance (diameter and flow).  Notably, mean arterial 
pressure and heart rate were not significantly different between groups, while the 
EPA+DHA group had significant increases in brachial artery diameter, blood flow, and 
conductance during exercise. (204) Conclusions from this study suggest increased 
erythrocyte deformality from the integration of the omega-3 FAs into the erythrocyte 
cell membrane (144, 196, 204).  This integration of omega-3 FAs reduces the stiffness of the 
cell, which, in turn, has been linked to a decrease in the peroxidation of membrane lipids 
and heightened oxygen and nutrient transport during submaximal exercise (196).  
The dynamics of the phospholipid layers are determined by fatty acid 
composition (141).   Such dynamics include the properties of saturated fatty acids, which 
create a rigid state (tightly-packed hydrocarbon chains) and, with increased unsaturation, 
MUFAs and PUFAs create a less-dense membrane (fewer hydrophobic attractions) (141).  
The longer hydrocarbon chains, such as omega-3 FA, display increased fluidity (141).  
Hulbert et al. (87) have suggested a membrane pacemaker theory to describe the effects of 
metabolic rate, as determined by MUFA and PUFA membrane composition. The 
pacemaker theory states that a phospholipid membrane that has more unsaturated fatty 
acids will not only have increased substrate transport, but also increased ionic transfer, 
resulting in more efficient ionic leak pumps (including Na+ and K+ transfers).  The 
authors suggest that the carbon double bonds of the unsaturated fatty acids found on 
mitochondrial membranes have a greater energy transfer potential (greater 
intermolecular collisions) with membrane bound proteins. This translates into a faster 
energy metabolism compared to membranes that have more saturated fatty acids.  (87) 
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Exercise has the potential to alter systemic free fatty acid composition.  During 
exercise, abdominal sub-cutaneous fat provides the majority of plasma free fatty acids to 
the skeletal muscle (84).  Cell membrane bound omega-3 FAs have been termed fuel 
regulators because of the enhanced signaling function to increase lipolysis and b-
oxidation, compared to cell membranes predominately comprised of omega-6 FAs (196). 
Brilla and Landerholm (20) conducted a 10 week study comparing exercise with 
supplementation of 4 g•day-1 omega-3 FA (from fish oil) and without supplementation 
on serum lipids and aerobic fitness sedentary males.  Following one-hour aerobic 
exercise bouts, three times per week, there was no difference in lipid profiles or body 
composition, in comparison to the control group. (20)  If omega-3 FAs were to augment 
the exercise performed, perhaps the exercise volume threshold was not met to elicit 
changes in lipids and body composition.   Interestingly, Warner et. al. (206) reported that 
after 12 weeks, there was a decrease in percent body fat and an increase in VO2max in 
hyperlipidemic subjects who ingested 50 mL of fish oil while exercising three times per 
week for one hour at an intensity of 50-80% VO2max.  The group that had the 
combination of exercise and fish oil had increases in HDL-C and reductions in LDL-C, 
LDL protein, and apo-B.  The fish oil only group did not show the same lipid reductions 
that the fish oil plus exercise group exhibited, but did have similar increases in HDL-C.  
(206) 
Effects of Omega-3 Fatty Acids on Lipids and Cardiovascular Disease Risk Factors 
Evidence for supplementing omega-3 polyunsaturated fatty acids suggests that 
there are many cardiovascular protective effects.  These include anti-atherosclerotic 
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effects, beneficial circulating lipid and lipoprotein composition changes, and alterations 
in response to exercise (103, 130, 131, 133, 176).  Some have used red blood cell omega-3 fatty 
acid content as a variable risk factor for CVD (103).  Moreover, remnant-like particle-
cholesterol indexed against ingestion of DHA has been correlated with less atherogenic 
effects on vessels (103).  Independent lipid risk factors for the development of CVD 
include elevated total cholesterol and LDL cholesterol, triacylglycerols and low HDL 
cholesterol, and total and small dense LDL particles (115, 129, 167).  Additionally, unique 
markers for the identification of risk factors for cardiovascular disease have been 
adopted.  These include a decreased ratio of plasma EPA to AA, increased plasma 
concentrations of remnant-like particle cholesterol (RLP-C), and a decreased n-3 index 
(erythrocyte EPA + DHA content) in the red blood cell membranes (103).  The n-3 index 
is comprised of the sum total of EPA and DHA as a percentage of the total fatty acid 
content (72).  An n-3 index of < 4% was associated with a 10 fold greater risk of death 
from coronary heart disease, compared to an n-3 index of > 8% (41).  A reduction in the 
inflammatory response is correlated with an increase in the ratio EPA to AA (164). DHA 
(not EPA) has been linked to decreasing resting blood pressure and heart rate by 5.8/3.3 
(systolic/diastolic) mm Hg and 3.7 bpm (daytime), respectively (131).  This same group of 
researchers determined that there must be endothelium-independent mechanisms that 
explain the selective blood pressure lowering effects of DHA; as coinfusion of 
acetylcholine with L-NMMA as well as sodium nitroprusside (both endothelium-
independent dilators) had enhanced vasodilatory responses with DHA supplementation 
(130). 
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Additionally, supplementing with 4 g•day-1 DHA for 6 weeks has led to a 20% 
reduction in triglycerides, a 29% increase in HDL2 cholesterol and an 8% increase in 
LDL cholesterol in mild hyperlipidemic men (133). At a smaller dosage of 1.52 g•day-1 
DHA, Maki et. al. (122) were able to demonstrate a reduction in LDL cholesterol carried 
by small dense particles.   Past research has demonstrated small dosages of 0.7 g•day-1 
DHA to alter resting lipoprotein concentrations (191), and an increased dose of 2 – 4 
g•day-1 of EPA + DHA has been shown to lower serum triglycerides in a sedentary 
population (115).   The relatively small dosage of 0.7 g•day-1 DHA elevated LDL 
cholesterol by 7%, but particle size change was not mentioned (191).   
Egert et al. (52) conducted a study in which normolipidemic participants were 
supplemented with either ALA (4.4 g•day-1), EPA (2.2 g•day-1), or DHA (2.3 g•day-1).  
Fasting serum triacylglycerol concentrations decreased significantly in each of the three 
interventions, EPA (-0.14 mmol/L), DHA (-0.30 mmol/L), and ALA (-0.17 mmol/L).  
DHA intake increased serum HDL cholesterol, in contrast to ALA and EPA intake 
which had no effect on HDL.  It was reported that possible interconversion of DHA to 
EPA led to differential enrichment in LDL due to isolated dietary EPA, ALA, and DHA 
intakes. (52) 
In a study of hypertriglyceridemic men, Kelley et al. (104) found that 
supplementation with DHA (3 g•day-1) lowered fasting and postprandial triacylglycerol 
concentrations by 25-30%.  Additionally, the n-3 index was increased, while lowering 
RLP-C, following the DHA supplementation for 90 days (103).  RLP-C concentrations, 
especially those triglyceride-rich, have been associated with increased atherogenic risk 
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(atherosclerosis) (103, 104).  Mechanisms proposed for these changes by omega-3 FA in 
RLP-C include: improving vascular reactivity, altering inflammation status, and 
decreasing platelet aggregation (115).   Harris (73) suggested the additional intake of 
omega-3 fatty acids could affect hepatic triglyceride metabolism through the attenuation 
of hormone-sensitive lipase, acetyl-CoA carboxylase FA synthase, while enhancing 
mitochondrial and peroxisomal β-oxidation.  Park (148) demonstrated that intake of 4 
g•day-1 of either DHA or EPA resulted in increased chylomicron triglyceride clearance 
via increased LPL activity causing smaller chylomicron particle sizes.  For the athletic 
population, this translates into a possible greater availability of energy which could lead 
to better endurance or recovery. 
Implications 
 The published literature mentioned above supports the assertion that the 
supplementation of DHA may attenuate inflammation and improve lipid profiles during 
strenuous training.  The specific aims will develop a model to explore the effects of 
incorporation of 2 g•day-1 algal DHA during voluntary summer training camp through 
the more rigorous (higher work volume) preseason training camp in Division I football 
players.  The underlying goal is to identify whether algal DHA does decrease or 
modulate inflammatory markers that would be elevated during preseason camp training.  
The modulation of inflammatory markers could reduce the risk of over-inflammation or 
chronic inflammation.  Additionally, lipid profiles may improve with algal DHA 
supplementation in the football players, leading to reduced cardiovascular risk. 
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Purpose & Specific Aims 
 The central purpose of this study is to determine if DHA supplementation in American 
football athletes impacts lipid profiles, leukocyte counts, and inflammation markers.   
Specific Aim #1 (Chapter II) – Inflammation and Immune Function.  Hypothesis: Pro-
inflammatory cytokine concentrations will be attenuated and leukocyte counts 
(neutrophil, monocyte, macrophage) will be suppressed with 2 g•day-1 DHA 
supplementation in collegiate Division I American football athletes during voluntary 
summer training through preseason training camp. 
Specific Aim #2 (Chapter III) – Lipids and Cardiovascular Disease.  Hypothesis: With 
the potential benefits of DHA improving blood lipid profiles, it is hypothesized that 2 
g•day-1 DHA will reduce cardiovascular disease risk by modifying lipid profiles 
including increased HDL-C (specifically HDL2-C) and decreased triglycerides as well as 
LDL-C in collegiate Division I American football athletes during preseason camp.  
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CHAPTER II 
EFFECTS OF DOCOSAHEXAENOIC ACID ON INFLAMMATORY 
MARKERS IN DIVISION I FOOTBALL PLAYERS DURING 
HEAVY PHYSICAL TRAINING 
 
Introduction 
Regulation and modification of the inflammatory response to exercise has the 
potential to accelerate an athlete’s recovery and enhance adaptation to the physical stress 
they encounter.  Inflammatory responses can occur in the absence of overt injury in 
skeletal muscle.  Regular exercise training can lead to a balance of inflammatory and 
anti-inflammatory responses (57).  The initial response of inflammation is necessary for 
repair and has the potential to effect muscle adaptation (109, 120, 145).  Acute exercise, more 
specifically mechanical loading of skeletal muscle, can activate the inflammation 
cascade of cytokine signaling and granulocyte accretion as a normal part of the response 
to exercise (109, 172).  Moderate exercise training has been linked to a reduction in illness 
and increased resistance to minor infections (152).  In the well-rested athlete, resting 
immune function concentrations are similar to those of a non-athlete, with the exception 
that athletes demonstrate higher natural killer cell activity, and slightly lower neutrophil 
activity (152).  However, intensive exercise with absence of sufficient regenerative time 
can lead to transient immunosuppression, which increases risk for infection (57).  An 
increase in training volume with a concomitant decrease in performance, known as 
overtraining,(180) includes the accumulation of non-training stressors shown in 
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physiological symptoms such as: decreased muscular strength, decreased work capacity 
maximums, loss of coordination, persistent high fatigue ratings, decrease in the quality 
of sleep, and/or decreased maximal heart rate  (69, 114, 121, 180).  Delayed recovery from 
intensive physical activity may lead to an over-trained state, which may be associated 
with prolonged or unresolved inflammation.  From an athletic perspective, inflammation 
is an essential part of the training and preparation that all athletes undertake to improve 
performance (109).  The acute response phase is necessary for repair and has the potential 
to effect muscle adaptation (109, 120, 145). 
Immune system regulation may be of particular concern to American collegiate 
football athletes during their preseason of repetitive, intensive practice sessions with 
minimal recovery.  American college football has been described as a sport characterized 
by short rest periods with intervals of high-intensity exertion which, when coupled with 
environmental stress, cause heavy physiological strain (47, 89).  The intensity of preseason 
football camp is evidenced by the Hoffman et. al. (80) report of elevated creatine kinase 
concentrations, an important marker of skeletal muscle damage, ten days following 
preseason camp training. 
Various dietary interventions have been explored in an attempt to find ways to 
regulate inflammation (26).  Interventional compounds include polyunsaturated fatty acids 
(PUFAs), fish oils, quercetin, carbohydrate isoforms, antioxidants, nitrites, and 
bicarbonates (26, 92, 136, 139).  In this regard, the role of PUFAs in acute and chronic 
inflammatory responses, especially the role of omega-3 fatty acids (FA) as an anti-
inflammatory agent, continues to gain attention among researchers (25-32, 36, 59, 97, 132, 162, 
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209).  Of particular interest is the effect of omega-3 FAs on cytokine production and 
signaling.  Cytokines mediate both the initiation and resolution phases of the 
inflammatory process.   Both phases are essential for cellular repair, growth, and 
adaptation (109); but a limiting of repair/adaptation occurs if the system remains in the 
initiation phase and the progression into the resolution phase is attenuated (118, 172).  
Furthermore, omega-3 FAs have a basis in animal models for acting as neural 
protective/recovery agents following head trauma, like concussion (10, 217), partly 
stemming from anti-inflammatory compounds produced from docosahexaenoic acid 
(DHA)(22:6n-3), such as D-series resolvins and neuroprotectins (25, 32, 97).  The most 
abundant omega-3 FAs comprising marine oil are eicosapentaenoic acid (EPA)(20:5n-3) 
and DHA.  DHA acts as a precursor to specific eicosanoids that function as lipid 
mediators for the production of cytokines.   
Relatively fewer studies have examined the impact of DHA and EPA 
supplementation on inflammation associated with exercise, when compared to studies 
examining the more generalized health benefits of omega-3 FA.  Jouris et al. (93) reported 
that arm circumference swelling and soreness were decreased after eccentric exercise 
following only a week of supplementing with 3 g•day-1 fish oil (2g EPA and 1g DHA).  
Additionally, six weeks of supplementation with 4.5 g•day-1 (half EPA, half DHA) 
lowered resting tumor necrosis factor alpha (TNF-α) and C-reactive protein 
concentrations in non-athlete, exercised-trained men (16).   
 Furthermore, there is research on the impact of DHA alone, without EPA, on 
inflammation (44, 45, 102, 219).  Zhao et. al. (219) demonstrated significant decreases of 
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proinflammatory cytokines interleukin – 6 (IL-6), interleukin – 1 beta (IL-1β), and TNF-
α in human monocytic THP-1 cells when incubated with DHA.  De Caterina et. al. (44, 45) 
found decreased leukocyte adhesion molecules/mediator signaling and cytokine 
signaling on adult human saphenous vein endothelial cells, notably IL-6, interleukin-8 
(IL-8), and TNF-α.  Exercise was not a part of these inflammation studies.   
The effects of supplementing with DHA as an exercise anti-inflammatory 
compound, in absence of EPA, remains to be fully elucidated.    Kelley et. al. (102) found 
that in young, healthy men, supplementation with 6 g•day-1 DHA, over 90 days, resulted 
in decreased natural killer cell activity, as well as reduced proinflammatory 
prostaglandin E2 and leukotriene B4 production. This reduction could be beneficial to 
those with chronic inflammatory diseases.  Additionally, Hill et. al. (79) reported 
overweight and obese subjects, with at least one additional cardiovascular risk factor, 
who consumed 6 g•day-1 fish oil (with 2 g n-3 PUFA, 1.6 g DHA) had effective 
suppression of neutrophil chemotaxis and adherence over the course of 12 weeks; which 
emulated the  results of 12 weeks of moderate aerobic exercise.  One study did note no 
difference with DHA supplementation on neutrophil function, with eight weeks of 
training, in volunteer soccer players; though they were also consuming a Mediterranean-
type diet during the study (124).  
  To the authors’ knowledge, there is no research published to date examining the 
putative anti-inflammatory effects of algal DHA supplementation during intense exercise 
training in Division I football athletes.  Our objective was to document the effects of 
DHA on cytokine concentrations and immune markers in American collegiate football 
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players during the period of voluntary summer training through preseason training camp.  
Common consumer dosages have ranged from 1-4 g of fish oil (with varying EPA to 
DHA ratios) as a possible health prophylactic.  We hypothesized supplementation of 2 
g•day-1 algal DHA would act as a chronic anti-inflammatory agent and reduce overall 
inflammation, as marked by either no-change or decreased pro-inflammatory cytokine 
and white blood cell concentrations. 
Methods 
Study Design and Dietary Intervention. Approval for this double-blind, placebo 
controlled study was given by the university Institutional Review Board for Research 
with Human Subjects.  Sixty male football athletes were recruited for participation from 
the student-athlete members of a NCAA Division I football team.  Subjects abstained 
from long-term anti-inflammatory or anti-hypertensive drug therapy.  Volunteers were 
randomly assigned (double blinded) to two groups, ingesting either 2 g•day-1 of algal 
DHA (n = 28) or a corn oil placebo (n = 32) (DSM, Columbia, MD).  During the 
supplementation, three measurement time points were established: the beginning of 
voluntary summer training (Summer), approximately 30 days after the beginning of 
Summer coinciding with the start of mandatory preseason training camp (Pre-camp) in 
August, and at the end of preseason training camp (Post-camp), 24 days after Pre-camp. 
Participant Exclusion.  To reduce potential outside sources of omega-3 ingestion, 
candidates for the study were excluded either by: 1) consumption of more than two 
servings of fish per week, or supplementation of omega-3 fatty acids and/or fish oil or 2) 
injury or the diagnosis of a concussion during the study, leading to reduced physical 
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activity.  Figure 6 (consort diagram) provides participant distribution and exclusion from 
final analysis for the study. Data from forty-three subjects were used for analysis (age = 
20 ± 1.5 years, height = 187.4 ± 6.1 cm, weight = 105.7 ± 18.9 kg), demographics are 
shown in Table 1. 
 
TABLE 1. Subject demographics 
  Placebo DHA 
N 21 22 
Age (yrs) 20.1 ± 1.4 20.5 ± 1.6 
Height (cm) 186.6 ± 6.9 188.1±5.2 
Weight (kg) 104.0 ± 18.1 107.3 ± 20.0 
BMI (kg/m2) 29.7 ± 3.9 30.2 ± 4.8 
Baseline at beginning of summer; No significant differences 
between groups. Values are mean ± SD. 
 
Supplementation Protocol.  Supplement compliance during the study was monitored by 
research staff member observation of the consumption of capsules, following weekday 
strength and conditioning training sessions.  For weekend supplementation, packets 
containing the prescribed capsules were sent home with the athlete and the packets were 
collected the following Monday and counted for capsule ingestion.  During this Summer 
to Pre-camp training, table snacks (i.e. fruits, nuts, protein/cereal bars) were available 
only before and after conditioning and strength training sessions, with the athlete being 
responsible for other food throughout the day.  Preseason camp dinners and training 
table snacks (post workout) were provided in accordance with NCAA 
guidelines.  Supplements were distributed and consumed at preseason camp dinners 
under visual supervision of research staff.  Athletes were instructed not to consume more 
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than one serving of fish per week for the entire duration of the study.  A registered 
dietician conducted a 24-hour dietary recall at each time point to ensure accuracy, and 
dietary data was analyzed with Nutribase 8.0 software (142).  
Physical Training.  One to three voluntary strength training and one to two anaerobic 
conditioning sessions were performed by the football players each week, as directed by 
their strength and conditioning coach, during the Summer to Pre-camp period.  
Conditioning sessions were approximately 0.75 hours, usually following a one hour 
strength training session.  Preseason camp (Pre-camp to Post-camp) introduced the 
athletes to two-a-day, or multiple practice and training sessions per day, conforming to 
NCAA limitations (134).  The frequency and volume of strength training and conditioning 
sessions were increased, while incorporating agility, sport-specific and position-specific 
practices.  Comparable to a study of similar training in college football players (80), 
preseason camp training in our study was deemed, by coaching and research staff, to be 
high intensity and high volume, resulting in a high workload.  
Blood Sampling and Preparation.  Blood was collected at each time point following at 
least eight hours of overnight fasting and prior to any exercise.  While seated, one 8.5 
mL serum vacutainer with a clot activator, and one 4 mL whole blood (2K EDTA) 
vacutainer were drawn from an antecubital vein.  Samples were placed into ice, allowed 
to clot for 30 minutes, followed by refrigerated centrifugation for 30 minutes (2,000 x G) 
for serum separation.  One mL aliquots of serum were then frozen at -80 ° C until 
cytokine assays could be performed.  The 4 mL (2K EDTA) vacutainer of whole blood 
was sent to St. Joseph’s Hospital (Bryan, TX) for CBC analysis by complementing 
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optical and hemoglobin flow cell with impedance transducer measurements (Abbot 
CELL-DYN Sapphire, Abbot Diagnostics, Abbott Park, IL).  
Measurement of Cytokines.  Assessment of cytokines from plasma was performed with 
two custom Milliplex multiplex cytokine assay kits (MPXHCYTO, EMD Millipore, 
Darmstadt, Germany).    One set of kits was used to detect concentrations of monokine 
induced by gamma interferon (MIG) while another set of kits was used to detect 23 other 
cytokines: IL-1β, IL-1ra, IL-2, IL-2R, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), 
IL-13, IL-15, IL-17, TNF-α, IFN-α, IFN-γ, GM-CSF, MIP-1 α, MIP-1β, IP-10, Eotaxin, 
RANTES, MCP-1.  All samples were run in triplicate for each respective time point and 
followed manufacturer’s guidelines and averages were assessed.  Inter-assay variation 
was controlled by having all triplicates and time points for the subject on the same assay 
plate (account for intra-assay variation), analyzed with a Luminex 200 (Luminex 
Corporation, Austin, TX).  Quality controls were added to each plate along with serum 
matrix for each well following the cytokine multiplex manufacturer’s instructions.  
Cytokine standards were made of increasing concentrations: 3.2, 16, 80, 400, 2000 
pg/ml.  
Statistical Analysis.  For analyses, difference scores were first calculated for each athlete 
and for each variable as; 1) Pre-camp minus Summer, and 2) Post-camp minus Summer.  
These calculated difference scores were subsequently converted to percent changes from 
Summer, then analyzed via one sample t-tests (α = 0.05) to determine if the percent 
changes within group were significantly different from zero.  Percent change differences 
between the DHA and Placebo groups were determined by independent t-tests at Pre-
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camp and Post-camp.  Independent t-tests were used to determine if there was a 
difference between groups’ baseline values at Summer. 
Results 
The percent changes from Summer and the average values for the cytokines 
detected are listed in Table 2.  Only data for Eotaxin, IL-6, IL-8, IL-17, RANTES, MCP-
1, IFN-γ, and TNF-alpha could be used, due to low detection of the other cytokines 
analyzed.  Inter-assay and intra-assay percent coefficient of variation for these cytokines 
are as follows (inter-assay, intra-assay): Eotaxin (28%, 20%), IL-6 (39%, 27%), IL-8 
(23%, 24%), IL-17 (30%, 22%), RANTES (33%, 14%), MCP-1 (30%, 21%), IFN-γ 
(31%, 22%), and TNF-alpha (25%, 19%). Comparison of similar assay kits using 
Luminex-based bead analysis have shown that with multiple bead analytes per well (13 
or more), replicate variation coefficients ranged from 18-44% for many analytes, as well 
as at least three analytes were undetectable in serum samples (214).  There were no 
differences detected in the initial cytokine concentrations between the DHA and Placebo 
groups at Summer (Table 2). 
Percent change from Summer increased at Pre-camp and Post-camp for all 
cytokines measured in the Placebo group, but reached statistical significance only for 
Eotaxin, MCP-1, and RANTES (Figures 7, 9, 10).  The increase in the DHA group for 
IFN-γ reached significance at Post-camp, and for RANTES at both Pre-camp and Post-
camp (Figures 8 and 10).   
By comparison, the Placebo group exhibited a significantly higher percent 
change in Eotaxin than the DHA group at Pre-camp (P<0.05) (Fig. 7). In addition, the 
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percent change in MCP-1 concentrations were higher at Pre-camp (P<0.05) and Post-
camp (P<0.05) in the Placebo group compared with the DHA group (Fig. 9).  Overall, 
there was a clear trend of a blunting effect in the DHA group as RANTES percent 
change increased by 54.0% and 48.6% compared to placebo’s 117.1% and 97.0%, 
respectively (Table 2 and Fig. 10).  Though statistical significance was not met for each 
analyte, the percent change of cytokine concentrations in the Placebo were greater by 1.7 
to 14.0 fold at Pre-camp as well as 1.9 to 8.9 fold at Post-camp, compared to the DHA 
group. 
 There were no treatment effects detected for percent neutrophils, percent 
lymphocytes, or percent monocytes.  The percent change of white blood cells was 
significantly elevated at Pre-camp by 12.3% in the DHA group, compared to 6.8% in the 
Placebo group.  Post-camp percent white blood cells were noted to have significant 
decreases in both DHA and Placebo group from Summer (11.1% and 11.9%, 
respectively). 
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Pre-Camp Post-Camp
Eotaxin
DHA 55.4 ± 5.0 58.7 ± 5.7 55.8 ± 4.5 7 ± 6 8 ± 8
Placebo 41.0 ± 6.3 53.7 ± 7.4 50.3 ± 6.6 57 ± 24 *† 44 ± 16 *
IFN-γ
DHA 49.3 ± 16.0 39.1 ± 12.2 51.0 ± 13.1 29 ± 25 71 ± 27 *
Placebo 36.7 ± 12.2 68.6 ± 29.0 69.5 ± 24.0 372 ± 270 307 ± 217
IL-6
DHA 39.5 ± 15.5 26.2 ± 9.9 23.6 ± 7.6  130 ± 83 112 ± 64
Placebo 27.0 ± 8.7 28.9 ± 11.7 32.0 ± 10.3 219 ± 171 217 ± 134
IL-8
DHA 27.7 ± 7.1 19.9 ± 4.1 21.7 ± 4.2 20 ± 21 70 ± 52
Placebo 29.5 ± 11.1 40.3 ± 15.0 38.2 ± 12.9 136 ± 72 135 ± 66
IL-17
DHA 21.8 ± 7.0 13.2 ± 3.5 14.6 ± 4.2 18 ± 21 121 ± 108
Placebo 33.9 ± 15.6 52.9 ± 26.5 42.2 ± 16.2 252 ± 148 227 ± 132
MCP-1
DHA 262.3 ± 30.8 291.2 ± 32.0 239.0 ± 13.7 23 ± 11.43 5 ± 8
Placebo 190.7 ± 17.6 300.9 ± 24.8 239.1 ± 16.4 74 ± 18 *† 40 ± 13 *†
RANTES
DHA 3247.0 ± 444.4 3614.6 ± 392.0 3599.9 ± 436.4 54 ± 26 * 49 ± 23 *
Placebo 3069.7 ± 556.3 4503.8 ± 500.0 4102.3 ± 499.4 117 ± 34 * 97 ± 36 *
TNF-α
DHA 7.7 ± 1.2 7.4 ± 0.8 7.8 ± 0.8 4 ± 6 15 ± 10
Placebo 7.1 ± 1.9 8.0 ± 1.7 9.2 ± 3.0 38 ± 23 41 ± 21
Summer Pre-Camp Post-Camp
Cytokine Placebo N=21, DHA N=22; except for RANTES Placebo N=20.  Percent Change from Summer calculated from 
individual scores.  Time Point Cytokine - (pg/ml ± SEM).   * denotes P<0.05 % percent change from Summer; † denotes 
P<0.05 percent change difference between DHA and Placebo.
TABLE 2. Immune and inflammatory markers
Percent Change from SummerTime Point
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Figure 6. Study consort diagram. 
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Figure 7. Change serum Eotaxin concentration. * Placebo Pre-camp 
P=0.030; Post-camp P=0.015. † DHA vs Placebo Pre-camp P=0.049  
Placebo (N=21), DHA (N=22). 
 
 
 
 
 
 
Figure 8. Change serum Interferon-gamma concentration. * DHA Post-
camp P=0.015. Placebo (N=21), DHA (N=22). 
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Figure 9. Change serum MCP-1 concentration. * Placebo Pre-camp 
P<0.001; Post-camp P=0.005. † DHA vs Placebo Pre-camp P=0.019; 
Post-camp P=0.016. Placebo (N=21), DHA (N=22). 
 
 
 
 
 
 
Figure 10. Change serum RANTES concentration. * DHA and Placebo 
Pre-camp and Post-camp P<0.05. Placebo (N=20), DHA (N=22). 
 
 
Discussion 
  This is the first study to examine the possible anti-inflammatory effects of 2 
g•day-1 algal DHA in Division I football athletes during a period of intense training.  
Results indicate that athletes are more susceptible to higher elevations in inflammatory 
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cytokine markers during preseason camp, which is likely related to this increased 
workload.  In comparison to cytokine concentrations measured in healthy adults ≥ 18 
years-old (108), our study had lower baseline values for IFN- γ, RANTES, and Eotaxin 
while MCP-1 concentrations in both groups were at least 4.6 times greater.  This 
difference in baseline could be due to differences in training experience and training 
status.  Our subjects’ inflammatory baseline values may be explained by previous 
training or stimulus, compared to healthy adults that may not undergo the same amount 
or type of training experienced by an athlete.  It should be noted that the healthy adult 
study was comparing age effects on cytokine concentrations; the ≥ 18 years-old group 
was comprised of 9 males and 26 females and had a median age of 36 years, with 
minimum and maximum ages at 21 and 86, respectively (108).  A population with a higher 
median age has the potential to have age-related, chronic low-grade inflammation which 
could create higher baseline cytokine concentrations than those in our study population 
(22). 
Eotaxin and MCP-1 significantly increased in the placebo group while the anti-
inflammatory effects of DHA were demonstrated by maintaining concentrations similar 
to Summer baseline (Fig. 7 and 9). The percent change in both cytokines was lower in 
the DHA group than in the Placebo group, but only MCP-1 was significantly lower at 
Post-camp compared to the Placebo group.   Elevated MCP-1 has been associated with 
the formation of atherosclerotic lesions; the reduction in the DHA group may be 
cardioprotective (218).  Eotaxin reductions have been associated with exercise training, 
while elevations in eotaxin have been strongly correlated with obesity and/or allergen-
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induced asthma (39). For other cytokine markers, a trend existed in which DHA appeared 
to attenuate cytokine concentrations.   
Chronic high-intensity training, as occurs in football, could lead to a prolonged 
initial inflammation phase (180, 182).  When overtraining occurs, athletes have the potential 
to remain in the initial inflammation phase, and are slow to progress into the resolution 
phase (121, 180, 181).  If numerous cytokine concentrations remain elevated, it may indicate 
that the body is in a state of repair and has not yet recovered, or that the body is under 
constant stress (not yet reaching homeostasis or baseline concentrations) (109, 180).  In our 
study, the increased workload from Summer baseline through Post-camp has the 
potential elevate pro-inflammatory cytokine concentrations. 
IL-17 can induce expressions of IL-6 and RANTES, directly or indirectly, 
through vascular endothelial cells and migrating fibroblasts (185).  Though statistical 
significance was not met, the percent change of IL-17 from Summer to Pre-camp for the 
DHA group was minimal compared to Placebo group (Table 2).  In comparison, a two-
hour exercise bout at 60% VO2max on a cycle ergometer has been shown to elicit 
significant increases in both IL-6 and TNF-alpha (19).  Similarly, in our study, the 
increased workload from summer to preseason camp demonstrated a trend of higher 
concentrations of TNF-α (more pro-inflammatory) for the Placebo group compared to 
the DHA group (though not significant).  Additionally, it should be noted that blood 
samples were collected at least 12 hours following training sessions -- this extended 
elevation post-exercise represents prolonged inflammation.  Studies on acute moderate 
aerobic bouts, as well as acute moderate resistance exercise bouts, usually see reductions 
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in the elevated cytokine concentrations such as IL-6 and TNF-alpha within three to six 
hours (99). 
 Other researchers note that chronic elevations of IL-6, and C-reactive protein 
could be a feedback result of increased systemic TNF-α production (147, 180, 184).  During 
the initiation phase, IL-6 is pro-inflammatory, as it stimulates production of TNF-α; 
while in the resolution phase, it inhibits the endotoxin-induced TNF-α production (57).  
The placebo group had a steady increase in IL-6 over the course of study, almost 
doubling the percent change of the DHA group (Table 2).  IL-6 is known as a myokine 
and has been reported to affect the sensation of fatigue (increased IL-6 correlating with 
increased fatigue) during and following exercise. The more contractions or time under 
tension of the exercised muscle correlates with increased expressions of IL-6 (100).  The 
metabolic status of the exercised muscle can determine the effectiveness of IL-6 being 
released (57, 156).  Elevations in IL-6 are thought to be the result of the influx of calcium 
ions from the sarcoplasmic reticulum (55, 100). Glycogen content of the exercised muscle 
determines the potency at which IL-6 influences lipolysis and lipid oxidation (55, 156).  
Additional factors which can influence IL-6 expression include exercise intensity, 
duration, and mass of muscle recruited.  This response following exercise has been 
shown even without muscle damage. (156) 
Researchers have demonstrated that exercised-trained (regularly aerobic and 
resistance trained) men who ingested 2.2 g•day-1 EPA and 2.2 g•day-1 DHA had lower 
resting TNF-α and C-reactive protein concentrations following six weeks of 
supplementation.  Conversely, the supplementation was not effective in moderating 
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similar cytokine concentrations during low intensity exercise training. (16)  Those who 
undertake excessive exercise or long durational exercise (e.g. marathon or triathlon) 
might benefit from the anti-inflammatory effects of DHA (16, 17).   Since training and 
competition in American football has higher intensities and varying volume compared to 
a recreational population, and potentially different workloads from an endurance-trained 
population, additional research into appropriate dosages of DHA for football athletes is 
needed. 
There are confounding factors to consider in this study and future measurements 
of inflammation in football athletes. In a 2000 review (151) of cytokines and exercise, it 
was noted that the magnitude and variation of cytokine concentrations can be affected, 
not only by duration of exercise, but also the specificity and sensitivity of assay kits 
used.  The accumulation of work performed by the athletes during these training periods, 
as well as the large multiplex cytokine kit could increase variation.  All samples were 
run in triplicate and all wells per subject and time point were on the same plate.  Also, 
the larger stature of football athletes could impact results.  Many non-exercise-related 
studies have used subjects of lesser weight, with dosages of EPA and DHA similar to the 
2 g•day-1 used in the present study (54, 115, 163).  One possibility is that, due to their large 
body mass, football players could metabolize DHA to a greater extent than someone of a 
smaller body mass.  Also, diet can affect fatty acid oxidation and liberation during 
exercise (84). Validation of DHA incorporation, through analysis of erythrocyte 
phospholipid membrane fatty acid composition, marked significant increases of DHA in 
the DHA group (142).  However, it is possible that the erythrocyte uptake of DHA might 
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be limited (119).  Thus, excess ingested DHA (accounted for in an adipose tissue biopsy) 
might not be accounted for in the erythrocyte composition of a larger sized individual.  
Adipose tissue lipid storage has been shown to have sizable capacity for omega-3 
PUFAs (111).  In lieu of an adipose biopsy to compliment an erythrocyte sample, 
additional data (142) found significant elevations in plasma DHA free fatty acid 
composition from Summer baseline and continuing throughout Post-camp (Pre-camp 
2.32% and Post-camp 3.30% increases).   
The impact of intensive preseason football training is widespread, with over 640 
university teams comprised of 70 to 125 players per team competing annually (1).  The 
preliminary findings of this study may be of benefit to sport dieticians, athletic trainers, 
and team physicians who administer DHA for prolonged inflammation or post-
concussion therapy.   Eotaxin and MCP-1 were blunted with DHA supplementation 
during the strenuous preseason football camp.  Future studies are needed to explore the 
possibility of maximal dosing and adequate fueling during heavy exertional training, to 
ensure DHA is being used, not as a fuel, but as a membrane component and/or 
intracellular eicosanoid communicator.  These follow-up studies might shed light on 
other pro and anti-inflammatory cytokines that could be impacted by dietary DHA and 
proper exercise. 
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CHAPTER III 
EFFECTS OF DOCOSAHEXAENOIC ACID ON LIPID PROFILES 
IN DIVISION I FOOTBALL PLAYERS DURING HEAVY 
PHYSICAL ACTIVITY 
 
Introduction 
In the United States, 38% of all deaths are attributed to cardiovascular disease 
(101). Concern over the cardiovascular health of American football players has prompted 
much research regarding cardiovascular risk factors among this athletic population (12, 24, 
64, 70, 95, 112, 200). The large body size of football athletes has raised questions about an 
associated increase in the incidence of cardiovascular disease (CVD) compared to an 
aged-matched population (200).   A body mass index (BMI) > 28.4 kg/m2 is correlated 
with a higher incidence of CVD, regardless of the presence of extra lean mass (12).    The 
combination of increased in-game playtime and a BMI of ≥ 30 kg/m2, predicted a two-
fold increase in CVD mortality (12).  The statistics are particularly profound among 
linemen.  When compared to the general population, retired NFL linemen (both 
offensive and defensive) were 52% more likely to die from heart disease, in contrast to 
46% lesser CVD mortality for retired non-lineman players (11).    In order to 
accommodate rule changes over the past three decades, which have restricted blocking, 
player size and body mass has increased (95, 112).  Consequently, case 2 obesity was 
indicated for over a quarter of the players in the NFL in 2003 (70).  Limitations have been 
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noted when using BMI as an identifier of obesity among football players.  Lambert et. al. 
(116) reported clear delineations of college football player body composition comparing 
BMI and measurement techniques such as skin fold and DXA; BMI measures indicated 
obese measures for linemen, while skin fold and DXA did not indicate obese status.   
The latter measures accounted for the muscle mass of the athletes when calculating 
percent body fat and total body composition.  Of all the team positions, NFL linemen 
have been reported to have the highest total cholesterol and triglyceride concentrations 
and low density lipoprotein (LDL) cholesterol concentrations, while having the lowest 
high-density lipoprotein (HDL) cholesterol concentrations (64). 
In college, consumption of larger amounts of food to increase body mass, 
especially as traditional American football players or redshirt freshman,(107) could affect 
body composition (increased percent body fat), which in turn could be correlated with 
changes in lipid profiles.  One of the times when food consumption is increased is during 
preseason camp.  The intensity of preseason training requires increased fueling.  
Questions still exist on how high-level athlete lipid profiles respond to dietary 
interventions when combined with heavy physical training.  
Independent risk factors for the development of CVD include: elevated total 
cholesterol and LDL cholesterol, triacylglycerols and low HDL cholesterol, and total and 
small dense LDL particles (115, 129, 167).  The preponderance of evidence for omega-3 
polyunsaturated fatty acids suggests that there are many cardiovascular protective effects 
of supplementing with DHA.  These include anti-atherosclerotic effects as well as 
improved circulating lipid and lipoprotein composition in response to exercise, such as 
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lowered LDL-C and increased HDL-C (103, 130, 131, 133, 176).  Research in sedentary subjects 
has shown triglyceride and total cholesterol reductions with 1 g•day-1 algal DHA while 
increasing HDL concentrations by 5.5% (169).  Additionally, supplementing with 4 g•day-
1 DHA for 6 weeks resulted in a 20% decrease in triglycerides, a 29% increase in HDL2 
cholesterol and an 8% increase in LDL cholesterol in mild hyperlipidemic men (133). At a 
dosage of 1.52 g•day-1 DHA, Maki et. al. (122) demonstrated a reduction in LDL 
cholesterol carried by small dense particles.   Notably, 0.7 g•day-1 DHA elevated LDL 
cholesterol by 7%, although particle size change was not measured (191).  In a study of 
hypertriglyceridemic men, Kelley et al. (54) found that supplementation with DHA 
lowered fasting and postprandial triacylglycerol concentrations by 25-30%.  Moreover, 
research has shown that the n-3 index was increased while lowering the remnant-like 
particle cholesterol (RLP-C) following the DHA supplementation for 90 days (103).  RLP-
C concentrations, especially those triglyceride-rich, have been associated with increased 
atherogenic risk (103, 104).  
The n-3 index is comprised of the sum total of EPA and DHA as a percentage of 
the total fatty acid content in red blood cell membranes (72).  Factors associated with 
cardiovascular risk include a decreased ratio of plasma EPA to AA, increased plasma 
concentrations of remnant-like particle cholesterol (RLP-C), and a decreased n-3 index 
(erythrocyte EPA + DHA content) in the red blood cell membranes (103).    An n-3 index 
of < 4% was associated with a 10 times greater risk of death from coronary heart disease, 
compared to an n-3 index of > 8% (41). 
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Cardiovascular risk is decreased when individuals engage in habitual exercise 
(105), which is associated with decreased LDL-C and triglycerides, as well as increased 
HDL-C.  Studies using energy expenditures ranging from 1200-2200 kcals per week led 
to reductions in triglycerides of 5 to 38 mg/dL and increased HDL-C concentrations of 2 
to 8 mg/dL (51).   Acute exercise has been demonstrated to reduce triglycerides by 14-
50%, while following a regular exercise regime has been reported to have reductions of 
4-37% (51).  Acute aerobic exercise increases HDL3-C content while decreasing 
triglyceride and phospholipid content (61).  The effects of resistance training on altering 
lipids and lipoproteins have been mixed (105, 106, 110, 179, 193).  LDL-C reductions, without 
alterations in triglyceride or HDL-C, have been noted with resistance training (18).  In 
contrast, other resistance exercise training regimes have shown no change in LDL-C, 
while HDL-C increased and triglycerides decreased (189). Several studies have shown 
there to be no change in cholesterol except when associated with a decrease in percent 
bodyfat (5, 43, 188).  LPL activity has been reported to be elevated after a variety of acute 
exercise training regimes (188).  With exercise, LDL particles become richer in 
cholesterol and increase in size (85).  Exercise reduces LDL mass and increases HDL2 
mass (210).  It has been suggested that LPL activity following training is responsible for 
the transfer of LDL mass to smaller HDL particles, leading to the larger mass of HDL 
(105, 113).   
To the author’s knowledge, there has been no research published to date 
examining possible alterations of lipid profiles with supplementation of algal DHA 
during heavy physical activity in Division I football athletes.   The present study aimed 
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to determine the effects of DHA on lipid and lipoprotein concentration profiles during a 
heavy physical training, starting during voluntary summer training camp through 
mandatory preseason preparatory training camp.  With evidence that 0.7 g•day-1  can 
affect lipid profiles and the fact that the subject population for this study was larger in 
body mass,  the dosage of 2 g•day-1 algal DHA was explored to investigate if American 
collegiate football players’ lipid profiles would be altered resulting in increased HDL 
and lower LDL. 
Methods 
Participants.  The study was approved by the university Institutional Review Board for 
Research with Human Subjects.  Sixty student-athlete NCAA Division I football players 
volunteered for participation.  Volunteers were evaluated and excluded on the basis of 
the use of medications known to alter blood lipids and lipoproteins.  Moreover, prior 
consumption of more than two servings of fish per week, or supplementation of omega-3 
fatty acids and/or fish oil were also deemed reason for exclusion.  Additionally, if a 
player became injured or received a concussion during the study, they were excluded.  A 
consortium diagram outlines exclusion throughout the study to final subject numbers 
used for analysis (Fig. 11).  Subject distribution and demographics are reported in Table 
3. 
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Figure 11. Study consort diagram for lipids. 
 
Study Design. The study was double-blinded with subjects randomly assigned into either 
2 g•day-1 of algal DHA oil (n=28) or 2 g•day-1 corn oil placebo (n=32) (both provided by 
DSM, Columbia, MD).  Measurement and sample collection time points were 
established at voluntary summer training camp (Summer), beginning preseason training 
camp (Pre-camp) (30 days after Summer), and post preseason training camp (Post-camp) 
(24 days after Pre-camp). At each time point, body weight and a 24-hour dietary recall 
were collected by a registered dietician to ensure accuracy (Table 3).  Athletic 
department staff members observed consumption of capsules following training during 
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Pre-camp on week days, as well as distributing capsule envelopes to the subject for the 
weekends, with instructions to return empty envelopes on the subsequent weekday.  
During voluntary summer training camp, limited training table snacks were available, 
leaving the athlete responsible for deciding and supplying the majority of his diet.  
Preseason training camp dinners and training table snacks (post workout) were provided 
in accordance with NCAA guidelines. During mandatory preseason training camp, 
research staff distributed supplements at team dinners and athletes consumed 
supplements in their presence.   For the duration of the study, subjects were asked to 
refrain from consuming more than one meal per week consisting of fish.  
Strength and Conditioning Training. During voluntary summer training, one to two 
anaerobic conditioning sessions and one to three voluntary strength training sessions per 
week were performed by the football athletes.  On conditioning days, conditioning 
sessions would last 45 minutes followed by an hour of strength training.  Training during 
mandatory preseason training camp increased in both frequency and volume of strength 
training and conditioning (agility drills) sessions, as well as the inclusion of sport-
specific practices, two-a-day style practice/training, as allowed by the NCAA.   
Blood Analysis. Resting blood samples were collected in two, 8.5 mL vacutainers (BD 
SSTTM w/ gel 367988) from the antecubital vein, in a seated position, after an overnight 
fast (≥ eight hour, water allowed ad libitum), and before any exercise training session.  
Following sample collection, samples were immediately plunged into ice and allowed to 
clot for thirty minutes, followed by refrigerated centrifugation for thirty minutes (2,000 x 
g) for separation of serum. One mL aliquot of sample was sent to St. Joseph’s Hospital 
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(Bryan, TX) for analysis cholesterol and triglyceride concentrations through a 
combination of enzymatic assay and spectrophotometry.  Another aliquot of serum was 
immediately transported (over ice) to SpectraCell Laboratories, Inc. (Houston, TX) for 
lipoprotein density and particle size analysis.  The lipoprotein subgroup particle number 
analysis method was employed to complete a Lipoprotein Particle Profile™ 
(199).   Separation of lipoprotein particles were conducted through a continuous gradient 
generated by analytical ultracentrifugation (patent pending method). A separation 
gradient over a range of d = 1.000 - 1.300 g·cm-3 was established through application of 
a fluorescent dye onto lipoprotein particles.  HPLC-type flowmetry technique was 
utilized for quantifying lipoprotein particles and normalized to a standard cholesterol 
scale via a proprietary algorithm.  List of particles classified include: HDL (HDL 
number) and buoyant high-density lipoprotein2b (HDL2b number), remnant lipoprotein 
(RLP number), VLDL (VLDL number), IDL (IDL number), LDL (LDL number), dense 
low-density lipoprotein3 (LDL3 number), dense low-density lipoprotein4 (LDL4 
number).  A multiple Gaussian fit/integration routine was conducted for specific 
densities of lipoprotein subgroups (e.g. LDL mean lipoprotein density).  Standards have 
been reported at 2-3% coefficient of variation for this analytical technique. 
Statistical Analysis. Percent change from Summer to Pre-Camp and Summer to Post-
Camp was calculated and developed a basis for statistical significance testing.  
Independent t-tests were utilized for baseline comparisons of the Placebo and DHA 
group lipoproteins.  The use of one sample t-tests (α = 0.05) on the percent change for 
the treatment groups at Pre-camp and Post-camp were employed to identify effects of 
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treatment and training from Summer baseline. Independent t-tests were used to 
determine if there difference between groups’ baseline values at Summer.  For the 24-
hour recall, independent t-tests were used to determine differences between groups at 
each respective time point as well as dependent t-tests where used to determine within 
group difference over time.  The use of an α = 0.0125 was used for the 24-hour recall 
data (original α =.05 divided by four) to account for the multiple t-tests performed per 
time point. 
Results 
 Table 3 lists the dietary composition of the subjects throughout the study. 
Notably, total calories and carbohydrates significantly increased (P<0.0125) in both the 
DHA and the Placebo groups during preseason camp training, while total fat was 
reduced at both Pre-camp and Post-camp. Protein stayed relatively the same throughout 
the study in the DHA group and was only reduced at Post-camp in the Placebo group.  
There was no difference detected in caloric or macronutrient intake between groups. 
Table 4 reflects lipoprotein concentrations.  Notably, both groups had increased 
percent change in HDL2b-C and HDL2a-C at Pre-camp.  Percent change HDL3-C was 
only decreased in the DHA group at Post-camp.  The DHA group also had elevations in 
LDL3-C (Pre-camp) and LDL4-C (Post-camp).  Additionally, the DHA group had 
significantly (P < 0.05) higher IDL-C at Summer compared to the Placebo group.  RLP-
C increased from Summer baseline only in the Placebo group at Pre-camp, while the 
DHA remained relatively unchanged.  RLP number did not change throughout the study 
 65 
 
and there was no difference between groups. There was no difference in lipoprotein-a 
(LP(a)) concentrations for either group throughout the study. 
Table 5 provides particle numbers and densities for each time point.  LDL 
density decreased in the Placebo at Post-camp, along with decreased HDL density at 
Pre-camp.  The DHA group had no change in LDL density, while having a decreased 
HDL density at both Pre-camp and Post-camp. Percent change VLDL number was 
significantly (P < 0.05) increased at Pre-camp and Post-camp in the Placebo group, 
compared to Summer.   
Figure 12 shows the variance of total cholesterol concentration during Pre-camp 
and Post-camp, though no difference was detected with time or by group.  There was a 
significant decrease in Post-camp triglyceride concentration in the DHA group, while the 
Placebo group increased at Pre-camp (Fig. 13).  LDL concentration tended to be higher 
(significance not met) than Summer, at both time points in the DHA group (Fig. 14). The 
Placebo group had a significant decrease in LDL concentration at Pre-camp.  Percent 
change of HDL concentration did not significantly change in either group (Fig. 15). 
DHA group had a significant percent change decrease in insulin at Post-camp 
(Table 6).  There was no difference between DHA and Placebo groups C-reactive 
protein concentrations.  Both the groups demonstrated a percent change increase at Post-
camp.  Homocysteine concentrations were only altered in the DHA group, where Pre-
camp percent change was significantly higher than Summer. 
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TABLE 3. Subject demographics and nutritional intake
Age (years) 20 ± 0.11 - -
Body Mass (kg)
DHA 235.67 ± 8.80 236.50 ± 8.66 236.63 ± 8.44
Placebo 226.56 ± 7.96 227.96 ± 7.78 228.96 ± 8.04
Calories (kcal/d)
DHA 3527.22 ± 213.92a 3050.61 ± 195.95a 4526.43 ± 271.88b
Placebo 3916.25 ± 344.48a 3200.31 ± 145.39a 4412.86 ± 252.63b
Carbohydrate (g/d)
DHA 351.91 ± 24.04a 334.13 ± 27.13a 664.30 ± 37.03b
Placebo 398.39 ± 36.77a 352.78 ± 19.42a 657.39 ± 36.49b
Fat (g/d)
DHA 154.78 ± 9.30a 114.52 ± 8.17b 132.00 ± 11.63ab
Placebo 174.39 ± 16.75a 120.31 ± 5.93b 126.50 ± 10.27c
     MUFA (g/d)
DHA 21.52 ± 3.21a 9.61 ± 1.43b 17.83 ± 2.92ab
Placebo 25.11 ± 2.63a 11.94 ± 1.17b 16.79 ± 2.50c
     PUFA (g/d)
DHA 7.61 ± 1.31a 2.35 ± 0.44b 8.04 ± 1.29a
Placebo 7.89 ± 1.56a 3.39 ± 0.46a 5.89 ± 0.9b
     Saturated (g/d)
DHA 61.09 ± 4.49a 45.43 ± 3.22ab 46.39 ± 4.48b
Placebo 68.57 ± 6.94a 46.69 ± 2.28b 44.61 ± 4.53c
Protein (g/d)
DHA 179.78 ± 12.96a 170.61 ± 9.75a 176.96 ± 12a
Placebo 191.46 ± 17.59a 177.82 ± 7.75a 168.89 ± 11.64b
Summer Pre-camp Post-camp
24-hour recall analyzed by Nutribase 8.0 software; different letter superscript denotes P<0.0125 different from other superscript letter (dependent t-test) 
within group. DHA (N=23), Placebo (N=28), Represented as mean ± SEM.
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TABLE 4.  Lipid and lipoprotein concentrations
Total Cholesterol
DHA 174.45 ± 6.85 182.05 ± 7.85 172.45 ± 6.97
Placebo 174.92 ± 5.61 172.48 ± 5.97 175.36 ± 6.15
Triglycerides
DHA 115.32 ± 11.11 110.59 ± 9.87 85.18 ± 8.06*
Placebo 100.16 ± 9.88 128.16 ± 11.11*† 95.20 ± 9.55†
LDL-C
DHA 103.41 ± 6.38 109.55 ± 6.22 108.14 ± 6.39
Placebo 100.41 ± 4.13 93.76 ± 4.63*† 105.36 ± 4.42
LDL3-C
DHA 16.25 ± 1.25 20.35 ± 1.67* 17.86 ± 1.59
Placebo 15.79 ± 1.11 16.76 ± 1.36 14.94 ± 1.15
LDL4-C
DHA 5.63 ± 0.28 6.07 ± 0.30 6.22 ± 0.35*
Placebo 5.57 ± 0.31 5.85 ± 0.39 5.53 ± 0.28
IDL-C
DHA 19.71 ± 1.50 ‡ 18.02 ± 1.18 20.15 ± 1.66
Placebo 15.37 ± 1.66 17.75 ± 1.66 18.88 ± 1.87
RLP-C
DHA 22.42 ± 1.69 20.82 ± 1.29 22.93 ± 1.83
Placebo 18.10 ± 1.76 20.90 ± 1.92* 21.81 ± 2.18
VLDL-C
DHA 12.60 ± 1.38 13.03 ± 1.38 12.76 ± 1.34
Placebo 12.04 ± 1.55 15.33 ± 2.10 14.36 ± 2.36
HDL-C
DHA 47.86 ± 2.01 50.41 ± 2.78 47.18 ± 2.01
Placebo 54.48 ± 4.18 53.32 ± 4.76 50.92 ± 3.04
HDL2b-C
DHA 16.67 ± 1.28 19.13 ± 1.47* 16.13 ± 1.30
Placebo 17.97 ± 2.19 20.45 ± 2.64* 16.76 ± 1.84
HDL2a-C
DHA 6.81 ± 0.59 7.98 ± 0.73* 5.31 ± 0.34*
Placebo 6.50 ± 0.54 8.61 ± 0.73* 6.03 ± 0.46
HDL3-C
DHA 26.91 ± 1.03 25.63 ± 0.00 23.57 ± 0.96*
Placebo 26.58 ± 0.82 25.76 ± 0.76 25.54 ± 0.94
TC: HDL
DHA 3.10 ± 0.13 3.11 ± 0.13 3.54 ± 0.19*
Placebo 2.88 ± 0.15 2.98 ± 0.17 3.17 ± 0.16*
Lp(a)
DHA 38.67 ± 7.23 37.81 ± 6.15 36.09 ± 6.08
Placebo 43.58 ± 8.41 42.34 ± 7.41 43.71 ± 7.02
Summer Pre-camp Post-camp
Represented as mean (mg/dL) ± SEM; * denotes P <0.05 based from individual percent change from Summer averaged. † denotes P<0.05 percent change 
between DHA and Placebo; ‡ denotes p <0.05 DHA different from Placebo absolute values at Summer.
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TABLE 5. Lipid and lipoprotein particle numbers and densities
LDL# 
DHA 628.09 ± 35.40 676.61 ± 37.45 674.96 ± 41.72
Placebo 552.32 ± 28.41 592.46 ± 36.08 597.89 ± 36.97
LDL3# 
DHA 154.26 ± 11.84 193.30 ± 15.89* 169.57 ± 15.12
Placebo 146.32 ± 11.70 159.07 ± 12.90 141.71 ± 10.93
LDL4# 
DHA 69.61 ± 3.51 75.17 ± 3.67 76.83 ± 4.35*
Placebo 68.86 ± 3.86 72.50 ± 4.82 68.36 ± 3.49
LDL Density
DHA 1.030000 ± 0.000199 1.030565 ± 0.000294 1.030174 ± 0.000241
Placebo 1.030643 ± 0.000190 1.030500 ± 0.000184 1.030036 ± 0.000196*
RLP# 
DHA 95.22 ± 7.15 88.35 ± 5.47 97.26 ± 7.78
Placebo 77.93 ± 7.46 88.71 ± 8.18 92.68 ± 9.29
VLDL# 
DHA 48.39 ± 5.32 49.96 ± 5.28 48.91 ± 5.15
Placebo 46.18 ± 5.92 58.57 ± 8.05* 55.11 ± 9.03*
HDL# 
DHA 9738.09 ± 396.61 9824.87 ± 428.27 8556.74 ± 321.84*
Placebo 9718.61 ± 381.90 10091.18 ± 459.15 9246.32 ± 362.14
HDL2b# 
DHA 1496.17 ± 114.69 1717.96 ± 131.67* 1448.91 ± 116.58
Placebo 1613.32 ± 197.01 1836.82 ± 237.59 1503.71 ± 165.05
HDL Density
DHA 1.099522 ± 0.001126 1.096522 ± 0.000802* 1.097174 ± 0.001064*
Placebo 1.098750 ± 0.001301 1.096000 ± 0.000984* 1.098679 ± 0.001264
Summer Pre-camp Post-camp
Represented as mean (nmol/L) ± SEM; * denotes P <0.05  based from individual percent change from Summer averaged.
TABLE 6. C-reactive protein, insulin, homocysteine
C-Reactive Protein (mg/dL)
DHA 0.16 ± 0.04 0.11 ± 0.04 0.23 ± 0.04*
Placebo 0.13 ± 0.04 0.06 ± 0.01 0.18 ± 0.04*
Insulin (uIU/mL)
DHA 10.98 ± 1.65 7.80 ± 0.94 6.54 ± 0.53*
Placebo 11.38 ± 1.28 10.38 ± 1.48 8.01 ± 0.65
Homocysteine (umol/L)
DHA 9.05 ± 0.77 10.79 ± 1.88* 9.46 ± 1.46
Placebo 10.69 ± 2.41 10.76 ± 2.45 10.49 ± 2.38
Summer Pre-camp Post-camp
Represented as mean  ± SEM; * denotes P <0.05  based from individual percent change from Summer averaged.
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Figure 12. Percent change total cholesterol. Pre-camp represents the change from 
summer baseline to Pre-camp time point; and Post-camp represents the change from 
summer baseline to Post-camp time point.  DHA (N=23), Placebo (N=28). 
 
 
 
 
 
 
Figure 13. Percent change triglycerides. Pre-camp represents the change from 
summer baseline to Pre-camp time point; and Post-camp represents the change from 
summer baseline to Post-camp time point. * denotes P<0.05 significance from 
Summer. † denotes P<0.05 from Placebo at respective time point. DHA (N=23), 
Placebo (N=28). 
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Figure 14. Percent change LDL cholesterol concentration. Pre-camp represents the 
change from summer baseline to Pre-camp time point; and Post-camp represents the 
change from summer baseline to Post-camp time point. * denotes P<0.05 
significance from Summer. † denotes P<0.05 from Placebo at respective time point. 
DHA (N=23), Placebo (N=28). 
 
 
 
 
 
 
 
Figure 15. Percent change HDL cholesterol concentration. Pre-camp represents the 
change from summer baseline to Pre-camp time point; and Post-camp represents the 
change from summer baseline to Post-camp time point. DHA (N=23), Placebo 
(N=28). 
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Discussion 
Kirwan et. al (107) examined a similar cohort (American college football without 
dietary intervention) to the one in our study, over an 8-week training period.  The 
investigators reported an increase in total cholesterol and LDL-C following training; 
while subjects from our study had significant decreases percent change in LDL-C in the 
Placebo group (Pre-camp), but no significant change in the DHA group (Fig. 14).  
Additionally, the DHA group in our study exhibited increases in LDL3 particle number 
(Pre-camp) and LDL4 particle number (Post-camp).  Triglycerides were similarly 
reported as no change following Kirwan et. al.’s (107) study. Our Placebo group did have 
significant triglyceride elevation at Pre-camp but returned to similar Summer baseline 
concentrations at Post-camp.  The DHA group did not demonstrate a percent change in 
triglycerides from Summer baseline at Pre-camp, but did have a significant reduction 
from Summer baseline at Post-camp, which was also significantly different from 
Placebo at the same time point (Fig. 13). 
Triglycerides are transported throughout the body, primarily by chylomicrons 
and VLDL, to provide energy to specific muscle tissues.  During exercise, triglycerides 
are liberated to deliver free fatty acids to working muscles, as well as to provide energy 
for post-workout tissue repair.  Though not significant, the total amount of fat intake 
(g•day-1) at Pre-camp and Post-camp was lower than Summer (Table 3).  Hill et. al. (77) 
reported, when comparing isocaloric diets, that the diets higher in long-chain or 
medium-chain triglycerides or fish oil, resulted in altered concentrations of LDL, HDL, 
and triglyceride concentrations compared to diets lower in fat with no alterations 
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reported.  Following a standard strength and conditioning program and consuming a 
high-fat, high-calorie diet, redshirt freshman players had elevations in LDL and total 
cholesterol (+31.8 mg/dl and + 29.1 mg/dl, respectively), as well as increased total body 
fat (+1.4 kg) (107). 
In several studies using fish oil (majority EPA to DHA composition), subjects 
deemed normotriglycerolemic demonstrated a 25% reduction in serum triglycerides, and 
hypertriglycerolemic subjects had a 34% reduction (74).  This reduction in triglycerides is 
similar to our DHA group, which demonstrated a significant reduction at Post-camp 
(Fig. 13).  Notably, Mori et. al. (133) reported significant decreases in serum triglycerides 
with DHA supplementation, in mildly hyperlipidemic men.  The combination of DHA 
and increased training in our study resulted in decreased serum triglycerides at Post-
camp.  Besides triglycerides, cholesterol is the other molecule transported by 
lipoproteins.  Our study showed no difference in total cholesterol for either group (Fig. 
12). The lack of cholesterol alteration is similar to previous research using fish oil in 
both normotriglycerolemic and hypertriglycerolemic men (74) and exclusive DHA 
supplementation in hypertriglycerolemic men (133).  
Lipid particle numbers had mixed results over the course of this study for both 
groups.  VLDL particle number significantly increased at Pre-camp and Post-camp in the 
Placebo group, along with increased triglycerides at Pre-camp.  Increased VLDL particle 
number could be the result of increased energy demands due to training (106), as well as 
the reduction of total fat intake from Summer.  Other studies have demonstrated EPA 
supplementation reduces VLDL concentrations, while DHA supplementation does not 
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affect VLDL (130, 133).  During voluntary summer training, LDL3 particle number tended 
to be increased at Pre-camp in both groups (significant for the DHA group), while at 
Post-camp, the DHA group still displayed a higher total amount of LDL3 particle 
number following preseason training camp. The increase in LDL peak particle size has 
been related to increased aerobic exercise (215), which enhances cholesterol transport to 
phospholipid cell membranes.  Changes in LDL concentrations were only significantly 
decreased at Pre-camp in the Placebo group, though the DHA and the Placebo groups 
tended to have higher LDL concentrations at Post-camp (Fig. 14).  Similar to previous 
studies (107), HDL concentrations were unaffected (Fig. 15), though particle number was 
decreased in the DHA group following preseason training camp (Table 5). 
Mechanisms proposed for altering lipid profiles by omega-3s include improving 
vascular reactivity, altering inflammation status, and decreasing platelet aggregation (115).   
Harris (73) suggests the additional intake of omega-3 fatty acids could affect hepatic 
triglyceride metabolism through the attenuation of hormone-sensitive lipase, acetyl-CoA 
carboxylase FA synthase while enhancing mitochondrial and peroxisomal B-oxidation.  
Additionally, Park (148) demonstrated an increased chylomicron triglyceride clearance via 
increased LPL activity and smaller chylomicron particle sizes.  For the athletic 
population, this translates into a possible greater availability of energy which could lead 
to increased endurance or more efficient recovery. 
Our study also highlights lipid particle number and density fluctuations in 
football athletes from Summer through preseason camp training, in preparation for the 
season.  These fluctuations may be due to increased energy demands of training sessions 
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and sports practice, necessitating an increased need for cholesterol mobilization for 
cellular (skeletal muscle) membrane and structural repair.  Practitioners and dieticians 
who supplement athletes with DHA should consider adequate caloric and macronutrient 
needs in order to limit the possibility of the omega-3 fatty acid of being used as fuel in β-
oxidation.  Further investigation is needed to examine differing dosages of DHA, as well 
as diets with higher fat content, to determine if either factor mitigates lipid profile 
alterations during heavy physical activity. 
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CHAPTER IV 
CONCLUSIONS 
 
The primary purpose of this research was to document the effects of algal DHA, 
combined with intense physical training, on inflammatory and lipid responses associated 
with such training, in Division I football players.  The first study describes changes in 
inflammatory cytokines during intensive physical training with DHA supplementation in 
football athletes.  The second study describes lipid and lipoprotein responses during 
intensive physical training with DHA supplementation. From our current study, the 
knowledge of the incorporation of DHA into plasma and tissue in this power-dominated 
athletic population, coupled with the potential anti-inflammatory effects of DHA, could 
positively alter lipid profiles, immune functions, body composition, and inflammatory 
issues such as insulin resistance, or recovery from injuries (e.g. concussions); these 
beneficial effects remain to be demonstrated. 
  There are large numbers of athletes who train every day, in various sports, and 
at various levels.  In the U.S. alone, over 7 million high school athletes, over 450,000 
college athletes, and nearly 15,000 professional athletes compete each year (2, 90, 190).    
Though our study of DHA supplementation focused on Division I college football 
players, other athletes of different sports who participate in intense training regimes 
could benefit from DHA supplementation as well. Buckley et al.(23) found that 
supplementation with DHA-rich fish oil (6 g•day-1) improved cardiovascular function in 
elite Australian Rules football players, by means of lower heart rates at submaximal 
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exercise.  Even though reduced cardiovascular risk factors were seen with this type of 
supplementation, endurance performance and recovery were deemed uneffected in the 
athletes. (23)  Walser and Stebbins (203) reported the combination of 2 g•day-1 of DHA, plus 
3 g•day-1 of EPA improved stroke volume and cardiac output during low and moderate 
work-intensity exercise in recreationally-fit, healthy subjects, following 6 weeks of 
supplementation.  Moderate exercise with fish oil (1.6 g•day
-1 DHA) supplementation 
has also been linked to improved immune function and reduced cellular inflammation in 
sedentary individuals.  Following twelve weeks of supplementation and moderate 
aerobic exercise (3 sessions of walking for 45 minutes at 75% maximum heart rate), 
leukocyte function and cytokine production were altered to improve body composition, 
reduce cardiovascular risk, and lessen inflammation.(78)   
The anti-inflammatory and neuroprotective characteristics of DHA and exercise 
working in concert are especially important among the collegiate athletic population. 
Though researchers using animal models have demonstrated the neuroprotective effects 
of DHA on neural tissue following head-trauma (216), the ability of DHA to affect human 
neuropathies is not known (146).  Wu and colleagues (216)  reported that, not only does the 
combination of DHA and exercise complement each other to enhance brain development 
in rats (marked by elevated brain-derived neurotropic factor); but also following brain 
trauma in rodents, DHA provided a resistive effect to oxidative stress and promoted  
cognitive capacity and enhanced neuroplasticity (217). 
Significantly, in 1998, the Center for Disease Control and Prevention (CDC) 
reported that there are approximately 300,000 traumatic brain injuries related to sport 
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each year (194).  From 2001-2005, the CDC reported 207,830 patients with nonfatal sport-
related traumatic brain injuries, of which the highest number of incidents were recorded 
in young athletes (35).  Guskiewicz and colleagues (68) found a 6.3% occurrence of 
concussions after tracking 19 Division I, three Division II, and three Division III football 
teams over three years.  Moreover, it was concluded that football players who had three 
or more concussions are three times more likely to have another concussion (68).  Though 
we did not utilize a direct measure of DHA in brain/neural cell membranes, it is 
reasonable to assume that 2 g•day-1 algal DHA would be adequate to increase DHA in 
neural tissues (217), as we found DHA incorporation at a systemic level (erythrocyte 
phospholipid cell membrane composition) in these athletes (142).  This finding may be of 
great benefit to sport dieticians, athletic trainers, and team physicians who administer 
DHA for post-concussion therapy. Further research is needed to determine whether or 
not this dosage will also provide improved lipid profiles, anti-inflammatory benefits, and 
neuroprotection. 
Inflammation and DHA Supplementation 
  During preseason camp, Eotaxin and MCP-1 elevations were attenuated after 
supplementing with 2 g•day-1 DHA.  RANTES was significantly elevated in both the 
DHA and Placebo groups. However, the percent change increase in the Placebo group 
was nearly two times that of the DHA group.  In both groups, white blood cell counts 
decreased during preseason camp. With no change noted in several other cytokine 
markers, the effectiveness of the 2 g•day-1 DHA dosage as an anti-inflammatory agent 
for intense physical training is uncertain. 
 78 
 
Lipoproteins and DHA Supplementation 
Following supplementation, total cholesterol as well as lipoprotein cholesterols 
HDL-C and LDL-C were not affected (Post-camp not different from Summer) by 
training when supplemented with DHA.  With increased training, both groups had 
increased in HDL2b-C and HDL2a-C at Pre-camp.  Notably, preseason camp did decrease 
LDL-C in the Placebo group. LDL3-C (at Pre-camp) and LDL4-C (at Post-camp) 
increased in only the DHA group.  Summer IDL-C was significantly (P < 0.05) different 
between groups, with the DHA group having higher initial concentrations compared to 
the Placebo group.  Percent change VLDL number was significantly (P < 0.05) increased 
at Pre-camp and Post-camp in the Placebo group, compared to Summer.  RLP-C 
increased from Summer baseline in only the Placebo group while the DHA remained 
relatively unchanged.  RLP number did not change throughout the study and there was 
no difference between groups. LDL density decreased in the Placebo at Post-camp along 
with decreased HDL density at Pre-camp.  The DHA group had no change in LDL 
density but did have decreased HDL density at both Pre-camp and Post-camp. Pre-camp 
percent change TG concentrations were significantly (P < 0.05) increased only in the 
Placebo group, as well as being significantly (P < 0.05) greater than the DHA group.  
Pre-camp percent change TG concentrations were significantly (P < 0.05) decreased 
from Summer in the DHA group and was significantly different from the Placebo group 
at Post-camp as well.  There was no difference in lipoprotein-a (LP(a)) concentrations 
for either group throughout the study. Moreover, there was no difference between DHA 
and Placebo groups C-reactive protein concentrations.  Insulin concentrations decreased 
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from Summer to Post-Camp in both groups, but the DHA group also had a significant 
percent change decrease from Summer at Post-camp.  Homocysteine concentrations 
were only altered in the DHA group, where Pre-camp percent change was significantly 
higher than Summer. 
Limitations 
There are certain limitations that pertain to studying a collegiate football 
population.  One such limitation is relying on the athletes to supplement themselves over 
the weekends.  The athletes have the potential to return empty supplement envelopes 
without actually having ingested the supplement.   Additionally, the extent to which the 
athlete will tolerate (digestion and absorption) a median dosage of DHA was out of our 
control.  In our study, we only had one participant drop out from digestive issues with 
supplementation.  This study used algal DHA for supplementation - a DHA source 
which can be refined and purified.  There seems to be less incidence of gastro-intestinal 
distress with algal DHA, when compared to supplementation with fish oil.  Ryan et. al. 
(165) noted less taste dissatisfaction and gastrointestinal upset with higher doses of algal 
DHA compared to fish oil.  Athletes who want to supplement with omega-3 fatty acids 
could benefit from trying this form of omega-3 oil.  Future studies might examine the 
use of algal DHA to investigate supplementation of higher doses of DHA with less 
chance of gastro-intestinal upset than could be tolerated with fish oil. 
Additionally, consideration must always be taken with self-reported diets, as 
errors of quantity or omission of food can occur.   For our study, having a certified 
dietician who regularly works with the athletes studied may have mitigated major 
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over/under-estimations.   Reported diets may then be closer to what was actually 
consumed, when compared to an investigator interviewing a subject with whom he has 
no prior relationship. 
The development of a college athlete varies from institution to institution. 
Differing training philosophies of individual strength coaches can impact athletes’ 
training, rest, volume, and recovery.  Dieticians for each team may have different 
recommendations or meal plans.  Athletes from other sports may train differently, based 
on performance needs, and have different concentrations of baseline inflammation. 
Athletes of differing sizes, across a variety of sports, may experience differences in the 
incorporation and the utilization of DHA in the resolution phase of inflammation. The 
amount of stress placed on the muscle, in addition to the amount of adipose tissue, 
combined with IMTG containing DHA would influence the inflammatory outcome.  
One additional consideration is the prior training experience of the athletic 
population.  Pizza et. al. (159) noted a training effect on isolated myotubes following bouts 
of eccentric exercise where the first bouts were accompanied with higher concentrations 
of circulating neutrophils at 3, 6, and 9 hours post-exercise in comparison to the 
following exercise bouts.  The football players in this study have years of training 
experience and could have previously adapted to the exercise immune response of fall 
training camp when compared to a sedentary population. 
Delimitations  
Certain delimitations were considered in the design of this study.  The first 
delimitation is the population we investigated.  This study focused on a collegiate 
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student athlete population (Placebo 20.1 ± 1.4 years, DHA 20.5 ± 1.6 years) under 
training conditions.  Future studies would need to be conducted to determine whether 
DHA supplementation would affect lipid profiles, immune and inflammation markers in 
a younger or older population following similar training regimes.  Supplementation in 
younger athletes could more efficiently aid in recovery and further enhance training 
adaptations.  The aging athlete that wants to prolong their athletic career may seek 
supplementation to allow them to continue training and perform optimally for another 
season.   
Caloric expenditure could also affect the systemic incorporation of DHA in each 
athlete.  Using the mean anthropometrics of our subjects and an activity factor of 2.2, the 
predicted caloric expenditure, based on the Harris Benedict equation, (71) was 4,668 
calories per day.   The activity factor of 2.2 was based on discussions with coaching staff 
and observations of the athletes’ daily activity during each training period.  When 
examining caloric intake from dietary recall, all time points had lower intakes than the 
estimated expenditure (142).  This higher expendiure to intake ratio, coupled with the 
decreased total fat consumed by the athletes from Summer through preseason training 
(142), could have affected whether the ingested PUFAs were oxidized as fuel, or 
incorporated into tissue membranes.  Nevertheless, there continued to be an increase in 
percent change of DHA content in plasma and erythrocyte cell membranes, regardless of 
lower fat intake and fewer calories consumed than expended (142).  We speculate that a 
higher caloric expenditure and lower fat intake might explain the signifcant drop in 
percent change of DHA of the Placebo group at Pre-camp in erythrocyte cell 
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membranes, as the placebo group might have been utilizing PUFAs stored in adipose 
tissue for fuel. 
Future Studies  
Future studies may aim to incorporate a performance outcome.   Initially, this 
study included a vertical jump and triple jump measurement, but coaching staff was 
unable to execute the test with accuracy and reliability, and the performance 
measurement was eliminated.  Future steps include having certified researchers establish 
performance tests at each of the supplementation time points. Strength, speed, agility, 
and endurance measurements would be recorded to determine increases, decreases, or 
the preservation of said attribute during the rigorous preseason training. 
Further investigations are needed into other tissues, such as skeletal, cardiac (cell 
or animal model), neural (cell or animal model), and adipose tissues to see the impact of 
DHA supplementation on incorporation and inflammation.  Muscle and adipose biopsies 
may shed light on potential storage and release of DHA, as well as remodeling factors 
following training.  Moreover, measurements should occur at different times throughout 
the season, to determine if performance is maintained or enhanced with inflammation 
and recovery.  Football players usually play over the weekend and complete at least two 
training sessions during the week, all while managing classes and travel to the next 
competition.  The goal of training during the season is to maintain strength and speed for 
the upcoming game. 
Additionally, suggestions for future studies involve addressing particular 
limitations in the above studies.  First, this specific subject population’s body stature and 
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performance obligations affect supplementation, diet, and exercise interventions.  
Ideally, a dose response for algal DHA would be utilized to determine if there is a 
regression that would fit a range of individual body sizes and compositions, for 
inflammatory and lipid markers.  Controlling the exercise regime and exploring various 
intensities and volumes of activity, in conjunction with DHA supplementation, could 
provide additional information about lipoprotein, immune, and inflammatory responses.  
Second, follow up studies are needed examining the effects of DHA supplementation, 
with adequate fueling, so the DHA ingested is not potentially oxidized as fuel.  Adequate 
incorporation could further be validated with the addition of an adipose tissue biopsy 
prior to the beginning of the playing season. 
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APPENDIX A 
CONSENT FORM 
 
Algal DHA Supplementation:  Effects on Markers of Inflammation, Muscle Power, 
and Lipid CHD Risk in Collegiate Football Athletes During Sport Training 
 
Introduction 
The purpose of this form is to provide you information that may affect your decision as 
to whether or not to participate in this research study.  If you decide to participate in this 
study, this form will also be used to record your consent. 
 
You have been asked to participate in a research project studying the effects of DHA 
(docosahexaenoic acid) during summer and fall football camp.  DHA is an omega-3 fatty 
acid that is used in the body for making cell membranes.  It is a very important fatty acid 
in nervous tissue, like the brain, but is also found in muscle.  DHA is often obtained 
through eating certain fish, like tuna and salmon.  The DHA in fish comes from the algae 
they eat as food.  Since people usually don’t get enough fish in their diet, DHA 
supplements can provide an extra source of this important nutrient.  DHA supplements 
are usually found in capsule form, and come from fish oil or from algae.  Taking DHA 
has been shown to reduce muscle inflammation, like the type that makes you sore and 
weak after a hard workout.  Also, DHA has been shown to reduce the fats in the blood 
that can cause heart disease and high-blood pressure.  No one has studied football 
players to find out if taking DHA can reduce muscle inflammation caused by hard 
workouts.  You are being asked to participate in this study to determine if taking DHA 
supplements during your summer and fall training camps can help prevent some of the 
muscle inflammation that makes you sore, and causes you to lose muscle power.  You 
will also find out if taking DHA can help change the fats in your blood to make you less 
likely to get heart disease when you get older.   
  
You were selected to be a possible participant because you are an active student-athlete 
member of the Texas A&M University football team. 
 
What will I be asked to do? 
If you agree to participate in this study, you will be asked to provide three blood 
samples:  1) at the beginning of summer camp; 2) at the beginning of fall camp; and 3) at 
the end of fall camp.  All of these blood samples will be taken from a vein in your arm 
where your elbow bends, early in the morning before you eat breakfast.  You will be 
asked not eat or drink anything but water for 10 hours before the blood draw.  We will 
use the blood to measure blood fats and also markers of muscle inflammation that make 
you sore.   You will also be asked to take capsules daily containing either DHA or no 
DHA (placebo) for about 8 weeks starting in summer camp and continuing until the end 
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of fall camp.  Along with the supplement, you will be asked to fill out three diet records, 
just like you normally complete with the TAMU performance nutritionist.  On each day 
that a blood sample is taken, the football strength coaches will ask you to perform a 
vertical jump and horizontal jump test.  These tests will allow the coaches to measure 
your muscle power.  By agreeing to participate in this study, you are allowing us to have 
access to this information.  None of the procedures you will be asked to do for this study 
will interfere with your normal football meetings and practices.     
 
What are the risks involved in this study? 
The risks associated with this study include possible soreness and bruising in the arm in 
which we take your blood.   The supplements you take may have a “fishy” taste and 
could give you a slight stomach-ache, but this is rare.  Since we are not doing any other 
tests other than those you perform for the coaching staff, there are no other risks 
associated with this study.   
 
What are the possible benefits of this study? 
The possible benefits of participation are you will be provided information regarding the 
current level of fat in your blood as well as your risk for heart disease.  You will also 
receive information about whether or not DHA prevents soreness during summer and 
fall camp. 
 
Do I have to participate? 
No.  You do not have to participate.  You may decide not to participate or to withdraw at 
any time without your current or future relations with Texas A&M University being 
affected.  If you decide to participate, you will not receive any benefits from the football 
coaching staff on or off the field.  Additionally, if you decide not to participate, you will 
not be punished by the coaches on or off the field.  The choice to participate or not is 
freely yours.     
 
Who will know about my participation in this research study? 
The records of this study will be kept private and confidential.  No identifiers linking 
you to this study will be included in any sort of report that might be published or 
presented.  Research records with all of your data will be stored securely and only the 
researchers involved will have access to the records. 
 
Whom do I contact with questions about the research?  
If you have questions regarding this study, you may contact the Jon Oliver at 979-845-
3997 or joliver@hlkn.tamu.edu  or Dr. Stephen Crouse at 979-845-3997 or s-
crouse@tamu.edu. 
 
Whom do I contact about my rights as a research participant?   
This research study has been reviewed by the Human Subjects’ Protection Program 
and/or the Institutional Review Board at Texas A&M University.  For research-related 
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problems or questions regarding your rights as a research participant, you can contact 
these offices at (979)458-4067 or irb@tamu.edu. 
 
 
Signature   
Please be sure you have read the above information, asked questions and received 
answers to your satisfaction.  You will be given a copy of the consent form for your 
records.  By signing this document, you consent to participate in this study and 
understand that your participation is voluntary and will not result in any special 
treatment by coaches or football staff either on or off the field. 
 
Signature of Participant: ____________________________________    Date: ___________________ 
 
Printed Name: __________________________________________________________________   
 
Signature of Person Obtaining Consent: _____________________________    Date: ______________ 
 
Printed Name: ________________________________________________________________________ 
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IRB Office Use Only 
APPENDIX B 
ADVERSE EVENT REPORT 
Texas A&M University 
Protocol for Human Subjects in Research 
 
Complete this form and submit with all appropriate documentation to the Institutional Review Board, 
General Services Complex, 750 Agronomy Rd, Suite 3501, College Station, Texas 77843 (MS 1186).  
You may contact 
Ms. Melissa McIlhaney, Compliance Coordinator, at (979)458-4067.  NOTE: You are still required to 
report such events to the sponsor and/or FDA as applicable to your research project. 
 
IRB PROTOCOL #:        
 
Investigator Information 
Principal Investigator Name:        
Faculty      Staff      Graduate Student      Undergraduate Student  
Department:        College:        Mail Stop:       
Phone:        Email:        Fax:       
 
Co-Investigator Name:        
Faculty      Staff      Graduate Student      Undergraduate Student  
Department:        College:        Mail Stop:       
Phone:        Email:        Fax:       
 
Graduate Committee Chair/Faculty Advisor Name (if student):        
Department:        College:        Mail Stop:       
Phone:        Email:        Fax:       
 
Project Title:       
 
Funding Status:  Funded:    Not Funded  
Funding Agency:         Funding Amount:       
Funding Administrator:  RF   TAES   TEES   TAMU   TTI  
 
Adverse Event Information 
Is this a follow-up report?  Yes   No  
 
1.  Date of Event:        
 
2.  Describe the Adverse Event: 
           
 
3.  Attach a summary of all circumstances related to this event. All hospitalization and/or medical 
     treatment must be reported. Include all notifications, correspondence, and other related materials 
     of this adverse event from the study sponsor or study sites. Include a statement regarding this 
     adverse event and its relation to the study at Texas A&M University. 
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Signature of PI:                                                                                                             Date:         
 
Typed Name:               
 
Signature of Faculty Advisor (if student):                                                                          Date:        
 
Typed Name:               
 
Signature of Department Head:                                                                                             Date:        
 
Typed Name:                
 
The information provided will be reviewed by the Texas A&M University Institutional Review Board for compliance 
with federal regulations and the University’s Institutional Federal Wide Assurance document approved by OHRP. 
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APPENDIX C 
SUPPLEMENT ADHERENCE CHECKLIST (SAMPLE) 
 
LNAME FNAME 
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APPENDIX D 
24 HOUR DIETARY RECALL 
Online Diet Recall                    
Name:          Sex:    Average hours per day spent in class:    
        Height:    Days per week you have class:   
Sport / Position:                      
        Weight:     Average hours per day spent studying:   
Age / Birth Date:            Desired Weight:     Days per week that you study:    
                        
Year of eligibility:                  Average hours sleeping (weekday):    
i.e.  Redshirt fr, soph, 
junior,etc.                   Average hours sleeping (weekend):    
                        
              Average hours per day spent training:    
              Days per week you train:     
                        
Nutritional Goals (i.e. What would you like to get back from this record?):           
                        
DAY 1                          
Time:   Time:   Time:   Time:   Time:   Time:   
Breakfast   Snack / Recovery  Lunch   Snack / Recovery Dinner   Snack / Desert 
Description: 
   
Amt.: Description: 
 
Amt.: Description: Amt.: Description: Amt.: Description: Amt.: Description: Amt.: 
                        
How are you feeling? How are you feeling? How are you feeling? How are you feeling? How are you feeling? How are you feeling? 
                        
DAY 2    Date:  /  /                      
Time:   Time:   Time:   Time:   Time:   Time:   
Breakfast   Snack / Recovery  Lunch   Snack / Recovery Dinner   Snack / Desert 
Description: 
   
Amt.: Description: 
 
Amt.: Description: 
 
Amt.: Description: Amt.: Description: 
 
Amt.: Description: Amt.: 
                        
How are you feeling? How are you feeling? How are you feeling? How are you feeling? How are you feeling? How are you feeling? 
                        
DAY 3    Date:  /  /                      
Time:   Time:   Time:   Time:   Time:   Time:   
                        
Breakfast   Snack / Recovery  Lunch   Snack / Recovery Dinner   Snack / Desert 
Description: 
   
Amt.: Description: 
 
Amt.: Description: 
 
Amt.: Description: Amt.: Description: 
 
Amt.: Description: Amt.: 
How are you feeling? How are you feeling? How are you feeling? How are you feeling? How are you feeling? How are you feeling? 
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APPENDIX E 
SUPPLEMENT ADHERENCE QUESTIONNAIRE 
 
Supplement Adherence Questionnaire 
 
Name: ___________________________   
Age: ____________________________ 
Ethnicity: ________________________ 
Position: _________________________ 
 
 
Algal DHA Supplementation:  Effects on Markers of Inflammation, Muscle Power, and Lipid CHD Risk 
in Collegiate Football Athletes During Sport Training 
 
1. Have you taken all the supplements as prescribed?  Yes  □  No  □ 
a. If no, why not?  _______________________________  
 
2. Have you had anything to eat or drink, except water, since 10:00 PM last night?  Yes  □  No  □ 
a. If yes, then what have you had to eat or drink?  _______________________________  
 
3. How many servings of fish have you had in the last week? 1  2  3  4  5  
a. What kind of fish have you had to eat in the last week?  _________________________ 
 
4. Have you taken any other supplements in the last week?  Yes  □  No  □   
a. If yes, then what kind of supplements have you taken?  _________________________ 
 
5. Have you had any injuries in the last week?  Yes  □  No  □   
a. If yes, then what type of injury? How treated?  _________________________________ 
 
6. Have you had an illness in the last week?  Yes  □  No  □   
a. If yes, what kind of illness did you have?  How treated?  _________________________ 
 
7. Were you excluded or limited from practice in the last week?  Yes  □  No  □   
a. If yes, what for and for how long were you limited or excluded?  ___________________ 
 
8. Have you taken ANY medications in the last week?  Yes  □  No  □   
(These include antibiotics, any over the counter medicines, including aspirin, Advil, 
Aleve, BC powder, allergy medicine or any other medications that have not been listed.) 
a. If yes, what were the names of the medications?  _______________________________ 
 
9. About how long ago since you last exercised (circle one)?  12hr    24hr    48hr    72hr    Longer  
1. Supplement Adherence Questionnaire 
Supplement Adherence Questionnaire 
 
Name: ___________________________   
Age: ____________________________ 
Ethnicity: ________________________ 
Position: _________________________ 
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Algal DHA Supplementation:  Effects on Markers of Inflammation, Muscle Power, and Lipid CHD Risk 
in Collegiate Football Athletes During Sport Training 
 
10. Have you taken all the supplements as prescribed?  Yes  □  No  □ 
a. If no, why not?  _______________________________  
 
11. Have you had anything to eat or drink, except water, since 10:00 PM last night?  Yes  □  No  □ 
a. If yes, then what have you had to eat or drink?  _______________________________  
 
12. How many servings of fish have you had in the last week? 1  2  3  4  5  
a. What kind of fish have you had to eat in the last week?  _________________________ 
 
13. Have you taken any other supplements in the last week?  Yes  □  No  □   
a. If yes, then what kind of supplements have you taken?  _________________________ 
 
14. Have you had any injuries in the last week?  Yes  □  No  □   
a. If yes, then what type of injury? How treated?  _________________________________ 
 
15. Have you had an illness in the last week?  Yes  □  No  □   
a. If yes, what kind of illness did you have?  How treated?  _________________________ 
 
16. Were you excluded or limited from practice in the last week?  Yes  □  No  □   
a. If yes, what for and for how long were you limited or excluded?  ___________________ 
 
17. Have you taken ANY medications in the last week?  Yes  □  No  □   
(These include antibiotics, any over the counter medicines, including aspirin, Advil, 
Aleve, BC powder, allergy medicine or any other medications that have not been listed.) 
a. If yes, what were the names of the medications?  _______________________________ 
 
18. About how long ago since you last exercised (circle one)?  12hr    24hr    48hr    72hr    Longer  
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APPENDIX F 
ST. JOSEPH HEALTH CENTER FORM 
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APPENDIX G 
RANDOMIZATION DATA AND DEMOGRAPHICS 
 
 
Assignments 
 
   SID Ethnicity Position  COLOR TREATMENT 
MRTK001 B LB Burgundy Placebo 
MRTK002 W OL White DHA 
MRTK003 B DB Burgundy Placebo 
OL DL LB
MRTK002 4 MRTK009 4 MRTK001 3
MRTK016 2 MRTK011 4 MRTK005 4
MRTK017 2 MRTK023 3 MRTK008 4
MRTK026 3 MRTK056 3 MRTK010 2
MRTK036 4 MRTK018 3
MRTK049 2 MRTK020 4
MRTK027 3
MRTK037 2
MRTK043 1
MRTK058 1
DB QBR OB
MRTK003 3 MRTK004 2 MRTK021 1
MRTK007 4 MRTK006 4 MRTK024 1
MRTK019 2 MRTK013 2 MRTK031 2
MRTK025 2 MRTK014 2 MRTK032 1
MRTK030 2 MRTK028 4 MRTK033 4
MRTK035 1 MRTK029 3 MRTK034 2
MRTK038 1 MRTK040 4 MRTK051 3
MRTK041 2 MRTK042 3
MRTK044 4 MRTK050 2 K
MRTK060 4 MRTK052 2 MRTK012 2
MRTK055 1 MRTK015 2
MRTK057 4 MRTK022 2
MRTK039 3
Group # Capsules Color
3 placebo Burgundy
2 placebo Silver
1 active Blue
4 active White
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MRTK004 W QBR Silver Placebo 
MRTK005 B LB White DHA 
MRTK006 W QBR White DHA 
MRTK007 B DB White DHA 
MRTK008 B LB White DHA 
MRTK009 B DL White DHA 
MRTK010 B LB Silver Placebo 
MRTK011 B DL White DHA 
MRTK012 H DS Silver Placebo 
MRTK013 B QBR Silver Placebo 
MRTK014 B QBR Silver Placebo 
MRTK015 W K Silver Placebo 
MRTK016 W OL Silver Placebo 
MRTK017 W OL Silver Placebo 
MRTK018 B LB Burgundy Placebo 
MRTK019 W DB Silver Placebo 
MRTK020 W LB White DHA 
MRTK021 B OB Blue DHA 
MRTK022 H K Silver Placebo 
MRTK023 B DL Burgundy Placebo 
MRTK024 B OB Blue DHA 
MRTK025 B DB Silver Placebo 
MRTK026 H OL Burgundy Placebo 
MRTK027 B LB Burgundy Placebo 
MRTK028 W QBR White DHA 
MRTK029 W QBR Burgundy Placebo 
MRTK030 W DB Silver Placebo 
MRTK031 B OB Silver Placebo 
MRTK032 W OB Blue DHA 
MRTK033 B OB White DHA 
MRTK034 B OB Silver Placebo 
MRTK035 B DB Blue DHA 
MRTK036 W OL White DHA 
MRTK037 B LB Silver Placebo 
MRTK038 W DB Blue DHA 
MRTK039 W K Burgundy Placebo 
MRTK040 W QBR White DHA 
MRTK041 B DB Silver Placebo 
MRTK042 B QBR Burgundy Placebo 
MRTK043 B LB Blue DHA 
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MRTK044 B DB White DHA 
MRTK045 W K White DHA 
MRTK046 W QB Blue DHA 
MRTK048 H FB Burgundy Placebo 
MRTK049 B OL Silver Placebo 
MRTK050 W QBR Silver Placebo 
MRTK051 B OB Burgundy Placebo 
MRTK052 B QBR Silver Placebo 
MRTK053 W LB White DHA 
MRTK054 W TE White DHA 
MRTK055 B QBR Blue DHA 
MRTK056 B DL Burgundy Placebo 
MRTK057 B QBR White DHA 
MRTK058 W LB Blue DHA 
MRTK059 W K Burgundy Placebo 
MRTK060 W DB White DHA 
MRTK062 B OL Blue DHA 
 
Demographics 
 
    SID TREATMENT AGE HEIGHT WEIGHT BMI 
MRTK002 DHA 21 191.008 140.1599 38.41676 
MRTK005 DHA 19 186.182 97.52228 28.1338 
MRTK007 DHA 19 179.832 76.65705 23.70381 
MRTK008 DHA 21 189.23 109.7693 30.65496 
MRTK009 DHA 20 193.04 136.5312 36.63846 
MRTK011 DHA 21 193.04 124.2842 33.35196 
MRTK020 DHA 24 182.88 101.151 30.2439 
MRTK024 DHA 19 189.23 91.62558 25.58803 
MRTK028 DHA 23 184.912 80.73938 23.61322 
MRTK033 DHA 18 193.04 107.0477 28.7265 
MRTK035 DHA 19 180.594 84.36811 25.86853 
MRTK036 DHA 21 195.58 138.7992 36.2859 
MRTK038 DHA 22 195.58 119.7483 31.30548 
MRTK040 DHA 19 185.674 87.99685 25.52495 
MRTK043 DHA 22 177.8 90.7184 28.69669 
MRTK044 DHA 23 185.42 87.99685 25.59493 
MRTK045 DHA 20 193.04 117.9339 31.64784 
MRTK053 DHA 21 187.96 105.6869 29.9151 
MRTK057 DHA 20 193.04 99.79024 26.77894 
MRTK058 DHA 21 187.706 102.0582 28.9662 
MRTK060 DHA 20 191.008 120.2019 32.94641 
MRTK062 DHA 19 182.88 139.7063 41.77185 
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MRTK001 Placebo 18 177.8 102.5118 32.42726 
MRTK004 Placebo 22 192.278 98.42946 26.62355 
MRTK010 Placebo 19 184.404 108.8621 32.01371 
MRTK016 Placebo 21 196.85 138.3456 35.70215 
MRTK018 Placebo 21 187.96 105.6869 29.9151 
MRTK019 Placebo 23 187.96 95.25432 26.96211 
MRTK023 Placebo 20 189.23 117.9339 32.93508 
MRTK025 Placebo 19 172.72 73.02831 24.4797 
MRTK026 Placebo 20 195.58 129.2737 33.79569 
MRTK027 Placebo 20 192.278 100.2438 27.1143 
MRTK029 Placebo 20 170.434 84.36811 29.04463 
MRTK030 Placebo 18 185.166 89.35762 26.06208 
MRTK034 Placebo 23 187.96 102.0582 28.88797 
MRTK037 Placebo 20 186.944 95.25432 27.25597 
MRTK039 Placebo 20 186.436 87.54326 25.18623 
MRTK041 Placebo 18 191.77 112.4908 30.58833 
MRTK042 Placebo 19 191.77 100.2438 27.25815 
MRTK049 Placebo 20 190.5 141.5207 38.99689 
MRTK051 Placebo 21 178.816 88.45044 27.66223 
MRTK052 Placebo 20 182.626 87.08966 26.11208 
MRTK056 Placebo 20 189.484 125.1914 34.86819 
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APPENDIX H 
CHAPTER 2: CYTOKINE RAW DATA 
 
SID TREATMENT Eotaxin 1 Eotaxin 2 Eotaxin 3 IFN-g 1 IFN-g 2 IFN-g 3 IL-6 1 IL-6 2 IL-6 3
MRTK002 DHA 77.93 56.99 71.89 6.16 10.88 7.9 42.12 41.82 30.19
MRTK005 DHA 49.56 55.38 42.16 33.12 4.39 0.73 13.56 0.355 0.355
MRTK007 DHA 56.46 38.91 40.1 0.73 0.73 1.55 0.355 0.355 0.355
MRTK008 DHA 53.33 59.35 58.9 4.51 4.6 5.06 14.11 15.72 20.37
MRTK009 DHA 52.03 62.44 65.05 66.97 20.06 23.72 2.71 0.355 0.355
MRTK020 DHA 48.81 84.32 63.96 28.25 35.66 117 1.38 1.38 1.38
MRTK028 DHA 29.69 46.29 54.84 1.39 2.11 1.88 1.01 8.86 11.45
MRTK036 DHA 61.19 72.01 51.09 15.6 11.3 17.92 146 0.76 0.76
MRTK038 DHA 43 54.56 28.16 304 93.16 85.21 178 146 115
MRTK040 DHA 47.69 55.7 44.43 12.47 7.16 6.07 0.76 0.76 0.76
MRTK044 DHA 24.85 26.27 29.81 27.84 45.64 80.29 0.76 0.76 0.76
MRTK045 DHA 52.64 77.66 85.54 6.77 16.05 20.36 4.51 11.25 19.25
MRTK053 DHA 79.62 91.31 95.18 204 163 117 43.77 51 18.79
MRTK057 DHA 111 119 76.18 0.71 2.05 2.32 0.76 11.25 6.18
MRTK058 DHA 48.81 47.26 30.8 28.4 17.8 15.48 30.79 14.14 19.14
MRTK011 DHA 47.02 48.07 60.92 97.35 60.36 77.26 31.77 22.71 11.01
MRTK024 DHA 46.17 28.05 66.41 47.89 16.01 150
MRTK033 DHA 107 93.29 94.29 122 231 236 29.34 43.36 54.88
MRTK035 DHA 80.08 98.58 65 17.84 6.03 7.47 272 163 111
MRTK043 DHA 14.9 10.94 28.59 39.54 51.25 89.23 14.21 9.06 69.29
MRTK060 DHA 45.82 28.36 27.11 8.22 44.76 27.51 0.76 6.88 3.21
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SID TREATMENT Eotaxin 1 Eotaxin 2 Eotaxin 3 IFN-g 1 IFN-g 2 IFN-g 3 IL-6 1 IL-6 2 IL-6 3
MRTK062 DHA 40.22 36.98 46.55 10.14 15.48 32.24 0.76 0.76 0.76
MRTK001 Placebo 91.98 78.34 59.95 116 66.65 91.94 61.16 28.09 60.75
MRTK004 Placebo 29.94 48.53 40.02 0.73 1.61 0.73 0.355 0.355 0.355
MRTK010 Placebo 59.99 49.25 50.6 189 112 95.79 66.16 26.18 24.17
MRTK016 Placebo 16.53 45.22 28.83 4.55 4.24 2.76 1.38 1.38 1.38
MRTK018 Placebo 26.34 40.44 53.92 6.7 14.59 19.77 1.38 18.92 24.81
MRTK019 Placebo 28.63 163 104 16.8 347 187 7.15 198 119
MRTK023 Placebo 27.05 25.45 30.44 12.23 17.76 5.69 0.76 0.76 0.76
MRTK025 Placebo 30.72 49.92 44.19 9.76 539 450
MRTK026 Placebo 30.72 39 55.52 18.58 16.81 21.95
MRTK027 Placebo 139 129 160 46.43 74.3 239 111 65.44 121
MRTK029 Placebo 21.05 60.35 55.97 42.55 8.07 39.12
MRTK030 Placebo 36.13 63.86 42.23 28.76 113 129
MRTK034 Placebo 46.05 31.66 37.27 2.32 1.52 1.86 9.86 9.61 4.74
MRTK037 Placebo 13.92 27.17 35.07 3.89 6.03 9.89 0.76 0.76 5.45
MRTK039 Placebo 46.26 59.51 53.14 4.97 3.42 3.28 18.15 28.47 13.73
MRTK041 Placebo 68.92 53.76 45.9 178 61.65 97.85 86.48 40.52 92.59
MRTK042 Placebo 29.89 26.27 32.46 35.01 26.98 24.51 37.39 13.19 12.38
MRTK049 Placebo 28.36 32.74 41.63 1.99 4.37 4.33 0.76 0.76 0.76
MRTK051 Placebo 28.74 31.61 31.2 0.71 0.71 0.71 0.76 0.76 0.76
MRTK052 Placebo 31.39 37.66 30 50.23 19.75 34.33 55.48 56.84 60.3
MRTK056 Placebo 28.72 34.82 23.35 0.71 0.71 0.71 0.76 0.76 0.76
SID TREATMENT IL-8 1 IL-8 2 IL-8 3 IL-17 1 IL-17 2 IL-17 3 MCP-1 MCP-2 MCP-3
MRTK002 DHA 17.65 22.11 19.98 23.09 45.26 30.67 375 250 346
MRTK005 DHA 14.56 15.38 12.94 36.34 2.87 1.49 232 273 199
MRTK007 DHA 5.93 6.5 9.67 0.325 0.325 0.325 362 270 343
MRTK008 DHA 11.68 17.53 15.07 1.14 0.88 1.21 214 277 227
MRTK009 DHA 5.35 3.98 1.2 9.02 3.15 6.6 150 162 182
MRTK020 DHA 3.87 6.12 15.62 0.585 2.27 14.34 179 240 210
MRTK028 DHA 4.46 7.39 9.65 1.53 2.82 3.59 149 197 203
MRTK036 DHA 33.17 9.74 8.13 4.86 4.34 6.52 255 366 273
MRTK038 DHA 122 38.6 47.19 120 36.47 31.47 84.08 279 129
MRTK040 DHA 6.34 4.57 2.82 3.65 1.13 1.13 213 270 184
MRTK044 DHA 0.495 2.57 5.9 5.31 8.24 12.14 243 217 198
MRTK045 DHA 9.8 16.6 21.78 7.08 9.13 10.97 124 206 159
MRTK053 DHA 52.78 49.58 40.09 49.12 46.22 27.79 276 354 362
MRTK057 DHA 7.85 7.89 7.36 1.13 1.13 1.13 348 302 237
MRTK058 DHA 23.32 10.89 18.93 5.97 3.19 2.67 282 227 242
MRTK011 DHA 18.02 10.26 8.57 25.61 16.25 6.28 265 276 254
MRTK024 DHA 78.95 62.52 69.28 51.61 36.41 84.25 169 181 212
MRTK033 DHA 20.5 36.03 32.93 22.51 42.37 37.65 797 923 258
MRTK035 DHA 70.03 64.67 43.09 5.61 2.93 3.2 278 272 178
MRTK043 DHA 90.63 32.26 65.04 102 14.45 27.03 177 285 345
MRTK060 DHA 3.32 5.59 6.68 2.44 8.01 7.13 382 328 240
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SID TREATMENT IL-8 1 IL-8 2 IL-8 3 IL-17 1 IL-17 2 IL-17 3 MCP-1 MCP-2 MCP-3
MRTK062 DHA 7.65 6.82 15.01 1.13 2.4 2.81 216 251 277
MRTK001 Placebo 105 77.15 71.5 255 167 141 368 448 199
MRTK004 Placebo 7.74 11.55 10.4 2.38 2.34 2.54 226 423 267
MRTK010 Placebo 30.46 25.95 33.76 60.16 65.51 57.07 240 309 279
MRTK016 Placebo 2.45 3.2 1.82 0.585 0.585 0.585 210 514 328
MRTK018 Placebo 3.92 13.2 16.79 2.46 9.65 11.75 125 203 231
MRTK019 Placebo 9.43 59.9 37.23 9.29 143 88.19 137 470 327
MRTK023 Placebo 4.24 3.96 0.495 4.24 5.61 3.38
MRTK025 Placebo 7.71 119 108 1.74 50.76 48.65 77.33 200 145
MRTK026 Placebo 10.78 13.98 2.49 7.5 8.92 10.57 192 231 308
MRTK027 Placebo 51.86 41.95 64.47 39.8 31.07 74.35 143 295 217
MRTK029 Placebo 21.3 7.19 14.73 16.28 5.12 18.89 112 420 270
MRTK030 Placebo 7.35 23.18 20.68 3.75 19.5 20.24 193 395 261
MRTK034 Placebo 11.94 8.48 10.95 2.35 1.13 1.13 368 329 245
MRTK037 Placebo 2.98 5.66 9.39 1.13 3.17 4.81 176 312 410
MRTK039 Placebo 14.95 22.55 19.72 1.13 3.58 1.13 117 248 168
MRTK041 Placebo 36.29 18.6 26.34 15.82 4.84 14.06 289 249 168
MRTK042 Placebo 221 310 263 230 544 322 144 187 181
MRTK049 Placebo 5.27 6.52 8.65 1.13 1.13 1.13 218 291 301
MRTK051 Placebo 0.495 1.81 2.77 1.13 1.13 1.13 166 167 166
MRTK052 Placebo 61.35 67.48 71.82 54.64 42.54 63.07 142 144 139
MRTK056 Placebo 3.18 4.55 7.54 1.13 1.13 1.13 171 182 172
SID TREATMENT RANTES 1 RANTES 2 RANTES 3 TNF-a 1 TNF-a 2 TNF-a 3
MRTK002 DHA 1897 1607 1522 30.98 19.34 18.06
MRTK005 DHA 837 1515 1338 7.76 9.06 7.14
MRTK007 DHA 1859 3134 2480 8.51 8.83 8.84
MRTK008 DHA 2562 3078 2972 6.31 8.74 6.87
MRTK009 DHA 1579 1642 2025 9.54 10.59 13.77
MRTK020 DHA 433 451 432 7.17 6.98 8.73
MRTK028 DHA 1627 4244 4423 4.94 7.34 7.26
MRTK036 DHA 5737 5768 6214 6.94 6.77 6.98
MRTK038 DHA 953 3963 2937 8.4 10.57 5.75
MRTK040 DHA 3863 4210 5376 6.26 6.05 5.37
MRTK044 DHA 5104 5078 5987 3.8 2.69 4.12
MRTK045 DHA 0.945 5.43 5.12 4.05 5.51 5.51
MRTK053 DHA 5858 4658 3877 4.26 3.81 3.91
MRTK057 DHA 5002 5381 5730 5.11 6.71 4.93
MRTK058 DHA 3027 1577 3423 6.16 3.61 5.8
MRTK011 DHA 3232 5787 4830 5.35 5.85 7.08
MRTK024 DHA 3643 3840 5045 7.36 5.54 13.52
MRTK033 DHA 6505 5340 1282 11.45 13.79 11.85
MRTK035 DHA 7219 5072 5298 8.93 5.02 4.01
MRTK043 DHA 3757 6335 7068 3.68 5.33 10.12
MRTK060 DHA 1748 2481 1721 7.28 6.35 4.86
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SID TREATMENT RANTES 1 RANTES 2 RANTES 3 TNF-a 1 TNF-a 2 TNF-a 3
MRTK062 DHA 4991 4355 5212 4.15 4.19 6.44
MRTK001 Placebo 9068 8207 3413 14.28 8 6.2
MRTK004 Placebo 1680 3164 2369 5.85 6.34 6.4
MRTK010 Placebo 823 5577 6419 5.32 4.93 6.26
MRTK016 Placebo 1401 1624 1732 4.48 6.08 5.97
MRTK018 Placebo 4724 9877 9633 2.09 2.79 5.72
MRTK019 Placebo 861 2093 937 5.85 25.8 15.36
MRTK023 Placebo 2.18 2.57 0.655
MRTK025 Placebo 472 2124 1920 1.74 7.78 8.05
MRTK026 Placebo 2646 3005 3932 5.52 6.25 9.05
MRTK027 Placebo 2809 5216 4430 44.5 36.21 67.88
MRTK029 Placebo 657 2617 1650 5.25 8.15 5.16
MRTK030 Placebo 1296 2305 2303 6 7.09 6.48
MRTK034 Placebo 4202 4487 3665 6.26 5.16 6.03
MRTK037 Placebo 2119 2872 4518 4.1 5.55 9.02
MRTK039 Placebo 2519 5603 2842 4.31 6.39 4.52
MRTK041 Placebo 6517 3077 4197 5.7 4.17 3.71
MRTK042 Placebo 6888 6271 7282 5.96 3.08 4.03
MRTK049 Placebo 2171 5215 4854 5.84 6.69 7.75
MRTK051 Placebo 1300 4142 3764 4.64 4.01 5.04
MRTK052 Placebo 2322 5200 4535 4.31 4.32 6.79
MRTK056 Placebo 6919 7400 7651 5.75 6.59 2.95
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APPENDIX I 
CHAPTER 2: WBC RAW DATA 
SID TREATMENT WBC S WBC PR WBC PO RBC S RBC PR RBC PO
1 DHA 4.7 5.4 4.6 4.89 4.83 5.19
3 DHA 7.2 8.8 5.5 4.98 4.93 5.43
4 DHA 4.1 4.7 4.3 5.63 4.92 4.94
10 DHA 4.2 4.6 4.0 5.41 5.74 4.68
12 DHA 6.4 7.8 5.8 4.80 4.39 5.67
13 DHA 8.2 6.2 7.2 6.10 5.64 4.95
14 DHA 5.7 6.9 5.9 5.58 5.29 4.86
15 DHA 6.1 5.9 5.9 5.14 4.27 4.87
16 DHA 8.4 10.1 7.4 5.00 4.80 5.32
17 DHA 5.6 6.3 5.4 5.40 5.98 4.48
18 DHA 6.1 5.8 5.7 4.58 . 5.01
19 DHA 5.1 4.4 5.1 4.79 4.79 4.53
23 DHA 7.4 8.2 4.3 4.78 4.74 5.18
25 DHA 4.8 6.6 4.4 6.31 4.15 4.87
26 DHA 6.5 5.7 4.5 4.61 4.84 4.86
27 DHA 9.6 6.5 5.4 4.55 5.05 5.98
29 DHA 7.6 7.5 6.0 5.15 5.13 5.29
30 DHA 5.4 6.3 4.4 5.06 5.35 4.89
31 DHA 6.9 8.1 5.6 5.50 . 5.39
34 DHA 4.7 5.7 4.5 4.98 5.40 4.76
37 DHA 8.5 10.0 7.5 . 5.93 4.46
39 DHA 5.3 6.4 4.6 4.66 5.34 4.24
41 DHA 3.7 4.5 3.1 4.85 4.72 4.58
42 DHA 3.3 5.1 3.4 4.91 4.17 .
48 DHA 4.44 4.46 5.43
 135 
 
SID TREATMENT WBC S WBC PR WBC PO RBC S RBC PR RBC PO
49 DHA 4.7 5.6 4.1 . 4.78 5.01
50 DHA 5.35 5.24 4.99
51 DHA 5.4 5.5 5.6 4.92 5.22 4.55
52 DHA 7.0 6.9 6.3 5.05 . 5.35
56 DHA 5.9 9.6 6.0 5.39 4.18 4.76
2 Placebo 7.4 7.4 5.8 5.00 4.65 5.19
5 Placebo 6.1 5.7 4.8 6.24 4.34 5.14
6 Placebo 4.79 5.01 5.06
7 Placebo 5.0 5.2 3.7 4.57 4.91 6.28
8 Placebo 5.2 5.5 4.1 4.64 4.86 5.74
9 Placebo 5.6 6.2 5.5 5.15 5.55 5.04
20 Placebo 3.6 3.3 3.1 5.00 5.02 4.89
21 Placebo 5.4 5.1 4.3 4.95 4.96 5.11
28 Placebo 5.6 6.0 4.4 4.81 4.97 5.01
32 Placebo 4.61 4.24 5.30
36 Placebo 6.2 5.9 5.5 5.39
38 Placebo 8.0 7.3 6.8 4.67 4.84
40 Placebo 5.5 7.4 6.3 5.11 4.81
44 Placebo 6.3 5.9 5.3 5.22 4.13 4.75
45 Placebo 4.9 6.7 4.3 5.78 4.00 4.80
46 Placebo 4.34 4.72 4.76
53 Placebo 4.9 6.1 5.0 4.54 4.08 4.85
54 Placebo 5.43 5.08 4.75
55 Placebo 4.77 5.47 4.26
57 Placebo 6.5 8.6 6.4 4.87
58 Placebo 6.5 6.1 6.3 5.41 4.50
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SID TREATMENT PNEU S PNEU PR PNEU PO PLYM S PLYM PR PLYM PO
1 DHA 37.0 65.3 46.6 46.0 27.6 44.9
3 DHA 40.4 26.0 52.1 46.0 67.0 37.2
4 DHA 58.9 50.0 47.0 27.7 41.1 43.1
10 DHA 51.4 58.9 37.4 33.9 32.7 48.7
12 DHA 45.8 55.1 50.5 43.1 29.4 42.1
13 DHA 56.2 47.8 41.4 33.0 39.0 42.7
14 DHA 30.0 44.0 41.0 55.0 42.8 49.0
15 DHA 54.2 37.5 42.5 36.8 49.3 43.6
16 DHA 59.3 50.9 52.2 28.0 38.0 38.0
17 DHA 45.3 41.7 46.8 42.8 44.5 36.7
18 DHA 47.4 . 45.4 41.2 . 40.0
19 DHA 51.0 52.8 61.2 36.9 39.4 24.8
23 DHA 31.0 43.7 54.4 55.0 45.5 33.3
25 DHA 39.0 45.7 59.2 43.0 42.8 25.5
26 DHA 52.0 52.0 64.0 43.3 37.4 29.6
27 DHA 52.8 41.0 46.1 34.7 43.9 37.9
29 DHA 16.0 44.9 55.8 69.0 42.1 35.2
30 DHA 55.4 43.1 28.0 34.2 49.2 60.0
31 DHA 55.1 . 47.3 32.3 . 38.5
34 DHA 39.0 42.2 37.6 47.2 44.8 49.4
37 DHA . 54.0 42.0 . 34.7 41.1
39 DHA 35.0 55.8 59.2 49.0 37.2 27.7
41 DHA 21.0 64.0 55.1 63.0 30.6 37.9
42 DHA 49.7 58.4 . 39.0 27.6 .
48 DHA 48.7 40.6 37.0 35.5 42.7 52.0
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SID TREATMENT PNEU S PNEU PR PNEU PO PLYM S PLYM PR PLYM PO
49 DHA . 30.0 44.9 . 52.0 42.2
50 DHA 48.7 50.5 59.9 36.0 35.9 29.6
51 DHA 44.6 53.2 39.8 43.5 38.5 47.2
52 DHA 54.7 . 69.6 31.5 . 20.7
56 DHA 57.5 44.0 43.2 30.7 34.2 45.2
2 Placebo 40.7 58.5 61.8 45.9 27.5 28.8
5 Placebo 47.0 48.0 48.5 46.0 41.1 36.1
6 Placebo 63.9 52.9 48.5 27.2 34.7 40.2
7 Placebo 37.6 25.0 28.0 47.4 60.0 67.0
8 Placebo 35.0 40.6 39.0 45.0 42.5 47.3
9 Placebo 27.0 43.9 60.4 59.0 42.2 25.4
20 Placebo 41.6 56.2 34.0 43.9 30.9 53.0
21 Placebo 21.0 62.3 49.0 72.0 32.4 44.7
28 Placebo 42.4 43.7 12.0 45.3 41.6 73.0
32 Placebo 52.5 50.8 57.8 35.3 36.1 33.3
36 Placebo 49.0 42.8
38 Placebo 49.6 7.0 39.9 70.0
40 Placebo 55.4 36.0 33.4 56.0
44 Placebo 56.0 58.6 45.5 29.7 31.6 43.1
45 Placebo 50.6 51.6 66.1 37.5 36.9 20.8
46 Placebo 63.5 56.1 62.1 28.2 29.0 28.1
53 Placebo 48.8 60.4 50.8 38.4 23.4 40.6
54 Placebo 43.3 48.8 45.5 35.7 38.4 42.6
55 Placebo 40.1 48.1 38.2 38.4 38.3 45.5
57 Placebo 47.2 . 43.0
58 Placebo 56.0 53.1 23.0 28.2
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SID TREATMENT PMON S PMON PR PMON PO PEOS S PEOS PR PEOS PO
1 DHA 8.0 5.6 6.8 2.0 1.3 1.4
3 DHA 10.0 4.0 7.0 3.2 2.0 3.3
4 DHA 9.2 6.9 8.2 3.8 1.7 1.4
10 DHA 11.5 6.0 6.6 2.6 2.1 6.9
12 DHA 7.8 9.2 6.0 2.9 6.0 1.2
13 DHA 6.4 9.5 12.5 4.1 3.3 3.0
14 DHA 11.0 9.3 9.0 2.0 3.3 1.0
15 DHA 5.2 7.0 11.6 3.3 5.5 1.9
16 DHA 10.6 9.9 9.1 1.8 0.9 0.0
17 DHA 9.8 11.0 9.4 1.8 2.4 6.5
18 DHA 8.7 . 11.7 2.2 . 2.6
19 DHA 6.4 6.0 8.2 5.3 1.3 4.7
23 DHA 11.0 4.7 9.7 2.0 5.8 2.1
25 DHA 13.0 8.0 9.4 1.0 3.1 5.4
26 DHA 2.8 7.4 3.9 1.5 2.8 2.0
27 DHA 7.3 11.9 13.5 4.5 2.6 2.2
29 DHA 6.0 10.5 6.9 2.0 2.2 1.7
30 DHA 8.8 5.2 5.0 1.0 2.1 6.0
31 DHA 6.8 . 10.7 5.4 . 3.1
34 DHA 7.8 9.9 10.4 5.5 2.5 2.3
37 DHA . 9.9 9.3 . 0.9 7.2
39 DHA 1.0 5.4 8.2 3.0 1.2 4.5
41 DHA 11.0 4.1 5.4 3.0 0.9 1.2
42 DHA 9.3 11.6 . 1.4 1.7 .
48 DHA 7.1 13.3 11.0 8.0 2.6 .
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SID TREATMENT PMON S PMON PR PMON PO PEOS S PEOS PR PEOS PO
49 DHA . 15.0 8.1 . . 4.3
50 DHA 12.4 10.6 9.2 2.3 2.8 0.9
51 DHA 9.5 5.7 6.4 1.7 2.2 6.2
52 DHA 10.3 . 7.7 3.2 . 2.0
56 DHA 7.1 9.5 9.2 4.2 11.3 2.0
2 Placebo 11.5 10.7 6.5 1.6 2.8 2.5
5 Placebo 5.7 7.9 9.5 0.7 2.6 5.6
6 Placebo 7.0 8.6 6.3 1.7 3.5 4.3
7 Placebo 10.4 6.0 3.0 4.1 5.0 1.0
8 Placebo 9.0 12.8 8.4 2.0 3.4 4.9
9 Placebo 8.0 11.1 13.3 2.0 2.7 0.5
20 Placebo 12.6 7.6 8.0 1.5 4.8 5.0
21 Placebo 3.0 4.0 4.6 2.0 0.9 1.4
28 Placebo 9.8 12.8 9.0 2.1 1.4 2.0
32 Placebo 9.0 6.0 7.7 2.7 6.5 0.9
36 Placebo 7.8 . 0.0
38 Placebo 8.6 8.0 1.3 8.0 .
40 Placebo 7.7 3.0 3.2 2.0
44 Placebo 10.3 6.8 9.4 3.6 2.7 1.6
45 Placebo 10.4 8.9 10.0 1.1 2.1 2.7
46 Placebo 6.3 11.4 6.9 1.8 3.2 2.5
53 Placebo 9.2 6.9 7.4 3.0 8.7 0.8
54 Placebo 6.5 7.0 8.2 13.9 5.1 3.3
55 Placebo 8.8 10.6 14.3 12.0 2.5 1.1
57 Placebo . 9.1 0.0
58 Placebo 11.0 11.4 5.0 6.8
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SID TREATMENT PBAS S PBAS PR PBAS PR
1 DHA . 0.2 0.3
3 DHA 0.4 . 0.4
4 DHA 0.4 0.3 0.3
10 DHA 0.6 0.3 0.4
12 DHA 0.4 0.3 0.2
13 DHA 0.3 0.4 0.4
14 DHA . 0.6 .
15 DHA 0.5 0.7 0.4
16 DHA 0.3 0.3 0.7
17 DHA 0.3 0.4 0.6
18 DHA 0.5 . 0.3
19 DHA 0.4 0.5 1.1
23 DHA . 0.3 0.5
25 DHA . 0.4 0.5
26 DHA 0.4 0.4 0.5
27 DHA 0.7 0.6 0.3
29 DHA 2.0 0.3 0.4
30 DHA 0.6 0.4 .
31 DHA 0.4 . 0.4
34 DHA 0.5 0.6 0.3
37 DHA . 0.5 0.4
39 DHA 2.0 0.4 0.4
41 DHA . 0.4 0.4
42 DHA 0.6 0.7 .
48 DHA 0.7 0.8 .
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SID TREATMENT PBAS S PBAS PR PBAS PR
49 DHA . . 0.5
50 DHA 0.6 0.2 0.4
51 DHA 0.7 0.4 0.4
52 DHA 0.3 . 0.0
56 DHA 0.5 1.0 0.4
2 Placebo 0.3 0.5 0.4
5 Placebo 0.6 0.4 0.3
6 Placebo 0.2 0.3 0.7
7 Placebo 0.5 . .
8 Placebo 1.0 0.7 0.4
9 Placebo . 0.1 0.4
20 Placebo 0.4 0.5 .
21 Placebo 1.0 0.4 0.3
28 Placebo 0.4 0.5 1.0
32 Placebo 0.5 0.6 0.3
36 Placebo . . 0.4
38 Placebo 0.6 . .
40 Placebo . 0.3 .
44 Placebo 0.4 0.3 0.4
45 Placebo 0.4 0.5 0.4
46 Placebo 0.2 0.3 0.4
53 Placebo 0.6 0.6 0.4
54 Placebo 0.6 0.7 0.4
55 Placebo 0.7 0.5 0.9
57 Placebo . . 0.7
58 Placebo . 1.0 0.5
 142 
 
APPENDIX J 
CHAPTER 3: ST. JOSEPH’S LIPID PANEL RAW DATA 
 
SID TREATMENT CHOL S CHOL PR CHOL PO TRI S TRI PR TRI PO
MRTK002 DHA 205 208 208 133 119 124
MRTK005 DHA 219 221 211 94 107 76
MRTK007 DHA 147 147 173 76 91 59
MRTK008 DHA 129 144 112 63 88 48
MRTK009 DHA 175 171 158 45 57 47
MRTK011 DHA 175 182 151 76 75 59
MRTK020 DHA 162 153 142 171 86 85
MRTK021 DHA 132 102 121 210 105 58
MRTK028 DHA 198 228 218 45 74 44
MRTK033 DHA 162 188 198 93 227 70
MRTK035 DHA 113 137 137 90 89 77
MRTK036 DHA 175 167 149 155 158 110
MRTK038 DHA 237 216 223 108 211 195
MRTK040 DHA 226 218 192 143 135 77
MRTK043 DHA 154 144 158 86 71 100
MRTK044 DHA 152 220 228 138 75 79
MRTK045 DHA 189 194 165 123 127 88
MRTK053 DHA 192 229 180 88 90 59
MRTK057 DHA 199 225 190 230 118 108
MRTK058 DHA 174 160 159 102 61 70
MRTK060 DHA 178 205 168 200 178 168
MRTK062 DHA 145 146 153 68 91 73
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SID TREATMENT CHOL S CHOL PR CHOL PO TRI S TRI PR TRI PO
MRTK001 Placebo 140 145 145 71 86 53
MRTK003 Placebo 226 243 217 37 51 44
MRTK004 Placebo 145 133 167 63 97 91
MRTK010 Placebo 153 131 142 58 46 50
MRTK012 Placebo 216 198 204 188 172 212
MRTK013 Placebo 134 125 115 89 97 70
MRTK014 Placebo 174 160 153 61 159 47
MRTK015 Placebo 163 147 164 57 87 59
MRTK017 Placebo 175 150 146 163 194 84
MRTK018 Placebo 180 162 167 73 92 75
MRTK019 Placebo 166 182 173 60 65 64
MRTK023 Placebo 214 176 250 142 176 169
MRTK025 Placebo 168 185 199 54 138 80
MRTK026 Placebo 175 176 179 128 163 150
MRTK027 Placebo 160 206 173 120 162 106
MRTK029 Placebo 213 193 179 121 186 138
MRTK030 Placebo 142 168 158 86 99 54
MRTK031 Placebo 141 151 145 82 119 74
MRTK034 Placebo 183 158 162 210 181 121
MRTK037 Placebo 219 195 222 136 129 125
MRTK039 Placebo 146 150 141 83 87 65
MRTK041 Placebo 176 184 189 68 116 63
MRTK049 Placebo 189 224 207 197 186 186
MRTK051 Placebo 212 212 200 47 47 54
MRTK056 Placebo 163 158 187 110 269 146
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SID TREATMENT HDL S HDL PR HDL PO LDL S LDL PR LDL PO
MRTK002 DHA 31 37 33 147 147 150
MRTK005 DHA 50 52 38 150 148 158
MRTK007 DHA 49 46 52 83 83 109
MRTK008 DHA 46 36 41 70 90 61
MRTK009 DHA 55 43 45 111 117 104
MRTK011 DHA 68 62 66 92 105 73
MRTK020 DHA 46 44 39 82 92 86
MRTK021 DHA 37 39 48 53 42 61
MRTK028 DHA 56 72 56 133 141 153
MRTK033 DHA 40 49 52 103 94 132
MRTK035 DHA 36 38 37 59 81 85
MRTK036 DHA 39 39 38 105 96 89
MRTK038 DHA 52 44 43 163 130 141
MRTK040 DHA 50 56 49 147 135 128
MRTK043 DHA 56 58 58 81 72 80
MRTK044 DHA 35 51 58 89 154 154
MRTK045 DHA 49 64 51 115 105 96
MRTK053 DHA 57 59 51 117 152 117
MRTK057 DHA 61 88 65 92 113 103
MRTK058 DHA 46 41 38 108 107 107
MRTK060 DHA 55 53 42 83 116 92
MRTK062 DHA 39 38 38 92 90 100
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SID TREATMENT HDL S HDL PR HDL PO LDL S LDL PR LDL PO
MRTK001 Placebo 57 61 62 69 67 72
MRTK003 Placebo 137 155 109 82 78 99
MRTK004 Placebo 46 45 47 86 69 102
MRTK010 Placebo 56 47 53 85 75 79
MRTK012 Placebo 52 39 40 126 128 122
MRTK013 Placebo 34 34 36 82 72 65
MRTK014 Placebo 56 48 46 106 80 98
MRTK015 Placebo 69 58 60 83 72 92
MRTK017 Placebo 54 46 45 88 65 84
MRTK018 Placebo 55 53 46 110 91 106
MRTK019 Placebo 47 48 45 107 121 115
MRTK023 Placebo 71 54 54 115 87 162
MRTK025 Placebo 46 46 49 111 111 134
MRTK026 Placebo 37 37 40 112 106 109
MRTK027 Placebo 37 59 45 99 115 107
MRTK029 Placebo 31 26 28 158 130 123
MRTK030 Placebo 49 60 49 76 88 98
MRTK031 Placebo 51 48 46 74 79 84
MRTK034 Placebo 54 52 45 87 70 93
MRTK037 Placebo 70 61 64 122 108 133
MRTK039 Placebo 44 49 47 85 84 81
MRTK041 Placebo 58 54 55 104 107 121
MRTK049 Placebo 41 48 45 109 139 125
MRTK051 Placebo 75 76 72 128 127 117
MRTK056 Placebo 35 29 45 106 75 113
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APPENDIX K 
CHAPTER 3: SPECTRACELL’S LIPID PANEL RAW DATA 
    SPECTC SPECLDL SPECHDL 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 161 199 188 109 145 136 37 39 31 
MRTK005 DHA 157 193 192 99 124 130 51 57 49 
MRTK007 DHA 95 125 142 48 73 87 42 46 49 
MRTK008 DHA 81 133 83 44 84 41 34 36 36 
MRTK009 DHA 142 141 120 91 95 77 49 39 38 
MRTK011 DHA 166 177 138 93 109 69 68 60 62 
MRTK020 DHA 135 122 132 72 72 78 42 38 37 
MRTK021 DHA 114 93 94 54 47 50 45 34 37 
MRTK024 DHA 151 133 127 77 63 66 62 56 52 
MRTK028 DHA 208 203 159 116 121 105 84 74 46 
MRTK033 DHA 153 187 145 99 110 94 45 57 43 
MRTK035 DHA 125 141 140 76 89 94 41 43 35 
MRTK036 DHA 164 132 138 94 70 91 44 41 32 
MRTK038 DHA 206 198 224 146 114 149 45 53 43 
MRTK040 DHA 203 175 173 132 100 115 53 63 46 
MRTK043 DHA 135 116 153 66 56 87 58 54 52 
MRTK044 DHA 151 173 217 86 114 157 44 52 49 
MRTK045 DHA 170 160 155 97 84 91 48 64 50 
MRTK053 DHA 177 205 188 110 131 118 54 60 58 
MRTK057 DHA 181 229 195 100 125 111 63 89 68 
MRTK058 DHA 148 129 157 86 71 95 54 49 48 
MRTK060 DHA 174 196 146 100 109 88 57 59 35 
MRTK062 DHA 138 144 151 90 87 101 38 48 40 
MRTK001 Placebo 117 139 113 57 68 53 52 63 52 
MRTK003 Placebo 173 231 166 65 102 68 101 121 90 
MRTK004 Placebo 104 101 116 55 53 68 43 37 36 
MRTK010 Placebo 111 114 121 60 63 64 47 43 51 
MRTK012 Placebo 176 193 202 106 124 120 45 41 49 
MRTK013 Placebo 113 98 96 64 55 50 39 35 36 
MRTK014 Placebo 127 149 137 70 90 79 53 52 54 
MRTK015 Placebo 133 128 128 61 58 62 67 63 62 
MRTK016 Placebo 138 178 169 80 89 72 29 43 40 
MRTK017 Placebo 143 138 125 73 75 69 54 46 45 
MRTK018 Placebo 129 144 143 69 82 86 52 50 46 
MRTK019 Placebo 115 131 136 65 83 87 43 41 41 
MRTK023 Placebo 162 187 235 92 111 160 62 59 51 
MRTK025 Placebo 114 156 165 64 99 116 42 45 39 
MRTK026 Placebo 138 154 130 82 94 81 40 39 36 
MRTK027 Placebo 119 190 153 68 112 92 37 61 39 
MRTK029 Placebo 182 192 116 124 126 72 40 37 32 
MRTK030 Placebo 127 151 100 68 85 56 46 56 36 
MRTK031 Placebo 107 127 113 57 69 64 43 48 40 
MRTK034 Placebo 183 161 153 92 66 89 67 65 50 
MRTK037 Placebo 177 171 164 100 84 100 59 67 50 
MRTK039 Placebo 115 117 117 63 62 64 43 49 45 
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MRTK041 Placebo 160 165 158 93 87 96 60 66 53 
MRTK042 Placebo 117 126 134 59 62 74 51 60 52 
MRTK049 Placebo 203 209 201 123 127 132 51 56 43 
MRTK051 Placebo 175 168 191 105 84 111 63 75 71 
MRTK052 Placebo 147 170 187 76 89 112 64 73 64 
MRTK056 Placebo 141 162 199 91 88 117 37 44 50 
 
 
    SPECTRI SPEC_CRP SPECINS 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 139 116 123 1.01 0.18 0.41 14.4 9.3 12.8 
MRTK005 DHA 96 106 79 0.32 0.10 0.34 11.9 9.6 7.3 
MRTK007 DHA 74 93 53 0.02 0.02 0.04 6.2 5.8 3.9 
MRTK008 DHA 52 85 43 0.08 0.06 0.24 4.2 3.9 3.9 
MRTK009 DHA 46 53 49 0.21 0.20 0.17 10.6 11.5 7.5 
MRTK011 DHA 80 71 57 0.08 0.04 0.25 5.5 4.1 3.9 
MRTK020 DHA 167 85 84 0.11 0.05 1.01 10.2 10.5 5.5 
MRTK021 DHA 197 111 62 0.31 1.01 0.42 24.1 5.5 7.9 
MRTK024 DHA 110 191 56 0.07 0.02 0.06 8.7 4.8 5.8 
MRTK028 DHA 85 79 46 0.03 0.02 0.02 7.9 7.2 3.9 
MRTK033 DHA 88 217 68 0.05 0.06 0.29 26.0 20.7 5.5 
MRTK035 DHA 93 90 76 0.21 0.01 0.07 37.1 3.9 3.9 
MRTK036 DHA 152 147 109 0.17 0.10 0.23 5.3 5.3 6.7 
MRTK038 DHA 106 214 204 0.07 0.06 0.09 9.7 8.6 12.0 
MRTK040 DHA 143 139 73 0.02 0.01 0.02 8.7 4.2 7.3 
MRTK043 DHA 84 76 98 0.01 0.05 0.16 10.0 4.7 8.8 
MRTK044 DHA 140 71 81 0.31 0.11 0.10 3.9 4.1 7.9 
MRTK045 DHA 120 122 83 0.26 0.15 0.17 8.3 13.6 7.8 
MRTK053 DHA 91 91 64 0.04 0.04 0.14 6.7 16.9 3.9 
MRTK057 DHA 246 118 110 0.06 0.02 0.17 8.1 4.4 3.9 
MRTK058 DHA 103 61 71 0.02 0.02 0.24 4.7 3.9 5.1 
MRTK060 DHA 186 177 179 0.13 0.07 0.23 10.6 9.4 9.5 
MRTK062 DHA 69 94 74 0.06 0.15 0.52 9.8 7.5 5.8 
MRTK001 Placebo 74 89 46 0.05 0.02 0.07 6.9 4.2 3.9 
MRTK003 Placebo 52 48 37 0.04 0.05 0.11 13.5 5.8 8.7 
MRTK004 Placebo 64 93 94 0.09 0.07 0.03 12.8 4.8 3.9 
MRTK010 Placebo 56 46 46 0.12 0.04 0.15 14.9 7.0 9.6 
MRTK012 Placebo 187 169 202 0.10 0.05 0.10 14.7 16.1 9.3 
MRTK013 Placebo 89 90 64 0.06 0.11 1.01 12.0 12.9 11.8 
MRTK014 Placebo 64 168 44 0.05 0.05 0.10 4.5 17.1 7.9 
MRTK015 Placebo 52 87 53 0.01 0.02 0.26 6.1 10.3 10.3 
MRTK016 Placebo 327 782 319 0.07 0.06 0.08 22.3 39.3 12.4 
MRTK017 Placebo 162 187 78 0.15 0.05 0.32 5.1 24.0 4.0 
MRTK018 Placebo 72 95 70 0.04 0.05 0.25 6.6 6.9 6.7 
MRTK019 Placebo 60 61 61 0.13 0.11 0.23 7.8 4.7 4.8 
MRTK023 Placebo 153 169 167 0.38 0.07 0.14 19.9 13.0 13.5 
MRTK025 Placebo 53 122 75 0.03 0.03 0.07 3.9 4.9 3.9 
MRTK026 Placebo 144 158 143 0.04 0.04 0.15 5.9 8.9 12.4 
MRTK027 Placebo 114 143 96 1.01 0.03 0.11 8.6 3.9 3.9 
MRTK029 Placebo 123 182 136 0.07 0.07 0.09 7.2 4.6 7.8 
MRTK030 Placebo 97 94 48 0.02 0.01 0.02 6.1 8.9 6.5 
MRTK031 Placebo 80 116 70 0.06 0.09 0.34 6.9 3.9 8.9 
MRTK034 Placebo 225 181 116 0.04 0.04 0.14 19.1 7.7 13.0 
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MRTK037 Placebo 123 121 112 0.16 0.07 0.13 18.7 8.3 9.0 
MRTK039 Placebo 85 88 62 0.15 0.07 0.07 8.2 7.4 6.4 
MRTK041 Placebo 77 119 74 0.02 0.07 0.08 11.8 6.8 6.3 
MRTK042 Placebo 52 71 42 0.01 0.02 0.08 8.1 5.4 3.9 
MRTK049 Placebo 199 180 155 0.28 0.14 0.16 33.1 13.4 10.4 
MRTK051 Placebo 47 51 52 0.02 0.03 0.15 3.9 3.9 3.9 
MRTK052 Placebo 125 77 72 0.37 0.05 0.32 13.7 15.3 6.0 
MRTK056 Placebo 112 259 142 0.15 0.08 0.26 16.4 21.2 15.2 
 
 
    SPECHOMO SPECVLDL SPECLDLT 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 11.7 9.3 10.0 58 56 84 820 1012 988 
MRTK005 DHA 8.0 9.1 8.9 27 44 49 707 822 897 
MRTK007 DHA 7.5 6.9 6.8 18 24 26 353 530 605 
MRTK008 DHA 9.2 12.9 10.7 12 50 22 325 581 292 
MRTK009 DHA 8.8 10.4 9.4 11 26 20 629 634 557 
MRTK011 DHA 7.4 6.1 5.8 21 34 26 598 717 465 
MRTK020 DHA 24.9 51.4 40.7 81 44 67 502 501 545 
MRTK021 DHA 8.7 8.1 7.4 61 47 31 356 323 349 
MRTK024 DHA 6.7 7.7 6.4 42 56 32 552 464 452 
MRTK028 DHA 9.7 11.0 7.8 29 30 30 845 852 765 
MRTK033 DHA 6.8 7.7 7.4 31 78 31 666 773 651 
MRTK035 DHA 5.7 6.6 6.1 32 36 46 498 601 624 
MRTK036 DHA 8.2 9.4 6.8 96 78 57 644 546 634 
MRTK038 DHA 7.7 7.9 7.3 54 118 125 990 851 1028 
MRTK040 DHA 8.1 9.2 7.6 71 46 44 899 732 781 
MRTK043 DHA 8.2 9.7 10.7 42 21 51 464 408 597 
MRTK044 DHA 9.8 11.2 8.5 80 27 42 618 820 1067 
MRTK045 DHA 10.3 10.1 9.3 97 47 56 650 609 616 
MRTK053 DHA 7.4 8.1 9.2 48 55 44 785 908 841 
MRTK057 DHA 7.2 7.6 6.3 65 56 63 681 886 776 
MRTK058 DHA 9.2 8.7 9.4 30 33 55 593 542 675 
MRTK060 DHA 7.1 7.4 5.7 66 110 88 653 841 643 
MRTK062 DHA 9.9 11.6 9.4 41 33 36 618 609 676 
MRTK001 Placebo 9.4 8.6 9.0 29 33 29 417 483 380 
MRTK003 Placebo 8.0 8.5 7.3 29 31 29 487 765 509 
MRTK004 Placebo 6.6 7.3 7.0 26 43 44 391 390 450 
MRTK010 Placebo 7.4 8.4 7.5 16 26 24 427 444 433 
MRTK012 Placebo 8.0 8.9 6.9 94 105 129 765 856 857 
MRTK013 Placebo 10.8 10.4 11.4 42 30 40 458 104 338 
MRTK014 Placebo 7.1 8.1 7.4 18 26 15 494 626 545 
MRTK015 Placebo 7.0 7.0 6.3 19 25 16 428 432 445 
MRTK016 Placebo 8.0 3.6 8.3 113 178 215 561 635 506 
MRTK017 Placebo 8.2 9.7 9.2 62 68 39 517 526 491 
MRTK018 Placebo 9.2 9.7 9.6 30 49 44 489 580 593 
MRTK019 Placebo 9.0 7.7 8.5 27 30 31 464 569 599 
MRTK023 Placebo 9.4 9.1 7.9 30 67 94 653 760 1080 
MRTK025 Placebo 5.7 6.8 5.8 29 44 38 463 687 804 
MRTK026 Placebo 9.5 11.0 8.8 59 80 49 599 640 560 
MRTK027 Placebo 7.1 8.9 8.6 53 66 83 502 761 635 
MRTK029 Placebo 6.3 6.4 6.8 72 109 47 906 879 541 
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MRTK030 Placebo 6.4 6.9 5.9 49 42 30 493 596 407 
MRTK031 Placebo 8.1 8.0 7.1 27 37 37 417 480 434 
MRTK034 Placebo 8.8 8.3 11.1 94 114 55 627 453 600 
MRTK037 Placebo 11.2 12.1 11.2 71 76 55 679 599 661 
MRTK039 Placebo 6.1 3.7 6.5 37 22 34 439 443 452 
MRTK041 Placebo 9.6 8.3 8.3 26 46 32 623 593 666 
MRTK042 Placebo 11.4 12.4 9.1 26 13 31 430 463 530 
MRTK049 Placebo 10.4 9.7 8.9 111 101 102 863 961 888 
MRTK051 Placebo 75.4 76.2 74.3 26 33 36 720 625 752 
MRTK052 Placebo 7.5 7.6 7.5 26 33 40 555 655 814 
MRTK056 Placebo 7.7 8.0 7.5 52 113 125 598 584 771 
 
 
  
 
 
      
    SPECRLIPO SPECDLDLIII SPECDLDLIV 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 109 129 144 300 286 342 116 89 134 
MRTK005 DHA 77 128 129 199 165 209 88 65 96 
MRTK007 DHA 37 47 62 115 159 150 42 65 59 
MRTK008 DHA 29 86 45 106 125 75 46 65 39 
MRTK009 DHA 69 88 53 158 131 160 68 58 65 
MRTK011 DHA 133 117 62 95 123 91 67 68 45 
MRTK020 DHA 94 85 90 138 119 144 63 62 64 
MRTK021 DHA 91 82 55 51 51 64 62 62 64 
MRTK024 DHA 68 58 70 150 137 80 63 66 64 
MRTK028 DHA 59 69 40 223 193 208 108 93 88 
MRTK033 DHA 98 97 74 134 224 147 63 65 64 
MRTK035 DHA 95 95 121 61 144 103 63 46 67 
MRTK036 DHA 124 71 101 167 236 181 63 89 67 
MRTK038 DHA 140 114 184 225 314 326 79 115 88 
MRTK040 DHA 134 69 98 200 238 149 76 83 76 
MRTK043 DHA 76 49 124 127 131 138 56 52 73 
MRTK044 DHA 81 98 147 193 246 244 73 101 100 
MRTK045 DHA 164 83 107 152 211 124 59 69 65 
MRTK053 DHA 77 93 72 217 211 206 82 77 96 
MRTK057 DHA 125 125 122 151 270 200 67 86 100 
MRTK058 DHA 74 41 93 121 188 180 65 77 88 
MRTK060 DHA 141 124 120 127 389 243 62 107 91 
MRTK062 DHA 95 84 124 138 155 136 70 69 74 
MRTK001 Placebo 45 54 48 111 101 91 60 68 59 
MRTK003 Placebo 37 49 38 146 175 151 74 144 71 
MRTK004 Placebo 51 49 99 115 110 63 46 54 53 
MRTK010 Placebo 46 61 68 117 107 90 52 58 39 
MRTK012 Placebo 125 126 157 253 214 255 101 78 100 
MRTK013 Placebo 55 48 74 135 112 77 55 54 39 
MRTK014 Placebo 43 64 57 142 138 118 46 68 63 
MRTK015 Placebo 46 43 45 116 131 111 46 61 63 
MRTK016 Placebo 128 176 154 188 178 142 64 106 78 
MRTK017 Placebo 60 74 59 132 133 130 62 61 58 
MRTK018 Placebo 60 86 97 17 146 155 62 66 59 
MRTK019 Placebo 55 68 77 120 110 147 63 62 64 
MRTK023 Placebo 92 122 181 165 155 260 70 74 76 
MRTK025 Placebo 48 100 81 123 172 194 63 74 72 
MRTK026 Placebo 82 129 83 210 163 131 63 66 64 
MRTK027 Placebo 83 132 124 162 163 147 82 81 76 
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MRTK029 Placebo 128 142 52 303 268 205 123 81 64 
MRTK030 Placebo 63 72 33 146 143 86 63 66 64 
MRTK031 Placebo 41 64 72 110 127 70 63 45 64 
MRTK034 Placebo 122 113 129 143 124 113 75 45 67 
MRTK037 Placebo 126 103 126 143 186 113 71 64 67 
MRTK039 Placebo 71 64 59 91 133 97 63 52 67 
MRTK041 Placebo 112 111 86 124 125 151 79 71 75 
MRTK042 Placebo 40 32 56 129 161 126 56 53 67 
MRTK049 Placebo 149 147 162 264 412 218 92 120 73 
MRTK051 Placebo 75 43 97 147 194 156 69 73 77 
MRTK052 Placebo 59 69 87 132 161 206 109 116 130 
MRTK056 Placebo 140 143 194 113 112 165 56 69 65 
 
    SPECHDLT SPECBHDL SPECLDLMS 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 7661 7844 5999 839 1045 836 19.88 20.04 19.90 
MRTK005 DHA 10480 11006 9964 1004 1806 1400 20.08 20.25 20.16 
MRTK007 DHA 8727 9165 9593 945 1258 1440 19.97 20.01 20.16 
MRTK008 DHA 7000 6685 6980 899 1260 1104 19.96 20.19 20.08 
MRTK009 DHA 9919 7424 7310 1286 1235 1211 20.14 20.24 20.13 
MRTK011 DHA 11379 10096 10343 2806 2495 2603 20.36 20.38 20.33 
MRTK020 DHA 8709 7727 7526 1021 1011 897 20.03 20.12 20.12 
MRTK021 DHA 8584 6561 7249 1388 1067 1012 20.33 20.21 20.30 
MRTK024 DHA 11083 10156 8639 2157 2022 2345 20.09 19.99 20.34 
MRTK028 DHA 15821 13778 9110 2649 2474 1360 20.13 20.28 20.08 
MRTK033 DHA 9238 10592 8678 1149 1699 1098 20.32 20.03 20.20 
MRTK035 DHA 7950 7605 6622 1262 1511 1098 20.50 20.16 20.29 
MRTK036 DHA 9261 8091 6000 977 1149 948 20.08 19.80 20.10 
MRTK038 DHA 9486 10120 8312 1035 1560 1285 20.13 19.88 19.95 
MRTK040 DHA 10376 11231 9256 1487 2199 1252 20.19 19.98 20.28 
MRTK043 DHA 10974 9994 10209 1821 1773 1615 20.06 19.96 20.11 
MRTK044 DHA 8535 9605 9080 1391 1735 1782 19.97 19.99 20.18 
MRTK045 DHA 9051 11954 9350 1583 2026 1726 20.09 19.92 20.21 
MRTK053 DHA 10095 11337 11129 1784 1962 1838 20.11 20.20 20.17 
MRTK057 DHA 11245 14292 11172 2296 3833 3010 20.16 20.03 20.08 
MRTK058 DHA 10802 9812 9632 1535 1370 1282 20.24 19.94 20.03 
MRTK060 DHA 10968 11532 6890 1702 1560 958 20.21 19.78 19.83 
MRTK062 DHA 6632 9365 7762 1396 1463 1225 20.17 20.12 20.20 
MRTK001 Placebo 9836 11199 9674 1620 2148 1671 20.09 20.21 20.12 
MRTK003 Placebo 14961 16996 13583 5412 6825 4612 20.05 20.17 20.06 
MRTK004 Placebo 8659 7274 6510 1082 1012 1198 20.00 20.01 20.42 
MRTK010 Placebo 9204 8571 9360 1367 1160 1711 20.09 20.13 20.22 
MRTK012 Placebo 9490 8587 10025 990 963 1252 19.92 20.08 19.96 
MRTK013 Placebo 7721 7193 7297 1117 864 1023 20.00 20.02 20.11 
MRTK014 Placebo 9667 9783 10754 1835 1727 1629 20.10 20.21 20.22 
MRTK015 Placebo 11421 11281 11508 2726 2272 2061 20.11 19.99 20.13 
MRTK016 Placebo 5463 8125 8095 850 1434 1037 19.88 19.92 19.90 
MRTK017 Placebo 10779 8812 9244 1473 1406 1156 20.07 20.12 20.11 
MRTK018 Placebo 10774 9475 9350 1275 1404 1157 20.23 20.06 20.09 
MRTK019 Placebo 8875 8224 8647 1049 1096 897 20.15 20.27 20.18 
MRTK023 Placebo 10810 10833 9220 2270 1968 1735 20.15 20.22 20.24 
MRTK025 Placebo 8928 8797 7803 908 1320 1039 20.14 20.12 20.12 
MRTK026 Placebo 8486 7481 7279 881 1124 897 19.92 20.08 20.09 
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MRTK027 Placebo 7390 11515 7756 937 1855 1011 19.94 20.18 20.12 
MRTK029 Placebo 8295 7111 6269 893 1127 897 19.92 19.98 19.90 
MRTK030 Placebo 9356 10716 7357 1235 1659 897 20.09 20.16 20.3 
MRTK031 Placebo 8846 9237 8061 976 1361 982 20.14 20.06 20.37 
MRTK034 Placebo 12584 12012 9679 2155 2122 1496 20.13 20.01 20.29 
MRTK037 Placebo 11426 12734 10002 1751 1898 1373 20.18 20.00 20.28 
MRTK039 Placebo 8598 9474 9280 1149 1447 1008 20.18 19.98 20.27 
MRTK041 Placebo 10289 11362 9062 2470 2512 2188 20.20 20.17 20.18 
MRTK042 Placebo 9656 10449 9685 1701 2187 1741 20.05 19.96 20.16 
MRTK049 Placebo 10255 11356 8919 1390 1373 975 19.96 19.81 20.13 
MRTK051 Placebo 10896 12733 12350 2568 3148 2923 20.32 20.01 20.23 
MRTK052 Placebo 11680 12514 12092 2302 2898 2285 20.12 20.11 20.11 
MRTK056 Placebo 7776 8709 10036 791 1121 1253 20.29 20.26 20.23 
 
    SPECLPA SPECVLDLC SPECLDLCT 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 15.3 12.7 11.0 15.0 14.7 21.9 109.3 144.7 135.6 
MRTK005 DHA 111.1 88.1 88.3 7.0 11.6 12.9 98.9 123.8 130.1 
MRTK007 DHA 44.6 44.2 50.4 4.8 6.3 6.8 48.0 72.6 86.6 
MRTK008 DHA 11.3 14.7 15.4 3.0 12.9 5.9 43.7 83.9 41.3 
MRTK009 DHA 20.2 23.4 14.3 2.9 6.9 5.1 90.6 94.6 77.4 
MRTK011 DHA 9.8 10.7 10.1 5.6 8.8 6.9 93.2 108.6 68.9 
MRTK020 DHA 7.3 4.9 6.9 21.2 11.6 17.4 71.7 71.7 77.6 
MRTK021 DHA 16.3 23.8 22.5 15.8 12.2 8.0 54.0 46.6 49.6 
MRTK024 DHA 77.2 73.0 61.3 11.1 14.7 8.4 77.4 62.6 65.7 
MRTK028 DHA 92.7 88.6 68.2 7.5 7.8 7.7 116.2 121.8 104.6 
MRTK033 DHA 64.3 61.9 78.3 8.0 20.3 8.0 99.2 110.2 94.0 
MRTK035 DHA 12.7 22.6 14.1 8.3 9.3 11.9 75.5 88.7 93.5 
MRTK036 DHA 4.9 4.9 4.9 25.0 20.4 15.0 94.4 70.1 91.1 
MRTK038 DHA 15.5 9.9 9.8 14.1 30.7 32.6 146.2 113.8 148.6 
MRTK040 DHA 100.5 66.1 64.4 18.4 12.0 11.6 132.4 100.4 114.9 
MRTK043 DHA 30.6 31.5 23.0 10.9 5.4 13.3 65.7 56.0 87.1 
MRTK044 DHA 38.2 63.2 67.9 20.8 7.1 10.9 85.7 114.4 156.9 
MRTK045 DHA 65.9 74.4 71.4 25.2 12.1 14.6 96.9 83.6 90.5 
MRTK053 DHA 9.4 10.8 8.3 12.6 14.2 11.5 109.9 130.8 118.4 
MRTK057 DHA 14.2 21.0 21.7 17.0 14.6 16.4 100.3 125.3 110.7 
MRTK058 DHA 89.4 79.5 78.2 7.8 8.7 14.3 86.1 71.1 94.9 
MRTK060 DHA 4.9 4.9 4.9 17.1 28.8 23.0 99.5 108.6 87.9 
MRTK062 DHA 33.2 34.8 34.7 10.6 8.7 9.3 90.0 87.1 100.9 
MRTK001 Placebo 25.4 27.4 38.0 7.5 8.6 7.5 57.2 68.1 52.8 
MRTK003 Placebo 33.7 42.2 53.4 7.5 8.2 7.5 64.7 101.9 68.1 
MRTK004 Placebo 5.5 5.3 5.0 6.7 11.3 11.5 54.7 53.4 68.4 
MRTK010 Placebo 39.7 43.4 53.0 4.2 6.9 6.2 60.1 63.3 64.4 
MRTK012 Placebo 12.1 12.5 8.10 24.6 27.5 33.8 106.2 123.8 119.9 
MRTK013 Placebo 42.9 50.4 56.6 10.9 7.7 10.4 63.5 55.0 49.8 
MRTK014 Placebo 52.8 61.2 58.3 4.6 6.9 3.9 69.6 89.9 78.6 
MRTK015 Placebo 86.4 77.7 80.4 5.0 6.6 4.2 60.8 58.3 62.0 
MRTK016 Placebo 7.7 5.7 5.2 29.6 46.5 56.1 79.6 89.1 75.5 
MRTK017 Placebo 19.2 19.7 22.7 16.1 17.9 10.1 73.0 74.5 69.5 
MRTK018 Placebo 13.2 13.5 13.4 7.9 12.8 11.4 69.2 81.7 85.5 
MRTK019 Placebo 49.2 65.2 50.5 7.0 7.8 8.0 64.8 82.6 86.6 
MRTK023 Placebo 52.9 46.7 60.3 7.9 17.5 24.5 92.0 111.1 159.7 
MRTK025 Placebo 25.0 18.8 28.0 7.6 11.6 9.9 63.8 98.6 115.6 
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MRTK026 Placebo 5.3 7.7 7.9 15.5 21.0 12.9 82.5 93.9 81.1 
MRTK027 Placebo 22.9 17.7 19.90 13.9 17.2 21.6 67.9 111.7 92.4 
MRTK029 Placebo 5.8 5.5 4.9 18.7 28.5 12.2 124.0 126.1 71.8 
MRTK030 Placebo 4.9 4.9 4.90 12.8 11.0 7.7 67.5 84.5 56.0 
MRTK031 Placebo 23.7 28.7 30.6 7.0 9.7 9.7 57.0 69.1 63.8 
MRTK034 Placebo 92.8 79.7 85.20 24.6 29.7 14.3 91.8 65.7 89.4 
MRTK037 Placebo 85.6 69.9 72.4 18.6 19.7 14.3 100.2 84.2 99.6 
MRTK039 Placebo 45.0 40.4 43.8 9.6 5.8 8.8 62.7 62.4 63.9 
MRTK041 Placebo 95.2 84.0 90.8 6.7 12.0 8.4 93.2 87.4 96.3 
MRTK042 Placebo 51.0 59.7 66.0 6.7 3.5 8.2 58.7 62.3 74.5 
MRTK049 Placebo 10.5 12.8 13.1 28.8 26.4 26.7 123.1 127.0 131.8 
MRTK051 Placebo 101.7 94.2 84.8 6.7 8.7 9.3 105.5 84.3 110.7 
MRTK052 Placebo 181.5 158.8 140.0 6.7 8.7 10.5 75.8 89.2 112.2 
MRTK056 Placebo 28.6 31.7 26.7 13.6 29.5 32.6 90.9 88.1 117.2 
 
    SPECRLPC SPECIDLC SPECDLDLIIID 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 25.6 30.4 33.9 21.4 26.7 30.3 31.6 30.1 36.0 
MRTK005 DHA 18.0 30.3 30.3 16.3 27.5 26.7 21.0 17.3 22.1 
MRTK007 DHA 8.6 11.0 14.7 7.2 9.4 13.1 12.1 16.8 15.8 
MRTK008 DHA 6.7 20.4 10.7 5.8 17.1 9.2 11.2 13.2 8.0 
MRTK009 DHA 16.3 20.6 12.6 15.4 19.3 11.0 16.6 13.8 16.8 
MRTK011 DHA 31.5 27.5 14.7 29.8 25.3 13.4 10.0 12.9 9.6 
MRTK020 DHA 22.1 20.0 21.3 19.3 16.9 18.0 14.5 12.5 15.1 
MRTK021 DHA 21.5 19.4 12.9 19.6 16.0 11.3 5.4 5.3 6.8 
MRTK024 DHA 16.1 13.8 16.4 13.6 10.6 14.2 15.8 14.4 8.4 
MRTK028 DHA 13.8 16.3 9.3 11.7 14.4 7.4 23.5 20.3 21.9 
MRTK033 DHA 23.0 22.8 17.4 21.1 19.9 15.1 14.1 23.6 15.5 
MRTK035 DHA 22.4 22.4 28.6 19.8 19.6 24.5 6.4 15.2 10.9 
MRTK036 DHA 29.1 16.8 23.8 25.6 14.3 21.4 17.6 24.9 19.0 
MRTK038 DHA 33.0 26.8 43.2 29.4 22.5 38.8 23.7 33.1 34.3 
MRTK040 DHA 31.5 16.3 23.1 27.5 14.2 20.4 21.1 25.0 15.6 
MRTK043 DHA 17.9 11.5 29.1 15.2 10.0 25.1 13.3 13.8 14.6 
MRTK044 DHA 19.0 23.2 34.7 16.3 20.8 31.6 20.3 25.9 25.7 
MRTK045 DHA 38.6 19.4 25.1 32.5 16.7 21.4 16.0 22.2 13.0 
MRTK053 DHA 18.2 21.9 17.1 15.6 18.7 14.9 22.8 22.2 21.7 
MRTK057 DHA 29.5 29.5 28.8 25.3 25.7 25.4 15.9 28.5 21.1 
MRTK058 DHA 17.4 9.7 22.0 15.2 7.6 18.9 12.8 19.8 18.9 
MRTK060 DHA 33.3 29.1 28.3 29.9 23.9 25.0 13.4 40.9 25.6 
MRTK062 DHA 22.5 19.8 29.3 19.9 17.4 26.3 14.6 16.3 14.3 
MRTK001 Placebo 10.5 12.7 11.4 8.7 10.6 9.6 11.7 10.6 9.6 
MRTK003 Placebo 8.7 11.6 9.0 6.9 8.9 6.9 15.4 18.5 15.9 
MRTK004 Placebo 12.1 11.6 23.2 10.4 9.4 20.0 12.1 11.6 6.7 
MRTK010 Placebo 10.9 14.3 16.1 9.9 12.7 14.3 12.3 11.3 9.5 
MRTK012 Placebo 29.5 29.7 36.9 25.9 25.3 30.2 26.7 22.6 26.9 
MRTK013 Placebo 13.0 11.3 17.4 10.9 9.1 15.0 14.2 11.8 8.1 
MRTK014 Placebo 10.2 15.1 13.4 9.1 13.5 12.3 15.0 14.6 12.5 
MRTK015 Placebo 10.9 10.2 10.5 10.0 8.3 9.3 12.2 13.8 11.7 
MRTK016 Placebo 30.2 41.3 36.2 25.9 33.8 30.2 19.8 18.7 15.0 
MRTK017 Placebo 14.2 17.3 13.8 12.3 14.6 12.2 13.9 14.0 13.7 
MRTK018 Placebo 14.2 20.3 23.0 12.3 16.3 19.8 12.3 15.3 16.4 
MRTK019 Placebo 13.0 16.0 18.0 1.1 13.8 16.4 12.6 11.6 15.5 
MRTK023 Placebo 14.5 28.8 42.5 12.3 23.8 36.7 17.4 16.3 27.4 
 153 
 
MRTK025 Placebo 11.4 23.5 19.0 9.5 20.3 16.7 13.0 18.2 20.4 
MRTK026 Placebo 19.3 30.4 19.6 16.4 26.6 17.4 22.1 17.2 13.8 
MRTK027 Placebo 19.6 31.0 29.3 16.4 26.9 25.1 17.1 17.2 15.5 
MRTK029 Placebo 30.1 33.5 12.2 26.2 29.7 10.0 31.9 28.2 21.6 
MRTK030 Placebo 14.7 16.9 7.7 11.8 14.1 6.1 15.4 15.0 9.0 
MRTK031 Placebo 9.6 15.0 17.1 8.0 13.2 15.1 11.5 13.3 7.4 
MRTK034 Placebo 28.8 26.7 30.3 25.3 22.0 25.8 15.0 13.1 11.9 
MRTK037 Placebo 29.8 24.2 29.6 25.6 20.4 25.8 15.0 19.6 11.9 
MRTK039 Placebo 16.6 15.2 13.9 14.1 13.3 11.9 9.6 14.0 10.2 
MRTK041 Placebo 26.4 26.1 20.3 24.8 23.1 18.3 13.1 13.2 15.9 
MRTK042 Placebo 9.3 7.6 13.3 8.0 6.7 11.2 13.6 17.0 13.3 
MRTK049 Placebo 35.0 34.7 38.1 31.0 29.1 33.8 27.8 43.4 22.9 
MRTK051 Placebo 17.6 10.1 22.9 16.3 8.0 21.1 15.5 20.5 16.4 
MRTK052 Placebo 13.9 16.3 20.5 12.5 13.9 18.0 13.9 17.0 21.7 
MRTK056 Placebo 32.9 33.7 45.6 28.7 29.5 39.4 11.9 11.8 17.4 
 
    SPECDLDLIVC SPECHDLCT SPECBHDL2B 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 9.3 7.2 10.8 37.0 39.3 30.6 9.3 11.6 9.3 
MRTK005 DHA 7.1 5.2 7.8 51.1 57.2 49.2 11.2 20.1 15.6 
MRTK007 DHA 3.4 5.2 4.8 41.8 45.7 48.8 10.5 14.0 16.1 
MRTK008 DHA 3.7 5.2 3.2 34.3 36.3 35.7 10.0 14.0 12.3 
MRTK009 DHA 5.5 4.7 5.3 48.9 39.1 37.8 14.4 13.8 13.5 
MRTK011 DHA 5.5 5.5 3.6 67.7 59.7 61.8 31.2 27.8 29.0 
MRTK020 DHA 5.1 5.0 5.2 42.3 38.5 37.0 11.4 11.3 10.0 
MRTK021 DHA 5.1 5.0 5.2 44.6 34.4 36.7 15.5 11.9 11.3 
MRTK024 DHA 5.1 5.3 5.2 62.3 56.0 52.5 24.0 22.5 26.1 
MRTK028 DHA 8.7 7.5 7.1 84.0 73.9 46.4 29.5 27.5 15.1 
MRTK033 DHA 5.1 5.3 5.2 45.4 56.7 42.8 12.8 18.9 12.2 
MRTK035 DHA 5.1 3.8 5.4 41.3 42.7 35.0 14.1 16.8 12.2 
MRTK036 DHA 5.1 7.2 5.4 44.2 41.1 31.6 10.9 12.8 10.5 
MRTK038 DHA 6.4 9.3 7.1 45.4 53.4 42.8 11.5 17.4 14.3 
MRTK040 DHA 6.1 6.7 6.1 52.6 62.8 46.2 16.6 24.5 13.9 
MRTK043 DHA 4.5 4.2 5.9 57.9 54.1 52.4 20.3 19.7 18.0 
MRTK044 DHA 5.9 8.2 8.1 44.3 52.0 49.3 15.5 19.3 19.8 
MRTK045 DHA 4.8 5.6 5.3 47.9 64.2 49.9 17.6 22.6 19.2 
MRTK053 DHA 6.6 6.2 7.8 54.3 60.0 57.7 19.9 21.9 20.5 
MRTK057 DHA 5.4 6.9 8.1 63.3 89.2 67.6 25.6 42.7 33.5 
MRTK058 DHA 5.3 6.2 7.1 54.1 49.3 47.7 17.1 15.3 14.3 
MRTK060 DHA 5.0 8.7 7.3 56.9 59.0 35.0 19.0 17.4 10.7 
MRTK062 DHA 5.6 5.6 6.0 37.7 48.2 40.3 15.6 16.3 13.7 
MRTK001 Placebo 4.8 5.5 4.8 52.4 62.6 52.2 18.1 23.9 18.6 
MRTK003 Placebo 6.0 11.6 5.7 101.1 121.1 90.3 60.2 75.9 51.3 
MRTK004 Placebo 3.7 4.4 4.3 42.5 36.6 35.8 12.1 11.3 13.3 
MRTK010 Placebo 4.2 4.7 3.2 46.9 43.5 50.6 15.2 12.9 19.1 
MRTK012 Placebo 8.1 6.3 8.1 44.8 41.3 48.8 11.0 10.7 14.0 
MRTK013 Placebo 4.4 4.4 3.2 38.7 35.2 36.3 12.4 9.6 11.4 
MRTK014 Placebo 3.7 5.5 5.1 53.1 52.0 54.5 20.4 19.3 18.2 
MRTK015 Placebo 3.7 5.0 5.1 67.3 63.0 61.8 30.4 25.3 23.0 
MRTK016 Placebo 5.2 8.5 6.3 28.7 42.9 40.2 9.5 16.0 11.6 
MRTK017 Placebo 5.1 5.0 4.7 53.7 45.9 45.2 16.4 15.7 12.9 
MRTK018 Placebo 5.1 5.3 4.8 52.1 49.8 45.9 14.2 15.6 12.9 
MRTK019 Placebo 5.1 5.0 5.2 43.3 41.0 41.2 11.7 12.2 10.0 
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MRTK023 Placebo 5.7 5.9 6.1 61.9 58.8 50.9 25.3 21.9 19.3 
MRTK025 Placebo 5.1 5.9 5.8 42.3 45.4 39.1 10.1 14.7 11.6 
MRTK026 Placebo 5.1 5.3 5.2 40.4 39.1 36.1 9.8 12.5 10.0 
MRTK027 Placebo 6.6 6.6 6.1 36.7 60.7 38.6 10.4 20.7 11.3 
MRTK029 Placebo 9.9 6.6 5.2 39.7 36.9 32.2 9.9 12.5 10.0 
MRTK030 Placebo 5.1 5.3 5.2 46.4 56.0 36.4 13.8 18.5 10.0 
MRTK031 Placebo 5.1 3.6 5.2 42.6 47.8 39.6 10.9 15.2 10.9 
MRTK034 Placebo 6.1 3.6 5.4 66.9 65.5 49.6 24.0 23.6 16.7 
MRTK037 Placebo 5.8 5.1 5.4 58.6 66.9 50.0 19.5 21.1 15.3 
MRTK039 Placebo 5.1 4.2 5.4 42.9 48.9 44.5 12.8 16.1 11.2 
MRTK041 Placebo 6.4 5.7 6.1 60.3 66.0 53.1 27.5 27.9 24.3 
MRTK042 Placebo 4.5 4.3 5.4 51.3 60.0 51.7 19.0 24.3 19.4 
MRTK049 Placebo 7.5 9.7 5.9 51.3 55.5 42.8 15.5 15.3 10.9 
MRTK051 Placebo 5.6 5.9 6.2 62.7 75.3 70.7 28.6 35.0 32.6 
MRTK052 Placebo 8.8 9.4 10.5 64.1 72.5 64.5 25.6 32.3 25.4 
MRTK056 Placebo 4.5 5.6 5.3 36.9 44.4 49.6 8.8 12.5 14.0 
 
    SPECHDL2AC SPECHDL3C SPECTCHDL 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 4.8 5.5 4.8 22.9 22.2 16.5 4.36 5.05 6.15 
MRTK005 DHA 10.9 6.1 2.4 29.0 31.1 31.2 3.07 3.37 3.91 
MRTK007 DHA 4.3 4.4 4.5 26.9 27.2 28.2 2.26 2.73 2.91 
MRTK008 DHA 2.8 4.7 2.9 21.5 17.6 20.6 2.36 3.67 2.32 
MRTK009 DHA 4.4 5.0 3.0 30.1 20.4 21.3 2.91 3.60 3.18 
MRTK011 DHA 10.9 8.8 9.8 25.5 23.1 23.1 2.46 2.97 2.23 
MRTK020 DHA 5.1 5.0 5.2 25.9 22.2 21.9 3.19 3.16 3.6 
MRTK021 DHA 5.1 5.0 5.2 24.0 17.5 20.3 2.57 2.71 2.75 
MRTK024 DHA 12.6 7.5 7.4 25.6 26.0 19.0 2.42 2.38 2.41 
MRTK028 DHA 12.3 9.4 5.2 42.1 36.9 26.1 2.47 2.75 3.42 
MRTK033 DHA 5.1 11.4 5.2 27.5 26.4 25.4 3.36 3.30 3.38 
MRTK035 DHA 5.1 7.6 5.4 22.1 18.2 17.3 3.03 3.30 4.01 
MRTK036 DHA 5.1 5.4 5.4 28.2 22.9 15.6 3.70 3.20 4.35 
MRTK038 DHA 5.1 9.9 5.4 28.8 26.1 23.1 4.53 3.71 5.23 
MRTK040 DHA 6.1 11.4 5.4 29.9 27.0 26.9 3.87 2.79 3.74 
MRTK043 DHA 8.0 8.6 5.0 29.6 25.7 29.5 2.32 2.14 2.92 
MRTK044 DHA 4.8 7.6 5.0 24.0 25.0 24.5 3.40 3.34 4.40 
MRTK045 DHA 5.3 11.1 5.0 24.9 30.5 25.7 3.55 2.49 3.11 
MRTK053 DHA 8.3 7.3 5.3 26.1 30.9 31.9 3.26 3.42 3.25 
MRTK057 DHA 10.8 19.8 9.0 27.0 26.7 25.1 2.85 2.57 2.88 
MRTK058 DHA 5.0 5.6 5.0 32.0 28.5 28.5 2.74 2.62 3.29 
MRTK060 DHA 7.8 10.8 5.3 30.2 30.9 19.0 3.05 3.33 4.17 
MRTK062 DHA 7.0 5.6 5.3 15.2 26.4 21.3 3.67 2.99 3.74 
MRTK001 Placebo 9.0 12.3 9.3 25.3 26.3 24.3 2.24 2.22 2.16 
MRTK003 Placebo 13.5 19.2 14.4 27.4 26.0 24.6 1.71 1.91 1.84 
MRTK004 Placebo 4.4 4.4 6.7 26.0 20.9 15.8 2.44 2.77 3.23 
MRTK010 Placebo 4.8 6.9 6.8 26.8 23.7 24.8 2.37 2.61 2.39 
MRTK012 Placebo 3.7 4.4 3.6 30.1 26.1 31.2 3.92 4.67 4.15 
MRTK013 Placebo 3.0 4.4 3.0 23.2 21.2 21.9 2.92 2.78 2.66 
MRTK014 Placebo 8.0 6.1 4.1 24.6 26.7 32.3 2.40 2.86 2.52 
MRTK015 Placebo 11.0 9.9 8.1 25.9 27.8 30.8 1.98 2.03 2.07 
MRTK016 Placebo 4.9 4.4 4.8 14.3 22.6 23.9 4.81 4.16 4.20 
MRTK017 Placebo 5.4 6.1 3.9 31.9 24.2 28.4 2.66 3.01 2.76 
MRTK018 Placebo 5.1 10.0 5.0 32.9 24.1 28.1 2.48 2.90 3.11 
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MRTK019 Placebo 5.4 5.0 5.2 26.2 23.8 26.1 2.66 3.21 3.30 
MRTK023 Placebo 12.3 9.4 9.3 24.3 27.5 22.2 2.61 3.19 4.62 
MRTK025 Placebo 5.1 6.6 5.4 27.2 24.1 22.1 2.69 3.43 4.21 
MRTK026 Placebo 5.1 7.2 5.2 25.6 19.4 20.9 3.42 3.94 3.61 
MRTK027 Placebo 5.1 9.7 5.2 21.2 30.4 22.2 3.23 3.12 3.95 
MRTK029 Placebo 4.8 5.0 5.2 25.0 19.4 17.1 4.59 5.19 3.61 
MRTK030 Placebo 5.1 9.1 5.2 27.5 28.5 21.3 2.73 2.70 2.75 
MRTK031 Placebo 5.1 7.5 5.2 26.6 25.2 23.5 2.50 2.65 2.85 
MRTK034 Placebo 9.3 11.8 5.4 33.6 30.0 27.5 2.74 2.46 3.09 
MRTK037 Placebo 6.4 12.8 5.4 32.6 32.9 29.2 3.03 2.56 3.28 
MRTK039 Placebo 5.1 6.3 5.4 25.0 26.5 27.9 2.69 2.39 2.63 
MRTK041 Placebo 9.1 12.6 7.8 23.8 25.4 21.0 2.65 2.51 2.97 
MRTK042 Placebo 5.6 12.4 6.1 26.4 23.4 26.2 2.28 2.09 2.60 
MRTK049 Placebo 5.9 6.6 5.0 29.9 33.7 27.0 3.96 3.76 4.70 
MRTK051 Placebo 7.2 11.1 6.5 27.0 29.1 31.6 2.79 2.24 2.7 
MRTK052 Placebo 8.0 10.8 5.0 30.4 29.5 34.1 2.29 2.35 2.90 
MRTK056 Placebo 4.5 9.0 6.5 23.6 22.9 29.1 3.83 3.65 4.02 
 
    SPECLDLP SPECLDLMDPH SPECHDLMD 
SID TREAT SUM PRE POST SUM PRE POST SUM PRE POST 
MRTK002 DHA 437 391 501 1.032 1.030 1.032 1.105 1.099 1.099 
MRTK005 DHA 303 241 324 1.030 1.029 1.030 1.104 1.098 1.106 
MRTK007 DHA 165 236 220 1.031 1.031 1.030 1.108 1.102 1.103 
MRTK008 DHA 160 202 122 1.032 1.030 1.031 1.105 1.096 1.101 
MRTK009 DHA 238 199 237 1.030 1.029 1.031 1.106 1.098 1.100 
MRTK011 DHA 175 203 144 1.029 1.028 1.028 1.091 1.089 1.089 
MRTK020 DHA 212 192 220 1.031 1.030 1.031 1.102 1.100 1.103 
MRTK021 DHA 125 124 140 1.030 1.031 1.031 1.097 1.094 1.098 
MRTK024 DHA 224 215 155 1.030 1.032 1.029 1.091 1.093 1.085 
MRTK028 DHA 351 303 312 1.030 1.029 1.030 1.098 1.097 1.098 
MRTK033 DHA 209 302 222 1.029 1.030 1.029 1.105 1.097 1.101 
MRTK035 DHA 136 199 183 1.028 1.029 1.029 1.098 1.094 1.093 
MRTK036 DHA 242 342 261 1.030 1.033 1.031 1.104 1.102 1.096 
MRTK038 DHA 319 451 431 1.030 1.032 1.031 1.104 1.098 1.096 
MRTK040 DHA 290 336 238 1.029 1.031 1.029 1.102 1.094 1.100 
MRTK043 DHA 193 192 225 1.030 1.032 1.030 1.098 1.097 1.099 
MRTK044 DHA 279 366 363 1.031 1.031 1.029 1.098 1.097 1.094 
MRTK045 DHA 221 292 201 1.030 1.032 1.029 1.097 1.097 1.095 
MRTK053 DHA 314 303 320 1.030 1.029 1.030 1.095 1.097 1.099 
MRTK057 DHA 230 372 319 1.030 1.030 1.030 1.093 1.085 1.087 
MRTK058 DHA 199 280 284 1.029 1.032 1.031 1.101 1.100 1.101 
MRTK060 DHA 200 516 351 1.029 1.033 1.033 1.099 1.099 1.096 
MRTK062 DHA 221 236 224 1.030 1.030 1.030 1.088 1.097 1.096 
MRTK001 Placebo 182 181 162 1.031 1.030 1.031 1.095 1.093 1.094 
MRTK003 Placebo 234 346 235 1.031 1.031 1.030 1.081 1.077 1.081 
MRTK004 Placebo 169 174 126 1.031 1.031 1.028 1.106 1.099 1.092 
MRTK010 Placebo 179 176 136 1.030 1.030 1.029 1.103 1.099 1.097 
MRTK012 Placebo 373 307 374 1.032 1.030 1.032 1.110 1.103 1.107 
MRTK013 Placebo 200 177 123 1.031 1.031 1.030 1.104 1.102 1.103 
MRTK014 Placebo 196 219 193 1.030 1.029 1.030 1.097 1.096 1.104 
MRTK015 Placebo 170 203 186 1.030 1.031 1.030 1.091 1.093 1.098 
MRTK016 Placebo 264 303 235 1.032 1.032 1.033 1.096 1.096 1.105 
MRTK017 Placebo 206 206 198 1.031 1.030 1.030 1.102 1.098 1.106 
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MRTK018 Placebo 191 224 226 1.030 1.031 1.030 1.104 1.097 1.105 
MRTK019 Placebo 194 183 223 1.031 1.029 1.030 1.102 1.099 1.103 
MRTK023 Placebo 249 242 350 1.030 1.029 1.029 1.090 1.094 1.091 
MRTK025 Placebo 197 260 279 1.031 1.030 1.030 1.104 1.098 1.098 
MRTK026 Placebo 284 242 207 1.031 1.030 1.030 1.103 1.096 1.102 
MRTK027 Placebo 259 260 237 1.032 1.030 1.030 1.099 1.096 1.099 
MRTK029 Placebo 449 364 281 1.032 1.031 1.032 1.103 1.095 1.099 
MRTK030 Placebo 221 221 161 1.031 1.030 1.030 1.101 1.097 1.103 
MRTK031 Placebo 185 180 146 1.031 1.030 1.029 1.103 1.101 1.101 
MRTK034 Placebo 232 177 193 1.030 1.031 1.030 1.096 1.097 1.098 
MRTK037 Placebo 227 262 193 1.030 1.031 1.029 1.100 1.099 1.100 
MRTK039 Placebo 166 195 177 1.030 1.031 1.030 1.100 1.101 1.103 
MRTK041 Placebo 218 209 240 1.030 1.030 1.030 1.089 1.091 1.087 
MRTK042 Placebo 196 224 206 1.031 1.031 1.030 1.097 1.092 1.095 
MRTK049 Placebo 373 555 304 1.031 1.033 1.030 1.101 1.102 1.103 
MRTK051 Placebo 229 281 247 1.028 1.031 1.029 1.091 1.089 1.092 
MRTK052 Placebo 261 299 361 1.031 1.031 1.031 1.094 1.090 1.096 
MRTK056 Placebo 180 194 242 1.029 1.030 1.029 1.103 1.098 1.101 
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APPENDIX L 
SAMPLE OF EXCEL STATISTICS FORMULAS 
Statistics in Microsoft Excel 2010 
=Average function ; =stdev( of average function) ;  
SEE = (stdev value)/sqrt(count of group); 
t-value = mean/SEE; one sample ttest and treatment vs treatment  =ttest (treatment, zero 
range; ,2 tail, type 2); 
time point to time point comparison t-value = mean/SEE; one sample ttest  =ttest 
(treatment, zero range; ,2 tail, type 1); 
effect size = mean/stdev; CI CoEff =CONFIDENCE(0.05, SD,n) 
Lower Bound = mean - CI CoEff; Upper Bound = mean + CI CoEff 
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Example: 
 
Pre-Camp Post-Camp
DHA Eotaxin_CPR Eotaxin_CPO
mean 6.71 8.41
n 22 22
SD 29.39 38.19
SEE 6.27 8.14
t-value (mean/see) 1.07 1.03
one sample ttest 0.296384346 0.313713341
Effect Size 0.23 0.22
CI CoEff 12.28 15.96
Lower Bound -5.57 -7.55
Upper  Bound 18.99 24.36
Placebo
mean 56.70 43.61
n 21 21
SD 111.42 75.03
SEE 24.31 16.37
t-value (mean/see) 2.33 2.66
one sample ttest 0.030266854 0.01492606
Effect Size 0.51 0.58
CI CoEff 47.65 32.09
Lower Bound 9.05 11.52
Upper  Bound 104.35 75.70
